



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/86, 5/10, A61K 48/00	A1	(11) International Publication Number: WO 98/10087 (43) International Publication Date: 12 March 1998 (12.03.98)
(21) International Application Number: PCT/US97/15694 (22) International Filing Date: 4 September 1997 (04.09.97) (30) Priority Data: 60/024,700 6 September 1996 (06.09.96) US (60) Parent Application or Grant (63) Related by Continuation US 60/024,700 (CIP) Filed on 6 September 1996 (06.09.96) (71) Applicant (for all designated States except US): TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WILSON, James, M. [US/US]; 1350 N. Avigon Drive, Gladwyne, PA 19035 (US). FARINA, Steven, F. [US/US]; Apartment 1214, 1642 East 56th Street, Chicago, IL 60637 (US). FISHER, Krishna, J. [US/US]; 2338 Nashville Avenue, New Orleans, LA 70115 (US).		(74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: CHIMPANZEE ADENOVIRUS VECTORS (57) Abstract A recombinant vector comprises chimpanzee adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses chimpanzee adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CHIMPANZEE ADENOVIRUS VECTORS

This invention was supported by the National Institute of Health Grant No. DK47757. The United States government has rights in this invention.

5 Field of the Invention

The present invention relates to the field of vectors useful in somatic gene therapy and the production and use thereof, and also to the field of vaccines.

Background of the Invention

10 I. Gene Therapy

Gene therapy is an approach to treating disease, generally human disease, that is based on the modification of gene expression in cells of the patient. It has become apparent over the last decade that the
15 single most outstanding barrier to the success of gene therapy as a strategy for treating inherited diseases, cancer, and other genetic dysfunctions is the development of useful gene transfer vehicles.

Eukaryotic viruses have been employed as
20 vehicles for somatic gene therapy. Among the viral vectors that have been cited frequently in gene therapy research are adenoviruses. Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a therapeutic or reporter transgene to a variety of cell
25 types. Human adenoviruses are composed of a linear, approximately 36 kb double-stranded DNA genome, which is divided into 100 map units (m.u.), each of which is 360 bp in length. The DNA contains short inverted terminal repeats (ITR) at each end of the genome that are required
30 for viral DNA replication. The gene products are organized into early (E1 through E4) and late (L1 through L5) regions, based on expression before or after the initiation of viral DNA synthesis [see, e.g., Horwitz,

Virology, 2d edit., ed. B. N. Fields, Raven Press, Ltd., New York (1990)].

Recombinant adenoviruses types 2 and 5 (Ad2 and Ad5, respectively), which cause respiratory disease in humans, are currently being developed for gene therapy. Both Ad2 and Ad5 belong to a subclass of adenovirus and are not associated with human malignancies.

Recombinant adenoviruses are capable of providing extremely high levels of transgene delivery to virtually all cell types, regardless of the mitotic state. High titers (10^{13} plaque forming units/ml) of recombinant virus can be easily generated in an adenovirus-transformed, human embryonic kidney cell line 293 [ATCC CRL1573]. The 293 cell line contains a functional adenovirus E1a gene which provides a transacting E1a protein. It can be cryo-stored for extended periods without appreciable losses.

The efficacy of this system in delivering a therapeutic transgene *in vivo* that complements a genetic imbalance has been demonstrated in animal models of various disorders [K. F. Kozarsky et al, Somatic Cell Mol. Genet., 19:449-458 (1993) ("Kozarsky et al I"); K. F. Kozarsky et al, J. Biol. Chem., 269:13695-13702 (1994) ("Kozarsky et al II"); Y. Watanabe, Atherosclerosis, 36:261-268 (1986); K. Tanzawa et al, FEBS Letters, 118(1):81-84 (1980); J.L. Golasten et al, New Engl. J. Med., 309:288-296 (1983); S. Ishibashi et al, J. Clin. Invest., 92:883-893 (1993); and S. Ishibashi et al, J. Clin. Invest., 93:1885-1893 (1994)]. Indeed, a recombinant replication defective adenovirus encoding a cDNA for the cystic fibrosis transmembrane regulator (CFTR) has been approved for use in at least two human CF clinical trials [see, e.g., J. Wilson, Nature, 365:691-692 (Oct. 21, 1993)]. The use of adenovirus vectors in

the transduction of genes into hepatocytes *in vivo* has previously been demonstrated in rodents and rabbits [see, e.g., Kozarsky II, cited above, and S. Ishibashi et al, J. Clin. Invest., 92:883-893 (1993)]. Further support of
5 the safety of recombinant adenoviruses for gene therapy is the extensive experience of live adenovirus vaccines in human populations.

However, many humans have pre-existing immunity to human adenoviruses as a result of previous
10 natural exposure, and this immunity is a major obstacle to the use of recombinant human adenoviruses for gene therapy protocols.

II. Vaccines

Replication competent, recombinant
15 adenovirus (Ad) containing a variety of inserted genes have been used as vaccine compositions with some success [see, e.g. Davis, U.S. Patent No. 4,920,309]. Others have described the insertion of a foreign gene into a live [L. Prevac, J. Infect. Dis., 161:27-30 (1990)] and a
20 replication-defective adenovirus for putative use as a vaccine [See, e.g. T. Ragot et al, J. Gen. Virol., 74:501-507 (1993); M. Eliot et al, J. Gen. Virol., 71:2425-2431 (1990); and S. C. Jacobs et al, J. Virol., 66:2086-2095 (1992)]. Jacobs et al, cited above,
25 describes a recombinant E1-deleted, E3 intact, Ad containing encephalitis virus protein NS1 under the control of a heterologous cytomegalovirus (CMV) promoter. When mice were immunized with the recombinant Ad vaccines and challenged with virus, Jacobs et al obtained partial
30 protection (at most a 75% protection) for an average survival of 15 days. Eliot et al, cited above, describe a recombinant E1-deleted, partially E3-deleted Ad with pseudorabies glycoprotein 50 inserted into the E1 deletion site under the control of a homologous Ad
35 promoter. In rabbits and mice, after immunization and

challenge, only partial protection was obtained (i.e., about one-third). Ragot et al, cited above, describe a recombinant E1-deleted, partially E3-deleted Ad with Epstein Barr virus glycoprotein gp340/220 inserted into the E1 deletion site under the control of a homologous Ad promoter. In marmosets (tamarins) after three high dose (5X10⁹ pfu, 1X10¹⁰ pfu and 2X10¹⁰ pfu), intramuscular immunizations and viral challenge, full protection was obtained.

For certain highly infectious diseases, there is a demand for an effective vaccine. Desirably, a vaccine should be effective at a low dosage to control the occurrence of side effects or to enable sufficient amounts of vaccine to be introduced into the animal or human.

There exists a need in the gene therapy art for the development of additional adenovirus vector constructs that do not stimulate immediate immune responses which quickly eliminate the recombinant virus and the therapeutic transgene from the patient. There also exists a need in the vaccine art for new vaccine carriers, which are safe and effective in humans and other mammals.

Summary of the Invention

The present invention meets the need in the art by providing adenovirus nucleotide sequences of chimpanzee origin, a variety of novel vectors, and cell lines expressing chimpanzee adenovirus genes.

In one aspect the invention provides the nucleotide sequence of a chimpanzee C1 adenovirus. See SEQ ID NO: 1.

In another aspect the invention provides the nucleotide sequence of a chimpanzee C68 adenovirus. See SEQ ID NO: 2.

In a further aspect, the invention provides a recombinant adenovirus comprising the DNA sequence of a chimpanzee adenovirus and a selected heterologous gene operatively linked to regulatory sequences directing its expression. The recombinant virus is capable of infecting a mammalian, preferably a human, cell and capable of expressing the heterologous transgene product in the cell. In this vector, the native chimpanzee E1 gene, and/or E3 gene, and/or E4 gene may be deleted. A heterologous gene may be inserted into any of these sites of gene deletion. The heterologous transgene may encode a normal or therapeutic gene which, upon expression, replaces or modifies an inherited or acquired genetic defect. The heterologous gene may be an antigen against which a primed immune response is desired (i.e., a vaccine).

In another aspect, the invention provides a mammalian cell infected with the viral vector described above.

In still a further aspect of this invention, a novel mammalian cell line is provided which expresses a chimpanzee adenovirus gene or functional fragment thereof.

In still a further aspect, the invention provides a method for delivering a transgene into a mammalian cell comprising the step of introducing into the cell an effective amount of a recombinant virus described above.

Another aspect of this invention is a method for delivering to a mammalian patient having a disorder related to an inherited or acquired genetic defect a desired transgene. The method comprises the step of administering to the patient by an appropriate route an effective amount of an above-described recombinant

chimpanzee adenovirus containing a normal or therapeutic transgene, wherein the transgene product is expressed *in vivo*.

Still another aspect of this invention provides
5 a method for eliciting an immune response in a mammalian host to protect against an infective agent. The method comprises the step of administering to the host an effective amount of a recombinant chimpanzee adenovirus comprising a heterologous gene that encodes an antigen
10 from the infecting organism against which the immune response is targeted.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

15 Brief Description of the Drawings

Fig. 1A is a diagrammatic bar graph illustrating the structure of the chimpanzee adenovirus C1 (also referred to as C-1) and the location of the adenovirus genes thereon by nucleotide position and by
20 map unit numbers appearing under the bar graph. The locations of the late genes (L-1 through L-5) are represented by arrows below the graph with molecular weight indications above the arrows and nucleotide positions below the arrows. The location of the E2a
25 region early TATA box and transcriptional start site was not determined. The E2a region is estimated to begin approximately at nucleotide 27,100. The position of the translation initiation codon for the E2a encoded DNA binding protein is indicated by an asterisk.

30 Fig. 1B is a line graph showing the correlation between map units and nucleotide (base) pairs of the sequence of C1 [SEQ ID NO: 1].

Fig. 1C is a bar graph illustrating the various Bam HI clones obtained for the C1 Ad, indicating nucleotide numbers, fragment size in nucleotides, clone numbers, and fragment boundaries in nucleotides.

5 Fig. 2 is a tabular comparison of C1 and C68 predicted amino acid sequences examined for homology to previously described adenoviral protein sequences, Ad4, Ad5, Ad7, Ad12, and Ad40. Symbol "a" indicates that comparison of fragments of different size resulted in an
10 underestimate of homology. Symbol "b" indicates a 95% identity from Ad-4 aa 1-95. A possible mistake in sequence apparently resulted in a frameshift and premature termination in this comparison. Symbol "c" indicates that Ad-5 has 2 small ORF's in this region
15 encoding proteins of 64 and 67 residues with approximately 50% amino acid identity with, respectively, the amino and carboxy halves of the chimp Ad homologs. Symbol "d" indicates that Ad-3 and Ad-7 fragments were not sequenced for this protein. Symbol "e" indicates
20 that Ad-35 and Ad-4 were not sequenced for this protein. Symbol "f" indicates that the reported sequence for Ad-7 pVIII is 197aa, and the homology begins at aa30 of the chimp Ad sequences. The homology between the chimp Ad's and Ad-7 for the 197 aa region is 98% for C-1 and 90% for
25 C-68.

Fig. 3A is a diagrammatic bar graph illustrating the structure of the chimpanzee adenovirus C68 and the location of the adenovirus genes thereon by nucleotide position and by map unit numbers appearing
30 under the bar graph. The locations of the late genes are represented as described for Fig. 1A. The location of the E2a region early TATA box and transcriptional start site was not determined. The E2a region is estimated to begin approximately at nucleotide 26,800. The position
35 of the translation initiation codon for the E2a encoded

DNA binding protein is indicated by an asterisk. Although the entire genome of C68 has been cloned, certain of the fragments in Fig. 3 have been individually cloned (white bars) or not cloned (shaded bars).

5 Fig. 3B is a line graph showing the correlation between map units and nucleotide (base) pairs of the sequence of C68 [SEQ ID NO: 2]. White and shaded boxes are defined as in Fig. 3A.

10 Fig. 3C is a bar graph illustrating the various Pst fragments obtained for the C68 Ad, indicating nucleotide numbers, fragment sizes in nucleotides, clone numbers and fragment boundaries in nucleotides. White and shaded boxes are defined as in Fig. 3A.

15 Fig. 3D is a bar diagram illustrating Bam HI fragments of the C68 genome indicating nucleotide numbers, fragment size in nucleotides, clone numbers, and fragment boundaries in nucleotides. White and shaded boxes are defined as in Fig. 3A.

20 Fig. 3E is a bar diagram illustrating the HindIII-B fragment and its nucleotide boundaries and size. White and shaded boxes are defined as in Fig. 3A.

Fig. 4A is a more detailed schematic drawing of pC68-CMV-LacZ.

25 Fig. 4B is a schematic representation of pBS-Notx2.

Fig. 5A is a schematic drawing of plasmid pGPGK. The arrow indicates the direction of the murine PGK promoter. Restriction sites and marker genes are conventionally labeled.

30 Fig. 5B is a schematic drawing of plasmid pNEB-C68BamE. This plasmid contains fragments of the LacZ gene (small arrow) flanking either side of the bar indicating the C68 Ad BamE fragment. The large arrow illustrates the Amp^R gene. Restriction sites and marker genes are conventionally labeled.

35

Fig. 5C is a schematic drawing of plasmid pGPGK-C68BamE in which the BamE fragment from pNEB-C68BamE has been cloned downstream from the PGK promoter of pGPGK.

5 Fig. 5D is a representation of the PCR amplification of the C68 sequence from pNEB-C68BamE, illustrating the use of primers to introduce a KpnI site just upstream of the C68 E1 region translation initiation codon at nucleotide 576 of the C68 genomic DNA and reduce
10 the sequence distance between the promoter and C68 coding sequence. Location of the primers is indicated.

Fig. 5E is a schematic drawing of plasmid pGPGK-C68E1-ATG, in which the ATG translational start codon was moved closer to the PGK promoter.

15 Fig. 5F is a schematic drawing of plasmid pBS-C68BamF, in which the BamF fragment was cloned into the BamHI site of pGPGK-C68E1-ATG to generate pGPGK-C68E1 (Fig. 5G).

Fig. 5G is a schematic drawing of plasmid pGPGK-C68E1, containing the complete chimpanzee C68 Ad E1
20 region under the control of the murine PGK promoter.

Fig. 6A is a schematic drawing of plasmid pGPGK, a duplication of Fig. 5A for purposes of explaining construction of the C1 Ad E1 expression
25 plasmid.

Fig. 6B illustrates the isolation of the 5' end of the C1 E1 region as a 1.9kb SnaBI - XbaI fragment.

Fig. 6C illustrates the use of primers to introduce by PCR amplification a KpnI site just upstream
30 of the C1 E1 region translation initiation codon E1-ATG at nucleotide 577 of the C1 genomic DNA.

Fig. 6D is a schematic drawing of plasmid pGPGK-C1 mul.3-6.6 (7.4kb).

Fig. 6E is a schematic drawing of plasmid pGPGK-C1-E1ATG.
35

Fig. 6F is a schematic drawing of plasmid pBS-C1BamI.

Fig. 6G is a schematic drawing of plasmid pGPGK-C1E1, containing the complete chimpanzee C1 Ad E1 region under the control of the murine PGK promoter.

Fig. 7A is a schematic drawing of plasmid pSP72-Pac with indicated restriction endonuclease enzyme cleavage sites.

Fig. 7B is a schematic drawing of plasmid pNEB-C1-BamG.

Fig. 7C is a schematic drawing of plasmid pSP-C1-mu0-1.3.

Fig. 7D is a schematic drawing of plasmid pCMV- β .

Fig. 7E is a schematic drawing of plasmid pSP-C1-mu0-1.3-CMV- β .

Fig. 7F is a schematic drawing of plasmid pGEM-3Z.

Fig. 7G is a schematic drawing of plasmid pBS-C1-BamI.

Fig. 7H is a schematic drawing of plasmid pGEM-C1-mu9-10.

Fig. 7I is a schematic drawing of plasmid pBS-C1-BamE.

Fig. 7J is a schematic drawing of plasmid pGEM-C1-mu9-17.

Fig. 7K is a schematic drawing of plasmid pC1-CMV-LacZ, illustrating C1 Ad mu 0 to 1.3, followed by the CMV promoter, a splice donor/splice acceptor sequence (SD/SA), the LacZ gene, a SV40 poly A sequence and C1 Ad mu 9-17, and additional plasmid sequence. The plasmid also contains an ori and Amp^R sequence.

Fig. 8A is a schematic drawing of pSP72-Pac with indicated restriction endonuclease enzyme cleavage sites.

Fig. 8B is a schematic drawing of pNEB-C68-BamE.

Fig. 8C is a schematic drawing of pSP-C68-mu 0-1.3.

5 Fig. 8D is a schematic drawing of pCMV-B.

Fig. 8E is a schematic drawing of pSP-C68-mu 0-1.3-CMV-B.

Fig. 8F is a schematic drawing of pGEM-3Z.

Fig. 8G is a schematic drawing of pBS-C68-BamF.

10 Fig. 8H is a schematic drawing of pGEM-C68-mu9-10.

Fig. 8I is a schematic drawing of pBS-C68-BamB.

Fig. 8J is a schematic drawing of pGEM-C68-mu9-16.7.

15 Fig. 8K is a schematic drawing of pC68-CMV-LacZ, illustrating C68 Ad mu 0 to 1.3, followed by the CMV promoter, an SD/SA, the LacZ gene, a SV40 poly A sequence and C68 Ad mu 9-16.7, and additional plasmid sequence. The plasmid also contains an ori and an Amp^R sequence.

Fig. 9A is a schematic drawing of pEGFP-1 (Clontech, Palo Alto, CA).

Fig. 9B is a schematic drawing of a Not-I synthetic linker (New England Biolabs).

25 Fig. 9C is a schematic drawing of pEGFP-Notx2.

Fig. 9D is a schematic drawing of pC1-CMV-LacZ (from Fig. 7K).

Fig. 9E is a schematic drawing of pC68-CMV-LacZ (from Fig. 8K).

30 Fig. 9F is a schematic drawing of pC1-CMV-GFP, in which the GFP coding region replaces the LacZ gene of pC1-CMV-LacZ.

Fig. 9G is a schematic drawing of pC68-CMV-GFP, in which the GFP coding region replaces the LacZ gene of pC68-CMV-LacZ.

35

Fig. 10A is a schematic drawing of pC68-CMV-GFP as discussed in Fig. 9G.

Fig. 10B is a schematic drawing of the C68 genome.

5 Fig. 10C is a schematic drawing of the C68-SspI-A fragment, which is 35,199 nucleotides.

Fig. 10D is a schematic drawing of the C68-CMV-GFP genome, which is formed by homologous recombination between the C68 mu 9-16.7 sequence in pC68-CMV-GFP and
10 the homologous sequence in the C68-SspI-A fragment.

Fig. 11A is a schematic drawing of pNEB-C1-BamG.

Fig. 11B is a schematic drawing of the C1 genome.

15 Fig. 11C is a schematic drawing of pNEB-C1-AscI-B.

Fig. 11D is a schematic drawing of a Not-I synthetic linker (New England Biolabs).

Fig. 11E is a schematic drawing of pNEB-C1-AscI-B-NotI.
20

Fig. 11F is a schematic drawing of the C1 genome.

Fig. 11G is a schematic drawing of the AscI-A fragment of the C1 genome.

25 Fig. 11H is a schematic drawing of the C1 genome engineered to have a unique NotI site replacing the Spe-I site in the E1B 21K protein coding region.

Detailed Description of the Invention

30 The present invention provides novel adenovirus vectors and packaging cell lines to produce those vectors for use in the *in vitro* production of recombinant proteins or fragments or other reagents, and for use in the treatment of inherited or acquired genetic disorders and abnormalities in humans and other mammals. The

present invention also provides novel vaccine compositions which comprise those vectors, the vectors comprising an inserted heterologous gene encoding an antigen from an infectious agent.

5 The methods of the invention involve delivering one or more selected heterologous gene(s) to a mammalian patient by administering a vector of the invention. Because the various vector constructs are derived from chimpanzee rather than from human adenoviruses, the
10 immune system of the patient is not primed to respond immediately to the vector as a foreign antigen. A similar response would be expected where the patient was any mammal other than chimpanzee.

 Use of the compositions of this invention thus
15 permits a more stable expression of the selected transgene when administered to a non-chimpanzee, preferably human patient. Use of the compositions of this invention for vaccination permits presentation of a selected antigen for the elicitation of protective immune
20 responses. The recombinant chimpanzee adenoviruses of this invention may also be used for producing heterologous gene products *in vitro*.

I. Cloning of Chimpanzee Adenovirus Sequences

 Chimpanzee adenovirus, strain Bertha or C1
25 [ATCC Accession No. VR-20] and chimpanzee adenovirus, strain Pan-9 or CV68 [ATCC Accession No. VR-594] were obtained from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD. For convenience, the virus CV68 is referred to throughout this specification
30 as "C68". The viruses were originally isolated from feces [C1, Rowe et al, Proc. Soc. Exp. Med., 91:260 (1956)] or mesenteric lymph node [C68, Basnight et al, Am. J. Epidemiol., 94:166 (1971)] of infected chimpanzees.

Little is known about these viruses. However, limited restriction and immunological analyses have been published. For example, C1 was shown to be most similar to Subgroup B human adenoviruses, but it was
5 not neutralized by heterologous sera, and no hemagglutination inhibition was observed [Wigand et al, Intervirology, 30:1 (1989)]. Restriction analysis demonstrated that C68 was most similar to human Ad4 serotype (Subgroup E), but only 1 in 16 enzymes tested
10 did not distinguish C68 and Ad4 [Kitchingman, Gene, 20:205 (1982)].

Both chimpanzee adenoviruses grow well in human cells and were propagated in human embryonic kidney 293 cells. As described in detail in Examples 1 and 2
15 below, genomic DNA was isolated from purified virus stocks and digested with a panel of restriction enzymes and the restriction fragments cloned and sequenced. The genomic nucleotide sequence of C1 adenovirus is set out in SEQ ID NO: 1. The genomic nucleotide sequence of C68
20 adenovirus is set out in SEQ ID NO: 2.

Preliminary analysis of the sequence homology between C1, C68 and human adenoviruses was in agreement with the previously mentioned immunologic or restriction enzyme analysis. By reference to Figs. 1A-1C
25 and 3A to 3D, it is shown that the putative E1 region of C1 occurs between about nucleotides 480 and about 3958; and of C68 between about nucleotides 480 and about 3956.

Other gene regions of C1 are identified by homology of the C1 sequence of SEQ ID NO: 1 to the known
30 sequences of human adenoviruses Ad3, Ad5 and Ad7. Similarly, other gene regions of C68 are identified by homology of the C68 sequence of SEQ ID NO: 2 to the known sequence of human adenovirus Ad4 and Ad5. The genomic regions encoding early gene functions for E2a, E2b, E3,

E4, as well as the regions of C1 and C68 encoding late adenoviral gene products, are identified in Tables I and II below.

Table I

5		C1 Chimpanzee Genome		
	<u>Gene</u>	<u>Nucleotides</u>	<u>Map Units</u>	<u>Size</u> (nucl./mu)
	E1A	480-1540	1.4-4.3	1060/3.0
	E1B	1566-3958	4.4-11.1	2392/6.7
	E2A	23665-22065	66.6-62.1	1600/4.5
10	E2B	10379-3959	29.2-11.1	6420/18.1
	E3	27181-31375	76.5-88.3	4194/11.8
	E4	35228-32535	99.2-91.6	2693/7.6
	L1	10893-13864	30.7-39.0	2971/8.4
	L2	13925-17591	39.2-49.5	3666/10.3
15	L3	17641-22083	49.7-62.2	4442/12.5
	L4	23697-27813	66.7-78.3	4116/11.6
	L5	31556-32551	88.8-91.6	995/2.8

Table II

20		C68 Chimpanzee Genome		
	<u>Gene</u>	<u>Nucleotides</u>	<u>Map Units</u>	<u>Size</u> (nucl./mu)
	E1A	480-1521	1.3-4.2	1041/2.9
	E1B	1560-3956	4.3-10.8	2396/6.6
	E2A	23370-21787	64.0-59.7	1583/4.3
	E2B	10346-3957	28.3-10.8	6389/17.5
25	E3	26806-31877	73.4-87.3	5071/13.9
	E4	36193-33486	99.1-91.7	2707/7.4
	L1	10823-13817	29.6-37.8	2994/8.2
	L2	13884-17431	38.0-47.7	3547/9.7
	L3	17480-21804	47.9-59.7	4324/11.8
30	L4	23399-27439	64.1-75.1	4040/11.1
	L5	32134-33502	88.0-91.7	1368/3.7

Our preliminary experiments demonstrated that human antisera do not neutralize the chimpanzee adenoviruses in neutralizing antibody assays (see, e.g.,
 35 International patent application PCT95/03035), thus indicating the desirability of vectors prepared from these sequences for gene therapy in humans. As further described in the examples, plasmids establishing chimpanzee adenovirus E1-expressing cell lines and

recombinant E1-deleted adenoviruses expressing a transgene are prepared.

The viral sequences used in the vectors and cell lines described below may be generated by using the teachings and references contained herein, coupled with standard recombinant molecular cloning techniques known and practiced by those skilled in the art.

II. E1-Expressing Complementation Cell Lines

To generate recombinant chimpanzee adenoviruses (Ad) deleted in any of the genes described above, the function of the deleted gene region, if essential to the replication and infectivity of the virus, must be supplied to the recombinant virus by a helper virus or cell line, i.e., a complementation or packaging cell line. For example, to generate a replication-defective chimpanzee adenovirus vector, a cell line is needed which expresses the E1 gene products of the chimpanzee adenovirus. The protocol for the generation of the cell lines expressing the chimpanzee E1 gene products (Examples 3 and 4) is followed to generate a cell line which expresses any selected chimpanzee adenovirus gene.

Conventional assays were not useful in identifying the chimpanzee adenovirus E1-expressing cell line and a novel AAV augmentation assay was developed to identify the chimpanzee adenovirus E1-expressing cell line. This assay is useful to identify E1 function in cell lines made by using the E1 genes of other uncharacterized adenoviruses, e.g., from other species. That assay is described in Example 4B below.

According to this invention, the selected chimpanzee adenovirus gene, e.g., E1, is under the transcriptional control of a promoter for expression in a selected parent cell line. Inducible or constitutive promoters may be employed for this purpose. Among

inducible promoters are included the sheep metallothionine promoter, inducible by zinc, or the mouse mammary tumor virus (MMTV) promoter, inducible by a glucocorticoid, particularly, dexamethasone. Other
5 inducible promoters, such as those identified in International patent application W095/13392, published May 18, 1995, and incorporated by reference herein may also be used in the production of packaging cell lines according to this invention. Constitutive promoters in
10 control of the expression of the chimpanzee adenovirus gene may be employed also. The promoter used to express E1 as exemplified below is the well-known constitutive murine PGK promoter.

A parent cell is selected for the
15 generation of a novel cell line expressing any desired C1 or C68 gene. Without limitation, such a parent cell line may be HeLa [ATCC Accession No. CCL 2], A549 [ATCC Accession No. CCL 185], KB [CCL 17], Detroit [e.g., Detroit 510, CCL 72] and WI-38 [CCL 75] cells. These
20 cell lines are all available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA. Other suitable parent cell lines may be obtained from other sources.

The present invention provides an
25 exemplary cell line which contains and expresses the chimpanzee C68 or C1 Ad E1 gene, as described in detail in Examples 3 and 4 below. Briefly described, the entire chimpanzee adenovirus E1 region was cloned and, by a series of plasmid manipulations, it was placed under the
30 control of a murine PGK promoter in a desired shuttle vector. See Figs. 5A-5G and 6A-6G.

After the desired shuttle vector containing the adenoviral sequences (i.e., pGPGK-C68 E1 described in Example 3) was transfected into the selected
35 parental cell line (e.g., HeLa), expression of the E1

gene was detected. Conventional G418 selection as described in Example 4A was used to generate stable clones of these E1-expressing cells. The resulting cell line is thus able to provide chimpanzee Ad E1 gene products to the replication-defective recombinant virus (see Example 5) to allow productive infection and recovery of the recombinant virus.

The E1-expressing cell lines are useful in the generation of recombinant chimpanzee adenovirus E1 deleted vectors. Cell lines constructed using essentially the same procedures that express one or more other chimpanzee adenoviral gene products are useful in the generation of recombinant chimpanzee adenovirus vectors deleted in the genes that encode those products.

Further, cell lines which express other human Ad E1 gene products are also useful in generating the chimpanzee recombinant Ads of this invention.

III. Recombinant Viral Particles as Vectors

The compositions of this invention comprise desirable viral vectors, that deliver a functional, normal or therapeutic gene to cells. Such vectors comprise chimpanzee adenovirus DNA sequence and a selected heterologous gene operatively linked to regulatory sequences which direct expression of the gene. The vector is capable of expressing the gene product in an infected mammalian cell. The vector is preferably functionally deleted in one or more viral genes. A minigene comprises the heterologous gene under the control of regulatory sequences. Optional helper viruses and/or packaging cell lines supply to the chimpanzee viral vectors any necessary products of deleted adenoviral genes.

The term "functionally deleted" means that a sufficient amount of the gene region is removed or otherwise damaged, e.g., by mutation or modification, so

that the gene region is no longer capable of producing functional products of gene expression. If desired, the entire gene region may be removed.

5 The viral sequences, helper viruses, if needed, and recombinant viral particles, and other vector components and sequences employed in the construction of the vectors described herein are obtained as described above. The DNA sequences of the two chimpanzee
10 adenoviruses are employed to construct vectors and cell lines useful in the preparation of such vectors.

Modifications of the nucleic acid sequences forming the vectors of this invention, including sequence deletions, insertions, and other mutations may be generated using standard molecular
15 biological techniques and are within the scope of this invention.

A. The "Minigene"

The methods employed for the selection of the transgene, the cloning and construction
20 of the "minigene" and its insertion into the viral vector are within the skill in the art given the teachings provided herein. By "minigene" is meant the combination of a selected heterologous gene and the other regulatory elements necessary to transcribe the gene and express the
25 gene product in a host cell. The gene is operatively linked to regulatory components in a manner which permits its transcription. Such components include conventional regulatory elements necessary to drive expression of the transgene in a cell transfected with the viral vector.
30 Thus the minigene also contains a selected promoter which is linked to the transgene and located, with other regulatory elements, within the selected viral sequences of the recombinant vector.

Selection of the promoter is a
35 routine matter and is not a limitation of this invention.

Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the amount of the transgene to be expressed. For example, a desirable promoter is that of the
5 cytomegalovirus immediate early promoter/enhancer [see, e.g., Boshart et al, Cell, 41:521-530 (1985)]. Another desirable promoter includes the Rous sarcoma virus LTR promoter/enhancer. Still another promoter/enhancer sequence is the chicken cytoplasmic β -actin promoter [T.
10 A. Kost et al, Nucl. Acids Res., 11(23):8287 (1983)]. Other suitable or desirable promoters may be selected by one of skill in the art.

The minigene may also desirably contain nucleic acid sequences heterologous to the viral
15 vector sequences including sequences providing signals required for efficient polyadenylation of the transcript (poly-A or pA) and introns with functional splice donor and acceptor sites. A common poly-A sequence which is employed in the exemplary vectors of this invention is
20 that derived from the papovavirus SV-40. The poly-A sequence generally is inserted in the minigene following the transgene sequences and before the viral vector sequences. A common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence.
25 A minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional [see, e.g., Sambrook et al, "Molecular Cloning. A Laboratory
30 Manual.", 2d edit., Cold Spring Harbor Laboratory, New York (1989) and references cited therein] and many such sequences are available from commercial and industrial sources as well as from Genbank.

As above stated, the minigene is
35 located in the site of any selected deletion in the viral

vector, such as the site of the E1 gene region deletion or E3 gene region deletion, among others which may be selected.

B. Construction of The Viral Plasmid

5 *Vector*

The chimpanzee adenovirus vectors useful in this invention include recombinant, defective adenoviruses, that is, chimpanzee adenovirus sequences functionally deleted in the E1a or E1b genes, and
10 optionally bearing other mutations, e.g., temperature-sensitive mutations or deletions in other genes. It is anticipated that these chimpanzee sequences are also useful in forming hybrid vectors from other adenovirus and/or adeno-associated virus sequences. Homologous
15 adenovirus vectors prepared from human adenoviruses are described in the published literature [see, for example, Kozarsky I and II, cited above, and references cited therein, U. S. Patent No. 5,240,846].

In the construction of useful
20 chimpanzee adenovirus vectors for delivery of a gene to the human (or other mammalian) cell, a range of adenovirus nucleic acid sequences can be employed in the vectors. A vector comprising minimal chimpanzee adenovirus sequences may be used in conjunction with a
25 helper virus to produce an infectious recombinant virus particle. The helper virus provides essential gene products required for viral infectivity and propagation of the minimal chimpanzee adenoviral vector. When only one or more selected deletions of chimpanzee adenovirus
30 genes are made in an otherwise functional viral vector, the deleted gene products can be supplied in the viral vector production process by propagating the virus in a selected packaging cell line that provides the deleted gene functions in trans.

1. Recombinant Minimal Adenovirus

A minimal chimpanzee Ad virus is a viral particle containing only the adenovirus cis-elements necessary for replication and virion
5 encapsidation, which cis-elements flank the heterologous gene. That is, the vector contains only the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences of the adenoviruses of this invention (which function as origins of replication) and the native 5' packaging/enhancer
10 domains (that contain sequences necessary for packaging linear Ad genomes and enhancer elements for the E1 promoter). See, for example, the techniques described for preparation of a "minimal" human Ad vector in International Patent Application WO96/13597, published
15 May 9, 1996, and incorporated herein by reference.

2. Other Defective Adenoviruses

Recombinant, replication-deficient adenoviruses of this invention may also contain more than the minimal chimpanzee adenovirus sequences
20 defined above. These other Ad vectors can be characterized by deletions of various portions of gene regions of the virus, and infectious virus particles formed by the optional use of helper viruses and/or packaging cell lines, as described herein.

25 As one example, suitable vectors may be formed by deleting all or a sufficient portion of the adenoviral immediate early gene E1a and delayed early gene E1b, so as to eliminate their normal biological functions. Replication-defective E1-deleted viruses are
30 capable of replicating and producing infectious virus when grown on a chimpanzee adenovirus-transformed, complementation cell line containing functional adenovirus E1a and E1b genes which provide the corresponding gene products in trans. Based on the
35 homologies to known adenovirus sequences, it is

anticipated that, as is true for the human recombinant E1-deleted adenoviruses of the art, the resulting recombinant chimpanzee adenovirus is capable of infecting many cell types and can express a transgene, but cannot
5 replicate in most cells that do not carry the chimpanzee E1 region DNA unless the cell is infected at a very high multiplicity of infection.

As another example, all or a portion of the adenovirus delayed early gene E3 may be
10 eliminated from the chimpanzee adenovirus sequence which forms a part of the recombinant virus. The function of chimpanzee E3 is believed to be irrelevant to the function and production of the recombinant virus particle.

15 Chimpanzee adenovirus vectors may also be constructed having a deletion of the E4 gene. Still another vector of this invention contains a deletion in the delayed early gene E2a.

Deletions may also be made in
20 any of the late genes L1 through L5 of the chimpanzee adenovirus genome. Similarly, deletions in the intermediate genes IX and IVa₂ may be useful for some purposes. Other deletions may be made in the other structural or non-structural adenovirus genes.

25 The above discussed deletions may be used individually, i.e., an adenovirus sequence for use in the present invention may contain deletions of E1 only. Alternatively, deletions of entire genes or portions thereof effective to destroy their biological
30 activity may be used in any combination. For example, in one exemplary vector, the adenovirus sequence may have deletions of the E1 genes and the E4 gene, or of the E1, E2a and E3 genes, or of the E1 and E3 genes, or of E1, E2a and E4 genes, with or without deletion of E3, and so
35 on. As discussed above, such deletions may be used in

combination with other mutations, such as temperature-sensitive mutations, to achieve a desired result.

The minigene containing the transgene may be inserted optionally into any deleted
5 region of the chimpanzee Ad virus. Alternatively, the minigene may be inserted into an existing gene region to disrupt the function of that region, if desired.

The construction of exemplary E1-deleted chimpanzee Ad virus vectors is described in
10 detail in Example 5 below. Desirably, such a vector contains chimpanzee adenovirus sequences Ad m.u. 0-1.3, followed by a minigene containing the transgene of interest (e.g., a therapeutic gene for the correction of a genetic defect in a patient or a marker gene to
15 visualize infected cells) and the sequence Ad m.u. 9 to 100 of C1 or C68. These recombinant adenoviruses are functionally deleted of E1a and E1b.

C. *Production of the Recombinant Viral Particle*

20 1. Helper Viruses

Depending upon the chimpanzee adenovirus gene content of the viral vectors employed to carry the minigene, a helper adenovirus or non-replicating virus fragment may be necessary to provide
25 sufficient chimpanzee adenovirus gene sequences necessary to produce an infective recombinant viral particle containing the minigene.

Useful helper viruses contain selected adenovirus gene sequences not present in the
30 adenovirus vector construct and/or not expressed by the packaging cell line in which the vector is transfected. A preferred helper virus is desirably replication-defective and contains a variety of adenovirus genes in addition to the sequences described above. The helper

virus is desirably used in combination with the E1-expressing cell lines described herein.

Most preferably for C68, the "helper" virus is a fragment formed by clipping the C terminal end of the C68 genome with SspI, which removes about 1300 bp from the left end of the virus. This clipped virus is then co-transfected into the E1-expressing cell line with the plasmid DNA, thereby forming the recombinant virus by homologous recombination with the C68 sequences in the plasmid.

Because there is no similarly unique restriction site in the 5' end of C1, to create a recombinant virus, the SpeI site at position 1733 is replaced with a unique Not I site, generating the modified C1 NotI genome of about 35,526 bp. See, e.g., Figs 12A-12F.

Helper viruses may also be formed into poly-cation conjugates as described in Wu et al, J. Biol. Chem., 264:16985-16987 (1989); K. J. Fisher and J. M. Wilson, Biochem. J., 299:49 (April 1, 1994). Helper virus may optionally contain a second reporter minigene. A number of such reporter genes are known to the art. The presence of a reporter gene on the helper virus which is different from the transgene on the adenovirus vector allows both the Ad vector and the helper virus to be independently monitored. This second reporter is used to enable separation between the resulting recombinant virus and the helper virus upon purification.

2. Assembly of Viral Particle and Infection of a Cell Line

Assembly of the selected DNA sequences of the adenovirus, and the transgene and other vector elements into various intermediate plasmids and shuttle vectors, and the use of the plasmids and vectors

to produce a recombinant viral particle are all achieved using conventional techniques. Such techniques include conventional cloning techniques of cDNA such as those described in texts [Sambrook et al, cited above], use of
5 overlapping oligonucleotide sequences of the adenovirus genomes, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence. Standard transfection and co-transfection techniques are employed, e.g., CaPO_4 precipitation techniques. Other
10 conventional methods employed include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.

For example, following the
15 construction and assembly of the desired minigene-containing viral vector, the vector is transfected *in vitro* in the presence of a helper virus into the packaging cell line. Homologous recombination occurs between the helper and the vector sequences, which
20 permits the adenovirus-transgene sequences in the vector to be replicated and packaged into virion capsids, resulting in the recombinant viral vector particles. The current method for producing such virus particles is transfection-based. However, the invention is not
25 limited to such methods.

The resulting recombinant chimpanzee adenoviruses are useful in transferring a selected transgene to a selected cell. In *in vivo* experiments with the recombinant virus grown in the
30 packaging cell lines, the E1-deleted recombinant chimpanzee adenovirus demonstrates utility in transferring a transgene to a non-chimpanzee, preferably a human, cell.

IV. Use of the Recombinant Virus Vectors

The resulting recombinant chimpanzee adenovirus containing the minigene (produced by cooperation of the adenovirus vector and helper virus or adenoviral vector and packaging cell line, as described above) thus provides an efficient gene transfer vehicle which can deliver the transgene to a human patient *in vivo* or *ex vivo*.

The above-described recombinant vectors are administered to humans according to published methods for gene therapy. A chimpanzee viral vector bearing the selected transgene may be administered to a patient, preferably suspended in a biologically compatible solution or pharmaceutically acceptable delivery vehicle. A suitable vehicle includes sterile saline. Other aqueous and non-aqueous isotonic sterile injection solutions and aqueous and non-aqueous sterile suspensions known to be pharmaceutically acceptable carriers and well known to those of skill in the art may be employed for this purpose.

The chimpanzee adenoviral vectors are administered in sufficient amounts to transduce the human cells and to provide sufficient levels of gene transfer and expression to provide a therapeutic benefit without undue adverse or with medically acceptable physiological effects, which can be determined by those skilled in the medical arts. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to the liver, intranasal, intravenous, intramuscular, subcutaneous, intradermal, oral and other parental routes of administration. Routes of administration may be combined, if desired.

Dosages of the viral vector will depend primarily on factors such as the condition being treated, the age, weight and health of the patient, and may thus

vary among patients. For example, a therapeutically effective human dosage of the viral vector is generally in the range of from about 20 to about 100 ml of saline solution containing concentrations of from about 1×10^9 to 1×10^{11} pfu/ml virus vector. A preferred human dosage is estimated to be about 50 ml saline solution at 2×10^{10} pfu/ml. The dosage will be adjusted to balance the therapeutic benefit against any side effects and such dosages may vary depending upon the therapeutic application for which the recombinant vector is employed. The levels of expression of the transgene can be monitored to determine the frequency of dosage administration.

An optional method step involves the co-administration to the patient, either concurrently with, or before or after administration of the viral vector, of a suitable amount of a short acting immune modulator. The selected immune modulator is defined herein as an agent capable of inhibiting the formation of neutralizing antibodies directed against the recombinant vector of this invention or capable of inhibiting cytolytic T lymphocyte (CTL) elimination of the vector. The immune modulator may interfere with the interactions between the T helper subsets (T_{H1} or T_{H2}) and B cells to inhibit neutralizing antibody formation. Alternatively, the immune modulator may inhibit the interaction between T_{H1} cells and CTLs to reduce the occurrence of CTL elimination of the vector.

A variety of useful immune modulators and dosages for use of same are disclosed, for example, in Yang et al., J. Virol., 70(9) (Sept., 1996); International Patent Application No. WO96/12406, published May 2, 1996; and International Patent Application No. PCT/US96/03035, all incorporated herein by reference.

The recombinant chimpanzee adenoviruses may also be employed as vaccines or immune response-inducing compositions. The present invention provides a recombinant replication-defective chimpanzee Ad which can
5 contain in any of its adenovirus sequence deletions a gene encoding a desired antigen. The chimpanzee adenovirus is likely to be better suited for use as a live recombinant virus vaccine in different animal species compared to an adenovirus of human origin. The
10 recombinant adenoviruses can be used as prophylactic or therapeutic vaccines against any pathogen for which the antigen(s) crucial for induction of an immune response and able to limit the spread of the pathogen has been identified and for which the cDNA is available.

15 Because the recombinant chimpanzee adenoviruses described above are deleted in the E1 sequences, the adenoviruses are replication defective and thus highly unlikely to spread within a host or among individuals. The recombinant virus lacks oncogenic
20 potential because the E1 gene, that can function as an oncogene in some adenovirus strains, has been deleted.

With respect to efficacy, the recombinant, replication-defective adenoviruses of this invention are expected to be highly efficacious at inducing cytolytic T
25 cells and antibodies to the inserted heterologous antigenic protein expressed by the virus. This has been demonstrated with a recombinant, replication-defective human Ad containing a sequence encoding the rabies virus glycoprotein as the heterologous gene. See, e.g., Z. Q.
30 Xiang et al., Virology, 219:220-227 (1996).

As described above and in the examples below, in the site of the E1 deletion of either of the two chimpanzee adenoviruses of this invention, and under control of a promoter heterologous to adenovirus, a
35 sequence encoding a protein heterologous to the

adenovirus is inserted using techniques known to those of skill in the art. The heterologous nucleic acid encodes a protein which is desirably capable of inducing an immune response to a pathogen when administered to an immunocompetent host. Such a protein may be a protein from, among others, rabies virus, human papilloma virus, human immunodeficiency virus (HIV), and respiratory syncytial virus (RSV), as well as antigens associated with diseases of other mammals.

It is also anticipated that the vaccine method of the present invention may be employed with a tumor-associated protein specific for a selected malignancy. These tumor antigens include viral oncogenes, such as E6 and E7 of human papilloma virus, or cellular oncogenes such as mutated ras or p53. Particularly, where the condition is human immunodeficiency virus (HIV) infection, the protein is preferably HIV glycoprotein 120 for which sequences are available from GenBank. Where the condition is human papilloma virus infection, the protein is selected from the group consisting of E6, E7 and/or L1 [Seedorf, K. et al, Virology, 145:181-185 (1985)]. Where the condition is respiratory syncytial virus infection, the protein is selected from the group consisting of the glyco- (G) protein and the fusion (F) protein, for which sequences are available from GenBank. In addition to these proteins, other virus-associated proteins, including proteins which are antigens for disease-causing agents of other mammals, e.g., domestic animals, horses, farm animals, etc., are readily available to those of skill in the art. Selection of the heterologous proteins is not a limiting factor in the design of vaccine compositions of this invention.

A recombinant replication-defective chimpanzee adenoviral vector bearing a gene encoding an immunogenic protein may be administered to a human or other mammalian patient, preferably suspended in a biologically compatible solution or pharmaceutically acceptable delivery vehicle. A suitable vehicle is sterile saline. Other aqueous and non-aqueous isotonic sterile injection solutions and aqueous and non-aqueous sterile suspensions known to be pharmaceutically acceptable carriers and well known to those of skill in the art may be employed for this purpose.

Optionally, a vaccinal composition of the invention may be formulated to contain other components, including, e.g. adjuvants, stabilizers, pH adjusters, preservatives and the like. Such components are well known to those of skill in the vaccine art.

The recombinant, replication defective adenoviruses are administered in a "pharmaceutically effective amount", that is, an amount of recombinant adenovirus that is effective in a route of administration to transfect the desired cells and provide sufficient levels of expression of the selected gene to provide a vaccinal benefit, i.e., some measurable level of protective immunity.

Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, intranasal, intramuscular, intratracheal, subcutaneous, intradermal, rectal, oral and other parental routes of administration. Routes of administration may be combined, if desired, or adjusted depending upon the immunogen or the disease. For example, in prophylaxis of rabies, the subcutaneous, intratracheal and intranasal routes are preferred. The route of administration primarily will depend on the nature of the disease being treated.

Doses or effective amounts of the recombinant replication-defective Ad virus will depend primarily on factors such as the condition, the selected gene, the age, weight and health of the animal, and may thus vary among animals. For example, a prophylactically effective amount or dose of the Ad vaccine is generally in the range of from about 100 μ l to about 10 ml of saline solution containing concentrations of from about 1×10^4 to 1×10^7 plaque forming units (pfu) virus/ml. A preferred dose is from about 1 to about 10 ml saline solution at the above concentrations. The levels of immunity of the selected gene can be monitored to determine the need, if any, for boosters. Following an assessment of antibody titers in the serum, optional booster immunizations may be desired.

An additional use of the recombinant adenovirus vectors described herein resides in their use as expression vectors for the production of the products encoded by the heterologous genes. For example, the recombinant adenoviruses containing a gene inserted into the location of an E1 deletion may be transfected into an E1-expressing cell line as described above. The transfected cells are then cultured in the conventional manner, allowing the recombinant adenovirus to express the gene product from the promoter. The gene product may then be recovered from the culture medium by known conventional methods of protein isolation and recovery from culture.

The following examples illustrate the cloning of the chimpanzee adenoviruses and the construction and testing of the chimpanzee Ad E1 expressing cell line and the construction of exemplary recombinant adenovirus vectors of the present invention. These examples are illustrative only, and do not limit the scope of the present invention.

Example 1 - Virus Stocks and Propagation

The C1 [ATCC Accession No. VR-20] and C68 [ATCC Accession No. 594] virus stocks were obtained and propagated in 293 cells [ATCC CRL1573] cultured in Dulbecco's Modified Eagles Medium (DMEM; Sigma, St. Louis, MO.) supplemented with 10% fetal calf serum (FCS) [Sigma or Hyclone, Logan, UT] and 1 % Penicillin-Streptomycin (Sigma). Infection of 293 cells was carried out in DMEM supplemented with 2% FCS for the first 24 hours, after which FCS was added to bring the final concentration to 10%. Infected cells were harvested when 100% of the cells exhibited virus-induced cytopathic effect (CPE), collected, and concentrated by centrifugation. Cell pellets were resuspended in 10 mM Tris (pH 8.0), and lysed by 3 cycles of freezing and thawing.

Virus preparations were obtained following two ultra centrifugation steps on cesium chloride density gradients and stocks of virus were diluted to 1×10^{12} particles/ml in 10 mM Tris/100 mM NaCl/50% glycerol and stored at -70°C .

Example 2 - Cloning and Sequencing of Viral Genomic DNA

Genomic DNA was isolated from the purified virus preparations of Example 1, following standard methods [see, e.g., M. S. Horwitz et al, "Adenoviridae and Their Replication", Virology, second edition, pp. 1712, ed. B. N. Fields et al, Raven Press Ltd., New York (1990); B. J. Carter, in "Handbook of Parvoviruses", ed. P. Tijsser, CRC Press, pp. 155-168 (1990)] and digested with a panel of 16 restriction enzymes following the manufacturers' recommendations. Enzymes that cut the DNA 10-15 times were utilized for cloning of the viral DNA into pBluescript SK+. Except as noted, all restriction

and modifying enzymes used in this and the following examples were obtained from Boehringer Mannheim, Indianapolis, IN.

Manipulation of the genomic DNA to remove the covalently attached terminal protein was performed [Berkner and Sharp, Nucleic Acids Res., 11: 6003 (1983)]. Taking advantage of the absence of Pac-I restriction sites, synthetic PacI linkers (New England Biolabs, Beverly, MA) were ligated onto the ends of the genomic DNA. Genomic DNA was digested with BamHI, PstI, SalI or XbaI and the restriction fragments (all but the genomic terminal fragments) were cloned into pBluescript SK+ (Stratagene, La Jolla, CA). Fragments containing the left and right genomic termini were cloned into pNEB-193 (New England Biolabs, Beverly, MA) as Pac-I/BamHI or Pac-I/Pst-I fragments.

The clones generated for C1 and C68 are illustrated in Figs. 1C and 3C, respectively. The cloned fragments are described in Table III(C1) [nucleotide sequence numbers correspond with SEQ ID NO: 1] and Table IVA-IVB (C68) [nucleotide sequence numbers correspond with SEQ ID NO: 2].

Table III

	<u>Construct Name</u>	<u>Insert Size</u>	<u>Clone #</u>	<u>Sequence</u>
5	pBS:C1-Bam-A	8477	250,260 281	6135-14611
	pBS:C1-Bam-B	8253	285	24678-32930
	pBS:C1-Bam-C	3990	252	17259-21248
10	pBS:C1-Bam-D	3429	263,269 275	21250-24677
	pBS:C1-Bam-E	2537	251	3598- 6134
	pBS:C1-Bam-F	2203	267,270, 279	14612-16814
	pNEB:C1-Bam-G	1927	516	1-1927 left end
15	pBS:C1-Bam-H	1632	486,487	32931-34562
	pBS:C1-Bam-I	1538	288-293 483,485	2060- 3597
	pNEB:C1-Bam-J	962	519	34563-35524 right end
20	pBS:C1-Bam-K	288	256,295 296,,298	16971-17258
	pBS:C1-Bam-L	156	260	16815-16970
	pBS:C1-Bam-M	132	259,261 262	1928- 2059
25	pBS:C1-Bam-A/Pst		423-428	subclone of 250
	pBS:C1-Bam-B/HindIII		429-434	subclone of 285
	pNEB:C-1AscB	7937	955	1-7937 left end

Table IVA

	<u>Construct Name</u>	<u>Size</u>	<u>Clone #</u>	<u>Sequence</u>
	pBS:C68-Pst-A	6768		24790-31554
5	pBS:C68-Pst-B	6713	133,141 213-217, 303-305	4838-11550
	pBS:C68-Pst-C	5228	219-221	14811-20038
	pBS:C68-Pst-D	2739	78,140	12072-14810
10	pBS:C68-Pst-E	2647	127,129 146,151	20039-22685
	pBS:C68-Pst-F	1951	138,149	32046-33996
	pNEB:C68-Pst-G	1874	502,505 506	1-1874 left end
15	pBS:C68-Pst-H	1690	128,135 145,152	23094-24783
	pBS:C68-Pst-I	1343	222-224	33997-35339
	pNEB:C68-Pst-J	1180	508	35340-36519 right end
20	pBS:C68-Pst-K	1111	87,131 132,136 225-230	2763-3873
	pBS:C68-Pst-L	964	320,321, 323,324	3874-4837
25	pBS:C68-Pst-M	888	319,322	1875-2762
	pBS:C68-Pst-N	408	84,125 130	22686-23093
	pBS:C68-Pst-O	380		31666-32045
	pBS:C68-Pst-P	285	79,126	11551-11835
30	pBS:C68-Pst-Q	236		11836-12071
	pBS:C68-Pst-R	114	82	31552-31665

Table IVB

	<u>BamHI Fragments</u>	<u>Size</u>	<u>Clone #</u>	<u>Sequence</u>
	pBS:C68-Bam-A	16684		19836-36519 right end
5	pBS:C68-Bam-B	8858	95,99 101-103 119-121, 165, 166, 169,171	3582-12439
10	pBS:C68-Bam-C	4410	104,106 167,179 171	12440-16849
	pBS:C68-Bam-D	2986	195-197	16850-19835
	pNEB:C68-Bam-E	2041	537,545	1- 2041 left end
15	pBS:C68-Bam-F	1540	198-200	2042- 3581

HindIII Fragments

pBR:C-68-Hind-B	9150	489,419, 492	23471-32620
-----------------	------	-----------------	-------------

20 Cloned restriction fragments were ordered in the genome by comparison to known adenoviral sequences. The nucleotide sequence of both viruses was determined [Commonwealth Biotechnologies Incorporated, Richmond, VA]. The nucleotide sequence of the top strand of C1 DNA

25 is reported in SEQ ID NO: 1. The nucleotide sequence of the top strand of C68 DNA is reported in SEQ ID NO: 2. Restriction maps were generated using a number of enzymes and compared to data obtained from restricted genomic DNA following electrophoreses on agarose gels.

30 Regulatory and coding regions in the viral DNA sequences were identified by homology to known adenoviral sequences using the Mac Vector program (Oxford Molecular Group) and a MacIntosh Quadra 610 computer (Apple Computer, Cupertino, CA). See Tables I and II. Open

reading frames were translated and the predicted amino acid sequences examined for homology to previously described adenoviral protein sequences, Ad4, Ad5, Ad7, Ad12, and Ad40. See Fig. 2 below.

5 The C1 E1 coding region is defined as the sequences between the E1A translation initiation site at nucleotide 576 of SEQ ID NO: 1 and the E1B translation termination signal at nucleotide 3507 of SEQ ID NO: 1. The corresponding sequences in the C68 genome are located
10 at nucleotides 577 and 3510 of SEQ ID NO: 2. Other open reading frames and regulatory elements of the viruses are being examined for homology with other adenoviral sequences.

 Our preliminary experiments have demonstrated
15 that human antisera do not neutralize the chimpanzee adenoviruses in neutralizing antibody assays.

Example 3 - Generation of Plasmid Vectors Expressing the C1 and C68 E1 Genes

 Plasmid vectors were constructed which encode
20 the C1 and C68 E1 region genes, and these plasmids were used to generate stable cell lines expressing viral E1 proteins.

A. *pGPGK-C68 E1*

 pGPGK (gift of Gaung Ping Gao, University
25 of Pennsylvania, Philadelphia, PA) is illustrated in Fig. 5A. pGPGK is a 5.5 kb plasmid containing the known murine PGK promoter (indicated by the arrow on Fig. 5A), followed by a multiple cloning site, a growth hormone polyA sequence, an SV40 ori, a neomycin resistance gene,
30 an SV40 polyA sequence and an ampicillin resistance gene. The remainder of the plasmid is additional plasmid sequence.

As shown in Fig. 5B, the 5' end of the C-68 E1 region was derived from clone 245 which contains a defective version of the C-68 BamHI-E fragment (2042 base pairs) in pNEB-193, i.e., clone 245 was shown to
5 lack approximately the first 30 base pairs of the C-68 genomic sequence, a region not included in the final product of this construction scheme, pGPGK-C68 E1. This plasmid pNEB-C68BamE was digested with BamHI and HindIII and the 2.1kb fragment was ligated with similarly
10 digested pGPGK DNA. The resulting plasmid is designated pGPGK-C68 BamE, illustrated in Fig. 5C.

PCR primers SF-34

(GCAGGTACCGCGAGTCAGATCTACAC) [SEQ ID NO: 4] and SF-35 (CTGTCTGAGCTAGAGCTC) [SEQ ID NO: 5] were designed to
15 introduce a KpnI restriction site 31 base pairs upstream of the E1A translation initiation site (nucleotide 577 of SEQ ID NO: 2). Using clone 245 as template, a 293bp PCR product was obtained using reagents from Perkin Elmer (Foster City, CA) under the following conditions: 94 =
20 BOC x 5 minutes; 25 cycles of 94 = BOC x 1 minute; 54 = BOC x 1 minute; 72=BOC x 2 minutes; and a final extension cycle of 72= BOC x 7 minutes. The PCR product was purified and is indicated by the hatched bar in Fig. 5D.

The PCR product was digested with KpnI and
25 NheI, yielding a 253bp fragment, which was purified and ligated with similarly digested pGPGK-C68 BamE (Fig. 5C) DNA to yield pGPGK-C68 E1-ATG (Fig. 5E).

The region derived from the PCR step was sequenced for several isolates and the adenovirus insert
30 in pGPGK-C68E1-ATG was shown to match the expected sequence derived from C-68 genomic DNA. pGPGK-C68 E1-ATG (Fig. 5E) was digested with BamHI and the linearized plasmid treated with calf intestinal phosphatase. The purified/phosphatased backbone was ligated with the

1544bp C-68 BamF fragment isolated from pBS-C68 BamF (Fig. 5F) to yield the final plasmid, designated pGPGK-C68 E1 (Fig. 5G).

The C-68 derived sequence in plasmid pGPGK-C68 E1 ends at the BamHI site corresponding to nucleotide 3581 of SEQ ID NO: 2 in the C-68 genomic sequence, which is 80bp downstream of the end of the E1B coding region. This expression plasmid contains from about nucleotide 546 to nucleotide 3581 of SEQ ID NO: 2 which encodes E1a and E1b of chimpanzee Ad C68 under the control of the PGK promoter.

B. pGPGK-C1 E1

The C1 Ad E1 expression plasmid was constructed in a manner similar to that described above for the C68 E1 expression plasmid. Refer to Figs. 6A through 6G.

The 5' end of the C-1 E1 region is isolated as a 1.9kb SnaBI - XbaI fragment (Fig. 6B) and is cloned into pGPGK (Fig. 6A) digested with XbaI and EcoRV. The resulting pGPGK-C1 (map units 1.3-6.6) (Fig. 6D) is used as the template for PCR. Primers are designed to introduce a KpnI site just upstream of the C1 E1 region translation initiation codon (E1-ATG) at nucleotide 578 of the C1 genomic DNA. (See Fig. 6C).

The PCR product is double digested with KpnI and KspI and ligated with similarly digested pGPGK-C1 (m.u. 1.3-6.6) to yield pGPGK-C1 E1-ATG. Partial digestion of pGPGK-C1 E1-ATG (Fig. 6E) with BamHI and isolation of the full length linear DNA, followed by XbaI digestion and isolation of the full length band, followed by ligation with similarly digested pBS-C1 Bam-I (Fig. 6F) yields the final product, pGPGK-C1 E1 (Fig. 6G). The C-1 derived sequence in plasmid pGPGK-C1 E1 ends at the BamHI site corresponding to nucleotide 3599 in the C-1 genomic sequence, which is 90bp downstream of

the end of the E1B coding region. This expression plasmid contains from about nucleotide 548 to about nucleotide 3581 of SEQ ID NO: 1 which encodes E1a and E1b of Ad C1 under the control of the PGK promoter.

5 Example 4 - Generation of Cell Lines Expressing Chimpanzee Adenovirus E1 Proteins

Cell lines expressing viral E1 proteins were generated by transfecting HeLa (ATCC Acc. No. CCL2) and A549 (ATCC Acc. No. CCL185) cell lines with either
10 pGPGK-C1 E1 or pGPGK-68 E1 of Example 3. These cell lines are necessary for the production of E1 deleted recombinant chimpanzee adenoviruses by co-transfection of genomic viral DNA and the expression plasmids described above. Transfection of these cell lines, as well as
15 isolation and purification of recombinant chimpanzee adenoviruses therefrom were performed by methods conventional for other adenoviruses, i.e., human adenoviruses [see, e.g., Horwitz, cited above and other standard texts].

20 A. *Cell lines expressing C1 and C68 E1 proteins*

HeLa and A549 cells in 10cm dishes were transfected with 10 μ g of pGPGK-C1-E1 DNA or pGPGK-C68-E1 DNA using a Cellfect[™] kit (Pharmacia, Uppsala, Sweden)
25 and following the manufacturer's protocol. 22 hours post-transfection, the cells were subjected to a three minute glycerol shock (15% glycerol in Hepes Buffered Saline, pH 7.5) washed once in DMEM (HeLa) or F12K (A549; Life Technologies, Inc., Grand Island, NY) media
30 supplemented with 10% FCS, 1% Pen-Strep, then incubated for six hours at 37°C in the above described media. The transfected cells were then split into duplicate 15cm plates at ratios of 1:20, 1:40, 1:80, 1:160, and 1:320. Following incubation at 37°C overnight, the media was

supplemented with G418 (Life Technologies, Inc.) at a concentration of 1 μ g/ml. The media was replaced every 5 days and clones were isolated 20 days post-transfection.

Thirty-two A549 and 16 HeLa C1 E1 cell clones and 40 A549 and 37 HeLa C68 E1 cell clones were isolated and assayed for their ability to augment adeno-associated virus (AAV) infection and expression of recombinant LacZ protein as described below.

B. *AAV Augmentation Assay for Screening E1 Expressing Cell Lines*

AAV requires adenovirus-encoded proteins in order to complete its life cycle. The adenoviral E1 proteins as well as the E4 region encoded ORF-6 protein are necessary for the augmentation of AAV infection. A novel assay for E1 expression based on AAV augmentation is disclosed herein. Briefly, the method for identifying adenoviral E1- expressing cells comprises the steps of infecting in separate cultures a putative adenovirus E1- expressing cell and a cell containing no adenovirus sequence, with both an adeno-associated virus (AAV) expressing a marker gene and an AAV expressing the ORF6 of the E4 gene of human adenovirus, for a suitable time. The marker gene activity in the resulting cells is measured and those cells with significantly greater measurable marker activity than the control cells are selected as confirmed E1-expressing cells. In the following experiment, the marker gene is a lacZ gene and the marker activity is the appearance of blue stain.

For example, the cell lines described above, as well as untransfected control cells (A549 and HeLa) are infected with 100 genomes per cell of an AAV vector bearing a marker gene, e.g., AV.LacZ [K. Fisher et al., *J. Virol.*, 70:520 (1996)] and an AAV vector expressing the ORF6 region of human Ad5 (AV.orf6) (see SEQ ID NO: 3). The DNA sequence [SEQ ID NO: 3] of the

plasmid pAV.CMVALP.GRE-ORF6, also called AV.orf6, generates a novel recombinant adeno-associated virus (rAAV) containing the *LacZ* transgene and the Ad E4 ORF 6, which is an open reading frame whose expression product facilitates single-stranded (ss) to double-stranded (ds) conversion of rAAV genomic DNA. In SEQ ID NO: 3, the AAV 5' inverted terminal repeat (ITR) is at nucleotides 53-219; the cytomegalovirus (CMV) enhancer/promoter is at nucleotides 255-848; the human placenta alkaline phosphatase cDNA (ALP) is at nucleotides 914-2892; the SV40 polyadenylation (polyA) signal is at nucleotides 2893-3090; the glucocorticoid dependent (GRE) promoter is at nucleotides 3114-3393; the Ad5 E4-ORF6 cDNA is at nucleotides 3402-4286; the SV40 polyA signal is at nucleotides 4315-4512; and the 3' AAV ITR is at nucleotides 4547 - 4713. All other nucleotides are plasmid-derived. These vectors are incubated in medium containing 2% FCS and 1% Pen-Strep at 37°C for 4 hours, at which point an equal volume of medium containing 10% FCS is added. It should be understood by one of skill in the art that any marker gene (or reporter gene) may be employed in the first AAV vector of this assay, e.g., alkaline phosphatase, luciferase, and others. An antibody-enzyme assay can also be used to quantitate levels of antigen, where the marker expresses an antigen. The assay is not limited by the identity of the marker gene. Twenty to twenty-four hours post-infection, the cells are stained for *LacZ* activity using standard methods. After 4 hours the cells are observed microscopically and cell lines with significantly more blue cells than the A549 or HeLa cell controls are scored as positive.

Eight A549 (A-2,3,8,13,15,18,23,38) and five HeLa (H-3,4,15,16,20) cell clones are significantly positive in the AAV augmentation assay and the three best

of each cell type (A-18, A-23, A-13 and H-16, H-4, H-20), when tested, support the growth of E1 deleted recombinant C68 viruses.

Four A549 (A-3, 6, 19, 22) and nine HeLa
5 (H-2,5-7, 11-16) cell clones are significantly positive in the AAV augmentation assay and the three best of each cell type (A-3, A-19, A-22 and H-5, H-12, H-14), when tested, support the growth of E1 deleted recombinant C1 viruses.

10 Example 5 - Generation of Recombinant Chimpanzee
Adenoviruses

Recombinant chimpanzee adenovirus vectors are prepared using the C1 and C68 sequences described herein and HEK293 cells. The cell lines described in Example 4
15 may also be used similarly. Plasmids used to construct C68 and C1 recombinant adenovirus vectors are illustrated in Figs. 7A through 7K, and 8A through 8K, respectively. See also Figs. 11A-11K.

A. *pC1-CMV-LacZ*

20 pSP72 (Promega, Madison, WI) is modified by digestion with BglII, followed by filling-in of the ends with Klenow and ligation with a synthetic 12bp PacI linker (New England Biolabs, Beverly, MA) to yield pSP72-Pac (Fig. 7A), which contains a large multiple
25 cloning site with conventional restriction enzyme cleavage sites.

pSP72-Pac is digested with PacI and EcoRV and ligated with the 465bp PacI-SnaBI fragment isolated from pBSC1-BamG (Fig. 7B) to yield pSP-C1-MU 0-1.3 (Fig.
30 7C). The CMV promoter-driven LacZ gene is isolated from pCMV- β (Clontech, Palo Alto, CA; Fig. 7D) as a 4.5kb EcoRI/SalI fragment and ligated with similarly digested pSP-C1-MU 0-1.3 DNA to yield pSP-C1-MU 0-1.3-CMV- β .

For the initial step in the isolation of the C1 Ad map units 9-16 region, pGEM-3Z (Promega, Madison, WI; Fig. 7F) and pBS-C1-BamI (Fig. 7G) are digested with BamHI and SphI and the 310bp fragment from pBS-C1-BamI is ligated with the pGEM-3Z backbone to form pGEM-C1-MU9-10 (Fig. 7H). C1 map units 10-17 are isolated from pBS-C1 BamE (Fig. 7I) by digestion with BamHI. The 2.5 kb fragment is ligated with BamHI-digested pGEM-C1-MU9-10 to form pGEM-C1-MU9-17 (Fig. 7J). The 2.9 kb fragment containing C1 map unit 9-17 region is isolated from pGEM-C1-MU9-17 by digestion with HindIII and ligated with pSP-C1-MU 0-1.3- β (Fig. 7E) digested with HindIII to form the final plasmid, pC1-CMV-LacZ (Fig. 7K).

pC1-CMV-LacZ (Fig. 7K) thus contains C1 Ad mu 0 to 1.3, followed by the CMV promoter, an SD/SA, the LacZ gene, a SV40 poly A sequence and C1 Ad mu. 9-17, as well as additional plasmid sequence. This plasmid is co-transfected into the E1-expressing cell line with a left terminal clipped C1 Ad fragment (or a replication-defective C1 Ad helper virus) to produce by homologous recombination a recombinant chimpanzee adenovirus carrying the LacZ gene.

C. *pC68-CMV-LacZ*

pSP72-Pac (Fig. 8A; also Fig. 7A) is digested with PacI and EcoRV and ligated with the 465bp PacI-SnaBI fragment isolated from pBS-C68-BamE (Fig. 8B) to yield pSP-C68-MU 0-1.3 (Fig. 8C). As above, the CMV promoter-driven LacZ gene is isolated from pCMV8 (Clontech; Fig. 8D; also Fig. 7D) as a 4.5kb EcoRI-SalI fragment and ligated with similarly digested pSP-C68-MU 0-1.3 DNA to yield pSP-C68-MU 0-1.3-CMV8 (Fig. 8E).

For the initial step in the isolation of the map unit 9-16 region of C68, pGEM-3Z (Fig. 8F; also Fig. 7F) and pBS-C68-BamF (Fig. 8G) are double digested

with BamHI and SphI and the 293bp fragment from pBS-C68-BamF is ligated with the pGEM-3Z backbone to form pGEM-C68-MU9-10 (Fig. 8H). C68 map units 10-16.7 are isolated from pBS-C68 BamB (Fig. 8I) by digestion with XbaI, followed by filling in of the ends and digestion with BamHI. The 2.4 kb fragment is ligated with BamHI/EcoRV-digested pGEM-C68-MU9-10 to form pGEM-C68-MU9-16.7 (Fig. 8J). The C68 map unit 9-16.7 region is isolated from pGEM-C68-MU9-16 by digestion with EcoRI, filling in of the ends with Klenow and then digestion with HindIII. The 2.7 kb fragment is ligated with pSP-C68-MU 0-1.3-CMV β (Fig. 8E), digested with HindIII and PvuII to form the final plasmid, pC68-CMV-LacZ (Fig. 8K).

pC68-CMV-LacZ (Fig. 8K) thus contains C68 Ad mu 0 to 1.3, followed by the CMV promoter, an SD/SA, the LacZ gene, a SV40 poly A sequence and C68 Ad mu 9-16.7, as well as additional plasmid sequence. This plasmid is co-transfected into the E1-expressing cell line with another C68 Ad to produce by homologous recombination a recombinant chimpanzee adenovirus carrying the LacZ gene.

D. pBS-Notx2

The LacZ gene is removed from either pC1-CMV-LacZ (Fig. 7K) or pC68-CMV-LacZ (Fig. 8K) by digestion with NotI, and replaced by the coding sequence of any desired gene. This cloning step is facilitated by having the gene of interest flanked by NotI restriction sites, preferably with the upstream site in the 5' untranslated region of the gene.

Such a cloning vector is derived from pBluescript SK+ (Stratagene, La Jolla, CA) by digestion of SK+ with SalI, followed by filling in of the ends and

ligation with a synthetic 8bp NotI linker (New England Biolabs, Beverly, MA): GCGGCCGC.
CGCCGGCG

The resulting pBS-Notx2 shuttle vector
5 (Fig. 4B) is thus designed to facilitate cloning of cDNAs
into pC1-CMV-LacZ (Fig. 7K) and pC68-CMV-LacZ (Fig. 8K;
see also Fig. 4A) as a NotI fragment. pBS-Notx2 has two
NotI sites flanking a number of restriction sites
suitable for cloning the cDNA to be expressed in the
10 recombinant adenoviruses and the LacZ ORF from
pBluescript is maintained, allowing blue/white screening
of clones in pBS-Notx2.

E. Homologous Recombination with Helper Virus

To generate the recombinant adenoviruses
15 from the plasmids described above, the appropriate E1-
expressing packaging cell line, such as 293 cell line or
a cell line of Example 4, is co-transfected with a
replication defective C1 or C68 helper virus, or a left-
end clipped C1 or C68 fragment, as appropriate. These
20 helper viruses may be deleted of other non-essential
genes. The infected cell line is subsequently
transfected with an adenovirus vector as described above
bearing the transgene of interest. Homologous
recombination occurs between the helper and the plasmid,
25 which permits the adenovirus-transgene sequences in the
vector to be replicated and packaged into virion capsids,
resulting in the recombinant adenovirus.

Transfection is followed by an agar
overlay for 2 weeks, after which the viruses are plaqued,
30 expanded and screened for expression of the transgene.
See, for example, Figs. 10A-10D. Several additional
rounds of plaque purification are followed by another
expansion of the cultures. Finally the cells are
harvested, a virus extract prepared and the recombinant
35 chimpanzee adenovirus containing the desired transgene is

purified by buoyant density ultracentrifugation in a CsCl gradient. All of the above procedures are known to those of skill in the art.

F. Another C1 Recombinant Adenovirus

5 Another set of plasmids used to construct a C1 recombinant adenovirus is described as follows. Figs. 11A-11H illustrate the scheme employed to generate a unique restriction site in the left end of the C1 genome. A unique site is necessary in the procedure
10 employed in generating a recombinant adenovirus, but C1 has no such site. There are two Spe-I restriction sites, including one at position 1733, within the E1B 21K coding region. To replace this Spe-I site with a unique Not-I site, plasmid pNEB-C1-BamG (Fig. 11A), containing the
15 left end of the C1 genome, was digested with Spe-I and Asc-I, and ligated to the 6204 bp Spe-I/Asc-I fragment from the C1 genome (Fig. 11B). The resulting plasmid, pNEB-C1-AscI-B (Fig. 11C) is then digested with Spe-I, filled in with Klenow enzyme and ligated to the synthetic
20 8bp Not-I linker (Fig. 11D) described above, to yield pNEB-C1-AscI-B-NotI (Fig. 11E).

This plasmid is digested with Pac-I and Asc-I and the purified fragment is ligated overnight with the C1-Asc-I-A fragment (Fig. 11G). The ligation
25 reaction is extracted with phenol:chloroform:iso-amyl alcohol, then chloroform, and then 3 μ g of sheared salmon sperm DNA is added and the DNA is ethanol precipitated. The resuspended DNA is used to transfect 293 cells and DNA from viral plaques is tested for a Not-I site (11H).

30 *G. GFP as a Transgene*

Plasmids used to construct exemplary C68 expression plasmids containing the bacterial green fluorescent protein (GFP) gene are illustrated in Figs. 9A through 9G, respectively. To facilitate the cloning
35 of the GFP gene into the chimp Adeno expression vectors,

pEGFP-1 (Fig. 9A, Clontech, Palo Alto, CA) was digested with Sma-I and ligated to the previously described 8bp Not-I linker (Fig. 9B). The resulting plasmid, pEGFP-Notx2 (Fig. 9C) has the GFP gene flanked by Not-I sites.

5 The purified pEGFP-Notx2 Not-I fragment is ligated to Not-I digested pC1-CMV-LacZ (Figs. 7K and 9D) or pC68-CMV-LacZ (Figs. 8K and 9E) to yield the GFP expression vectors pC1-CMV-GFP (Fig. 9F) and pC68-CMV-GFP (Fig. 9G and Fig. 10A), respectively.

10 Example 6: Delivery of Transgene to Host Cell

 The resulting recombinant chimpanzee adenovirus described in Example 5 above is then employed to deliver the transgene to a mammalian, preferably human, cell. For example, following purification of the
15 recombinant C68-CMV-GFP virus of Example 5G, human embryonic kidney 293 cells and A549 cells were infected at an MOI of 50 particles per cell. GFP expression was documented 24 hours post-infection.

 In vivo studies have tested the
20 infectivity of the virus in murine liver (tail vein injection), lung (intratracheal injection) and muscle (intramuscular injection). Preliminary data indicate that the C68-CMV-GFP recombinant virus transduces all three tissues, and GFP expression can be detected.

25 When administered in vivo, a less severe immune response is produced by the human immune system (which is naive to the chimpanzee adenovirus sequences) than to a human adenovirus construct, thereby permitting subsequent administration of the same or another vector.

30 All references recited above are incorporated herein by reference. Numerous modifications and variations of the present invention are included in the scope of the above-identified specification and are expected to be obvious to one of skill in the art. Such

modifications and alterations to the compositions and processes of the present invention, such as selections of different minigenes or selection or dosage of the vectors or immune modulators are believed to be within the scope
5 of the claims appended hereto.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Trustees of the University of Pennsylvania
Wilson, James M.
Farina, Steven P.
Fisher, Krishna J.
- (ii) TITLE OF INVENTION: Chimpanzee Adenovirus Vectors
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Howson and Howson
 - (B) STREET: Spring House Corporate Cntr., P.O. Box 457
 - (C) CITY: Spring House
 - (D) STATE: Pennsylvania
 - (E) COUNTRY: United States of America
 - (F) ZIP: 19477
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/024,700
 - (B) FILING DATE: 06-SEP-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Bak, Mary E.
 - (B) REGISTRATION NUMBER: 31,215
 - (C) REFERENCE/DOCKET NUMBER: GNVPN.021CIP1PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 215-540-9200
 - (B) TELEFAX: 215-540-5818

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35524 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCATCATCAA TAATATACCT TAAACTTTTG GTGCGTGTTA ATATGCAAAT GAGGCGTTTG	60
AATTTGGGGA GGGTGAAAGG TGATTGGCTG TGGGGACGGC GACCGTTAGG GCGGGGGCGG	120

GTGACGTTTT	GATGACGTGG	TCGTGAGGCG	GAGTTGGTTT	GCAAGTTCTC	GTGGGAAAAG	180
TGACGTCAAA	CGAGGTGTGG	TTTGAACACG	GAAATACTCA	ATTTTCCCGC	GCTCTCTGAC	240
AGGAAATGAT	GTGTTTTTGG	GCGGATGCAA	GTGAAAATTC	CTCATTTCG	CGCGAAAAC	300
AAATGAGGAA	GTGAATTTCT	GAGTAATTTT	GTGTTTATGA	CAGGGTGGAG	TATTTACCGA	360
GGGCCGAGTA	GACTTTGACC	GATTACGTGG	AGGTTTCGAT	TACCGTGTTT	TTCACCTAAA	420
TTTCCGCGTA	CGGTGTCAAA	GTCCTGTGTT	TTTACGTAGG	TGTCAGCTGA	TCGCTAGAGT	480
ATTTAAACCT	GACGAGTTCC	GTCAAGAGGC	CACTCTTGAG	TGCCAGCGAG	AAGAGTTTTT	540
TCCTCGCAC	TGCGAGTCAG	ATCTCCACTT	TGAAAATGAG	ACACCTGCGC	TTCTGTCCC	600
AGGAGATAGT	CTCCACTGAG	ACTGGGAATG	AAATACTGCA	ATTTGTGGTA	AATACACTGA	660
TGGGAGACGA	TCCAGAGCCG	CCTGAGCCAC	CTTTTGATCC	TCCTACGCTT	CATGAATTAT	720
ATGATTTAGA	GGTAGACGGA	CCGGAGGACC	CTAATGAAAA	CGACGTGAAT	GGGTTTTTTA	780
CTGATTCTAT	GTTATTAGCT	GCTAATGAGG	GAGTGGATTT	AGACCCACCT	TCTGGAACCT	840
TTGATACTCC	AGGGGTGATT	GTGGAAAGCG	ACATAGATGG	GAAAAATTTA	CCTGATTGG	900
GTGCTGCTGA	ATTGGACTTA	TACTGCTATG	AAGAGGGTTT	TCCTCAGAGT	GATGATGAAG	960
ATGTGGAGAA	TGAGCAGTCA	ATTCAGACCG	CCGCGGGTGA	GGGAGTGAAA	GCTGCCAGTG	1020
ATGGTTTTAA	GTTGGACTGT	CCGGTGCTTC	CTGGACATGG	CTGTAAGTCT	TGTGAATTTT	1080
ACAGGAAAAA	TACTGGAGTA	AAAGAAATAT	TATGCTCGCT	TTGTTATATG	AGAGCGCATT	1140
GCCACTTTAT	TTACAGTAAG	TGTGTTTAAA	GTTAAATTTA	AAGGAACAGT	AGCTGTTTTA	1200
ATAACTCTTG	AATGGGTGAT	TTATGTTTTG	CTGATTTTTA	TAGGTCCTGT	GTCTGATGCT	1260
GATGAATCGC	CTTCTCCTGA	TTCAACTACC	TCACCTCCTG	AAATTCGGGC	ACCCGTTCCCT	1320
GCAAACGTAT	GCAAGCCCAT	TTCTGTGAAG	CTTAAGCCTG	GGAAACGCCC	TGCTGTGAAT	1380
AAACTTGAGG	ATTTGCTGGA	GGGTGTGGAT	GAACCTTTGG	ACTTGTGTAC	CCGGAAAATA	1440
CCAAGGCAAT	GAGTGCTCCG	CACCTGTGTT	TATCTAATGT	GACGTCAGTG	TTTTTGTGAG	1500
AGTGTCATGT	AATAAAATTA	TGTCAGCAGC	TGAGTGTTTT	ATTGTTTATT	GGGTGGGACT	1560
TGGGATATAT	AAGTAGGAGC	AGACCTGTGT	GGTTAGCTCA	CAGCAGCTTG	CTGCCATCCA	1620
TGGAGGTTTG	GGCCATATTG	GAAGATCTTA	GGCAGACTAG	GCAACTGCTA	GAAAACGCCT	1680
CGGACAGAGT	CTCTGGTCTT	TGGAGATTCT	GGTTCGGTGG	TGATCTAGCT	AGACTAGTCT	1740
TTAGGATAAA	GCAGGATTAC	AGGCAAGAAT	TTGAAAAGTT	ATTGGACAAC	TGTCCAGGAC	1800
TTTTTGAAGC	TCTTAACTTG	GGCCACCAGG	CTCATTTTTA	GGAGAAGGTT	TTATCAGTTT	1860
TGGATTTTTT	TACCCCTGGT	AGAACTGCTG	CTGCTGTAGC	TTTCCTTACA	TTTATATTTG	1920
ATAAATGGAT	CCCACAGACC	CACTTCAGCA	AGGGATACGT	TTTGGATTTT	ATAGCAGCAG	1980
CTTTGTGGAG	AACATGGAAG	GCTCGCAGGA	TGAGGACAAT	CTTAGATTAC	TGGCCAGTAC	2040

AGCCTCTGGG	TGTAGCAGGG	ATCCTGAGAC	ACCCACCGAC	CATGCCAGCG	GTTTTGGAGG	2100
AGGTGCAACA	AGAGGACAAT	CCGAGAGCCG	GCCTGGACCC	TCGGGTGGAG	GAGGCGGAGG	2160
AGTAGCTGAC	TTGTTTCCTG	AACTGCGACG	GGTGCTTACT	AGATCTACAA	CCAGTGGGCG	2220
GGACAGGGGC	ATTAAGAGGG	AAAGGAATCC	TAGTGGAACT	AATCCCAGAT	CTGAGTTGGC	2280
TTTAAGTTTG	ATGAGTCGCA	GACGTCCTGA	AACTATATGG	TGGCATGAGG	TTCAGAATGA	2340
GGGCAGGGAT	GAAGTATCAA	TATTGCAAGA	GAAATATTCT	CTAGAACAGG	TGAAAACATG	2400
TTGGTTGGAG	CCTGAGGATG	ATTGGGAGGT	TGCCATTAGG	AATTATGCCA	AGATAGCTTT	2460
GAGGCCTGAT	AAATTGTACA	GAATTACTAA	ACGGATTAAT	ATTAGAAATG	CATGCTATAT	2520
ATCAGGGAAT	GGGGCTGAGG	TAGTGATAGA	CACTCAGGAC	AGAACAGTTT	TTAGATGCTG	2580
TATGATGGGT	ATGTGGCCAG	GGGTGATTGG	CATGGAGGCG	GTAACCTTTA	TGAATGTAAA	2640
GTTTAGAGGG	GATGGGTATA	ATGGTGTGGT	TTTTATGGCT	AATACTAAAT	TGATTTTGCA	2700
TGTTGTAGC	TTTTTTGGTT	TTAATAATAT	ATGTGTGGAA	GCTTGGGGGC	AGGTCAGTGT	2760
AAGAGGCTGT	AGTTTCTATG	CATGCTGGAT	TGCAACATCA	GGCAGGACCA	AGAGTCAATT	2820
GTCTGTGAAG	AAATGTATGT	TTGAGAGATG	TAACCTGGGC	ATACTAAATG	AAGGAGAAGC	2880
CAGAGTCAGC	CACTGTGCTT	CTCCGAAAC	TGGCTGTTTC	ATGTTGATGA	AGGGAAATGC	2940
CAATGTGAAA	CATAATATGA	TCTGCGGACC	CTCAGATGAC	AGGCCTTATC	AGATGCTGAC	3000
ATGTGCTGGC	GGACATTGCA	ATATGCTGGC	TACCGTGCAT	ATTGTTTCTC	ACCCACGCAA	3060
GAAATGGCCT	GTTTTGGAAC	ATAATGTGAT	GACCAAATGT	ACCATGCACG	TAGGTGGACG	3120
CAGAGGAATG	TTAATGCCAT	ACCAGTGTA	CATGAATAAT	GTGAAAGTGA	TGTTGGAACC	3180
AGATGCATTT	TCCAGAATGA	GTTTAACAGG	AATCTTTGAC	ATGAATCTGC	AAATATGGAA	3240
GATCCTGAGA	TATGATGACA	CGAAGTCGAG	GGTACGCGCA	TGCGAGTGCG	GGGGCAAACA	3300
TGCCAGGTTT	CAGCCGGTGT	GTGTGGATGT	GACTGAAGAA	CTAAGGCCAG	ATCATTTGGT	3360
GATTGCCTGC	ACTGGAGCGG	AGTTCGGTTC	TAGTGGTGAA	GAAACTGACT	AAAGTGAGTA	3420
GTAGTGGGAT	ACTTTGGATG	GGCTCTTATG	TGAATATGGT	GGACAGATTG	GGTAAATTTT	3480
GTTCTTTCTG	TCTTGCAGCT	GTCATGAGTG	GAAGCGCTTC	TTTTGAGGGG	GGAGTCTTTA	3540
GCCCTTATCT	GACGGGCCGT	CTCCCACCAT	GGGCAGGAGT	TCGTCAGAAT	GTCATGGGAT	3600
CCACTGTGGA	TGGGAGACCA	GTCCAGCCCG	CCAATTCATC	AACACTGACC	TATGCCACTT	3660
TGAGCTCTTC	ACCCTTGGAT	GCAGCTGCAG	CTGCTGCGCG	TTCTGCTGCC	GCCAATACCG	3720
TCCTTGGAAT	TGGCTATTAT	GGAAGCATCG	TTGCCAATAC	CAGTTCCTCA	AATAACCCTT	3780
CGACCCTGGC	TGAGGACAAG	CTACTTGTTT	TTTTGGCGCA	GCTTGAGGCG	TTGACCCAGC	3840
GCCTGGGTGA	ACTGTCTCAG	CAGGTGGCCC	AGCTGCGCGA	GCAAACCTGAG	TCTGCTGTTG	3900
CCACAGCAAA	GTCTAAATAA	AGATTAATCA	ATAAATAAAG	GAGATACTTG	TTGATTTTAA	3960

ACTGTAATGA	ATCTTTATTT	GATTTTTTCGC	GCACGGTATG	CCCTGGACCA	CCGGTCTCGA	4020
TCATTGAGAA	CTCGGTGGAT	TTTTTCCAGG	ACCCTGTAGA	GGTGGGATTG	AATGTTTAGA	4080
TACATGGGCA	TTAGGCCGTC	TCGGGGGTGG	AGATAGCTCC	ATTGAAGAGC	CTCATGCTCC	4140
GGGGTAGTAT	TATAAATCAC	CCAGTCATAA	CAAGGTGGGA	GTGCATGATG	TTGCACAATA	4200
TCTTTAAGGA	GCAGGCTGAT	TGCAACTGGG	AGCCCCCTTG	TGTATGTGTT	TACAAATCTG	4260
TTAAGCTGAG	ATGGATGCAT	TCTGGGTGAA	ATTATATGCA	TTTTTGACTG	TATCTTGAGG	4320
TTGGCAATGT	TGCCGCCCAG	ATCCCGTCTC	GGGTTCATGT	TATGCAGGAC	CACCAAGACG	4380
GTGTATCCGC	TGCACTTAGG	AAATTTATCA	TGCAGCTTAG	ATGGAAGAGC	ATGAAAAAAT	4440
TTGGAGACGC	CTTTGTGTCC	GCCCAGATTC	TCCATGCACT	CATCCATGAT	GATAGCGATG	4500
GGGCCGTGGG	CGGCGGCACG	GGCAAACACA	TTCCGGTGGT	CTGACACATC	ATAGTTATGC	4560
TCCTGAGACA	GGTCATCATA	AGCCATTTTA	ATAAACTTTG	GGCGGAGGGT	GCCAGATTGG	4620
GGTATAAATG	TACCCTCGGG	CCCCGGAGCA	TAGTTTCCCT	CACAGATTTG	CATTTCCAG	4680
GCTTTCAATT	CAGAGGGGGG	GATCATGTCC	ACCTGAGGGG	CTATAAAAAA	TACCGTTTCT	4740
GGGGCTGGGG	TGATTAAGTG	TGATGATAGC	AAATTCCTGA	GCAGCTGTGA	CTTGCCACAC	4800
CCAGTGGGGC	CGTAAATGAC	CCCGATTACG	GGTTGCAGAT	GGTAGTTTAG	GGAGCGGCAG	4860
CTGCCGTCCT	CTCGGAGCAG	GGGGGCCACT	TCGTTTCATCA	TTTCCCTTAC	ATGGATATTT	4920
TCCCGCACCA	AGTCGGTTAG	GAGGCGCTCT	CCACCTAGCG	ATAAAAGTTC	CTGGAGGGAG	4980
GAGAAGTTTT	TGAGCGGCTT	TAGCCCGTCA	GACATGGGCA	TTTTGGAAAG	AGTCTGTTGC	5040
AAGAGCTCAA	GCCGGTCCCA	GAGCTCGGTA	ATGTGTTCTA	TGGCATCTCG	ATCCAGCAGA	5100
CCTCCTCGTT	TCGCGGGTTG	GGACGGCTCC	TGGAGTAGGG	TATCAGACGA	TGGGCGTCCA	5160
GCGCTGCCAG	GGTCCGGTCT	TTCCAGGGTC	GCAGCGTCCG	AGTCAGGGTT	GTTTCCGTCA	5220
CAGTGAAGGG	GTGCGCGCCT	GGTTGGGCGC	TTGCGAGGGT	GCGCTTCAGG	CTCATCCTGC	5280
TGGTCGAGAA	COGCTGCCGA	TCGGCGCCCT	GCATGTCAGC	CATGTAGCAG	TTTACCATGA	5340
GTTTCGTAGTT	GAGTGCCTCG	GCTGCGTGAC	CTTTGGCGCG	GAGCTTACCT	TTGGAAGTTT	5400
TCTGGCAGGC	AGGGCAGTAC	AGACACTTGA	GGGCATATAG	CTTGGGCGCG	AGGAAGATTG	5460
ATTCCGGGGA	GTATGCATCC	GCGCCGCAGG	AGGCGCAGAT	GGTTTCGCAT	TCCACGAGCC	5520
AGGTCAGATC	CGGCTCATCG	GGGTCAAAAA	CAAGTTTACC	GCCATGTTTT	TTGATGCGCT	5580
TCTTACCTTT	GGTCTCCATG	AGTTCGTGTC	CCCGCTGGGT	GACAAAGAGG	CTGTCCGTGT	5640
CCCCGTAGAC	CGATTTTATG	GGCCTGTCCT	CGAGCGGAGT	GCCTCGGTCC	TCTTCGTAGA	5700
GGAACCCAGA	CCACTCTGAT	ACAAAGGCGC	GCGTCCAGGC	CAGTACAAAA	GAGGCCACGT	5760
GGGAGGGGTA	GCGGTCGTTA	TCAACCAGGG	GGTCCACCTT	CTCCACAGTA	TGTAAACACA	5820
TGTCCCCCTC	CTCCACATCC	AAGAAGGTGA	TTGGCTTGTA	AGTGTAGGCC	ACGTGACCAG	5880

TTCCAGCCGG	TGGGGTATAA	AAGGGGGCGG	GTCTCTGCTC	GTCCTCACTG	TCTTCCGGAT	5940
CGCTGTCCAG	GAGCGCCAGC	TGTTGGGGTA	GGTATTCCCT	TTCGAAGGCG	GGCATAACCT	6000
CTGCACTCAG	GTTGTCAGTT	TCTAGGAACG	AGGAGGATTT	GATATTGACA	GTGCCAGTTG	6060
AGATGCCTTT	CATGAGACTC	TCGTCCATTT	GGTCAGAAAA	GACAATTTTC	TTGTTGTCAA	6120
GCTTGGTGGC	AAAGGATCCG	TATAGGGCAT	TGGATAAAAG	CTTGGCGATG	GAGCGCATGG	6180
TTTGTTTCTT	ATCCTTGTC	GCACGCTCCT	TGGCAGCAAT	GTTGAGTTGG	ACGTACTCGC	6240
GCGCCAGGCA	CTTCCATTCA	GGAAAGATGG	TCGTCAGTTC	ATCTGGCAGC	ATTCTGACTC	6300
GCCAGCCCG	ATTATGCAGG	GTGATTAGAT	CCACACTGGT	GGCCACCTCG	CCTCGGAGGG	6360
GCTCGTTGGT	CCAGCAGAGT	CGACCCCTT	TTCTTGAACA	GAAAGGGGGG	AGGGGGTCTA	6420
GCATGAGTTC	ATCAGGGGGG	TCTGCATCCA	TGGTGAATAT	TCCTGGGAGC	AGATCTTTGT	6480
CAAATAGCT	AATGTGAGCG	GGGTCATCCA	AAGCCATCTG	CCATTCTCGA	GCTGCCAGCG	6540
CGCGTTCATA	GGGATTGAGT	GGGGTGCCCC	ATGGCATGGG	GTGGGTGAGT	GCAGAGGCAT	6600
ACATGCCACA	GATGTCATAG	ACATACAGTG	GTTCTTCGAG	GATGCCGATG	TAGGTGGGAT	6660
AACAGCGCCC	CCCTCTGATG	CTTGCTCGCA	CATAGTCATA	GAGTTCATGC	GAGGGGGCGA	6720
GAAGACCCGG	GCCCAGATTG	GTACGGTTGG	GTTTTTCAGC	TCTGTAAACG	ATCTGGCGAA	6780
AGATGGCATG	GGAATTGGAA	GAGATGGTAG	GTCTCTGAAA	GATGTTAAAA	TGGGCATGAG	6840
GCAGGCCAC	AGAGTCCCTG	ACGAAGTGGG	CATAGGACTC	TTGCAGCTTG	GCCACCAGCT	6900
CGGCGGTGAC	GAGCACATCC	AGGGCGCAGT	AGTCAAGGGT	CTCTTGAATG	ATGTCATAAC	6960
CTGGTTGGTT	TTTCTTTTCC	CACAGCTCGC	GGTTGAGGAG	GTATTCTTCG	CGATCTTTCC	7020
AGTACTCTTC	GAGGGGAAAC	CCGTCTTTGT	CTGCACGGTA	AGAGCCCAGC	ATGTAGAACT	7080
GATTGACTGC	CTTGTAGGGG	CAGCATCCCT	TCTCCACGGG	GAGAGAGTAT	GCTTGGGCGG	7140
CCTTGCGCAG	AGAGGTATGA	GTGAGGGCAA	AGGTGTCCCT	GACCATGACT	TTAAGGAACT	7200
GATACTTGAA	GTCGATGTCA	TTACAGGCC	CCTGTTCCCA	GAGTTGGAAG	TCTACCCGCT	7260
TCTTGTAGGC	GGGATTGGGC	AAAGCGAAAG	TAACATCGTT	GAAGAGTATC	TTGCCTGCCC	7320
TGGGCATGAA	ATTGCGGGTG	ATGCGGAAAG	GCTGGGGCAC	TTTTGCTCGG	TTATTGATCA	7380
CCTGAGCGGC	TAGGACGATC	TCATCAAAGC	CATTGATGTT	GTGCCCCACT	ATGTACAGTT	7440
CTATGAATCG	AGGGGTGCCC	TTGACATGAG	GCAGCTTCTT	AAGTTCTTCG	AAAGTTAGGT	7500
CTGTGGGGTC	AGAGAGAGCA	TAGTGTTCGA	GGGCCCCATT	GTGCAGGTGA	GGGTTCGCAT	7560
TGAGGAAGGA	GGACCAAAGA	TCCACTGCCA	GTGCTGTTTG	TAACTGGTCC	CGGTACTGGC	7620
GAAAATGCTG	GCCGACTGCC	ATCTTTTCTG	GGGTGACACA	GTAAGAAGTT	TTGGGGTCCT	7680
GCTGCCAGCG	ATCCCACTTT	AGTTTCATGG	CGAGGTCGTA	GGCGATGTTG	ACGAGCCGCT	7740
CGTCCCCAGA	GAGTTTCATG	ACCAGCATGA	AGGGTATGAG	TTGCTTGCCA	AAGGACCCCA	7800

TCCAGGTGTA	GGTTTCCACA	TCGTAGGTGA	GGAAGAGCCT	TTCCGTGCGA	GGATGAGAGC	7860
CGATCGGGAA	GAAGTGGATC	TCCTGCCACC	AGTTGGAGGA	ATGGCTGTTG	ATGTGATGGA	7920
AGTAGAAATC	CCTGCGGCGC	GCCGAGCATT	CATGCTTGTG	CTTGACAGA	CGGCCGCACT	7980
ACTCGCAGCG	CTGCACGGGA	TGCACCTCGT	GAATGAGTTG	TACCTGGCTT	CCTTTGACGA	8040
GAAATTTTCAG	TGGGAAGTTG	AGGCCTGGCG	CTTTTACCTC	GCTCTCTACT	ATGTTATCTG	8100
CATCGGCCTG	GCCATCTTCT	GTCTCGATGG	TGGTCATGCT	AACAAGCCCC	CGCGGGAGGC	8160
AAGTCCAGAC	CTCGGCACGG	GAGGGGCGGA	GCTCGAGGAC	GAGAGCGCGC	AGGCCGGAGC	8220
TGTCCAGGGT	CCTGAGACGC	TGCGGAGTCA	GGTTAGTAGG	TAGGGTGAGG	AGATTGACTT	8280
GCATGATCTT	TTCGAGGGCA	AGCGGGAGGT	TCAGATGGTA	TTTGATCTCC	ACGGGTCCGT	8340
TGGTGAAAT	GTCGATGGCT	TGCAGGGTTC	CGTGCCCTTT	GGGCGCCACC	ACCGTGCCCT	8400
TGTTTTTCCT	TTTGGGCGGA	GGCGGTGGTG	TTGCTTCTTG	CATGTTTACA	AGCGGTGGCG	8460
AGGGCGCGCG	CCTGGCGGTA	GAGGCGGCTC	GGGCCCCGGC	GGCATGGCTG	GCAGTGGCAC	8520
GTGCGCGCCG	CGCGCGGTA	GGTCTGGTA	CTGCGCCCTG	AGAAGACTTG	CGTGCGCGAC	8580
AACGCGGCGG	TTGACGTCCT	GGATCTGTCT	CCTCTGGGTG	AAAGCTACCG	GCCCCGTGAG	8640
CTTGAACCTG	AAAGAGAGTT	CAACAGAATC	AATCTCGGTA	TCGTTGACGG	CGGCTTGTCT	8700
TAGGATCTCT	TGTACGTCGC	COGAGTTGTC	CTGGTAGGCT	ATCTCGGCCA	TGAACTGCTC	8760
GATTTCTTCC	TCCTGAAGAT	CTCCGCGGCC	TGCTCTCTCG	ACGGTGGCCG	CGAGGTGCTT	8820
GGAGATGCGA	CCCATGAGTT	GAGAGAATGC	ATTCATGCCT	GCCTCGTTCC	AGACGCGGCT	8880
GTAGACCACG	GCCCCCTCGG	GATCTCTCGC	GCGCATGACC	ACCTGGGCGA	GGTTGAGCTC	8940
CACGTGGCGG	GTGAAGACCG	CATAGTTGCA	TAGGCGCTGG	AAGAGGTAGT	TGAGTGTTGGT	9000
GGCGATGTGC	TCGGTGACGA	AGAAATACAT	GATCCATCGT	CTCAGCGGCA	TCTCGCTGAC	9060
ATCGCCCAGG	GCTTCCAAGC	GTTCCATGGC	CTCGTAAAG	TCCACGGCAA	AGTTGAAAAA	9120
CTGGGAGTTG	CGCGCGGACA	CGGTCAACTC	CTCCTCCAGA	AGACGGATGA	GTTGCGCGAT	9180
GGTGGCGCGC	ACCTCGCGCT	CGAAAGCTCC	CGGGATTCTT	TCCTCCTCTT	CTTCTATCTC	9240
CTCTTCCACT	AACATCTCTT	CTTCTCTTTC	AGGCGGGGGC	GGAGGAGGAG	GGGGCACGCG	9300
GCGACGCCCCG	CGGCGCACGG	GCAAACGGTC	GATGAATCTT	TCAATGACCT	CTCCGCGGGC	9360
GCGGCGCATG	GTCTCGGTGA	CGGCACGGCC	GTTTTCCCTG	GGTCTCAGAG	TGAAGACGCC	9420
TCCGCGCATC	TCCCTAAAGT	GGTGACTGGG	GGGCTCTCCG	TTGGGCAGGG	ACAGAGCGCT	9480
GATTATGCAT	TTTATCAATT	GCCCCGTAGG	GACTCCGCGC	AAGGACCTGA	TCGTCTCAAG	9540
ATCCACGGGA	TCGGAAAACC	TTTCGACGAA	AGCGTCTAAC	CAGTCGCAAT	CGCAAGGTAG	9600
GCTGAGCACT	GTTTCTTGTA	GGCGGGGGTG	GCTACACGCT	CGGTGCGGGT	TCTCTATTTT	9660
TTCTCCTTCC	TCCTCTCGGG	AGGGTGAGAC	GATGCTGCTG	GTGATGAAAT	TAAATAGGC	9720

AGTTCTGAGA	CGGCGGATGG	TGGCGAGGAG	CACCAGGTCT	TTGGGACCGG	CTTGCTGGAT	9780
GCGCAGGCGA	TTGGCCATTG	CCCAAGCATT	ATCCTGGCAC	CTGGCCAGAT	CTTTGTAGTA	9840
GTCTTGATA	AGTCGCTCCA	CGGGCACTTC	TTCTTCGCCC	GCTCTGCCAT	GCATGCGCGT	9900
GAGCCCAAAC	CCGCGCATGG	GCTGGACAAG	TGCCAGGTCC	GCTACGACCC	TTTCTGCGAG	9960
GATGGCTTGC	TGCACCTGGG	TGAGGGTGGC	TTGGAAGTCG	TCAAAGTCCA	CAAAGCGATG	10020
GTAGGCCCCG	GTGTTGATGG	TGTAAGAGCA	GTTGGCCATG	ACTGACCAGT	TGACTGTCTG	10080
GTGCCCCGGG	CGCACAACTC	CGGTGTACTT	GAGGCGCGAG	TAGGCGCGGG	TGTCAAAGAT	10140
GTAATCGTTG	CAGGCGCGCA	CCAGGTACTG	GTAGCCGATT	AGAAAATGTG	GTGGCGGCTG	10200
GCGGTATAGG	GGCCATCGCT	CTGTAGCCGG	GGCGECAGGA	GCGAGGTCTT	CCAGCATGAG	10260
GCGGTGATAA	CCGTAGATGT	ACCTGGACAT	CCAGGTGATA	CCGGAGGCGG	TGGTGGATGC	10320
CCGAGGGAAC	TCGCGTACGC	GGTTCAGAT	GTTGCGCAGC	GGCATGAAGT	AGTTCATGGT	10380
AGGCAOGGTT	TGGCCCGTGA	GGCGCGCACA	GTCGTTGATG	CTCTAGACAT	ACGGGCAAAA	10440
ACGAAAGCGG	TCAGCGGCTC	GACTCCGTGG	CCTGGAGGCT	AAGCGAACGG	GTTGGGCTGC	10500
GCGTGTACCC	CGGTTCGAAT	CTCGGATTAG	GCTGGAGCCG	CAGCTAACGT	GGTACTGGCA	10560
CTCCCGTCTC	GACCCAAGCC	TGCACAAAAC	CTCCAGGATA	CGGAGGCGGG	TCGTTTTTTTT	10620
TTTTTTTGCT	TTTCCTGGAT	GGGAGCCAGT	GCTGCGTCAA	GCTTTAGAAC	GCTCAGTTCT	10680
CGGGCCTGGG	AGTGGCTCGC	GCCCCTAGTC	TGGAGAATCA	ATCGCCAGGG	TTGCGTTGCG	10740
GCATGCCCCG	GTTCGAGTCT	TAGCGCGCCG	GATCGGCCGG	TTCCGCGGGC	AAACGAGGGT	10800
TTGGCAGCCC	CGTCATTCT	AAGACCCCGC	TAGCCGACTT	CTCCAGTTTA	CGGGAGCGAG	10860
CCCTCTTTTT	TTTTTTTGTT	TTTGTGCCCC	AGATGCATCC	CGTGCTGCGA	CAGATGCGCC	10920
CCCAGCAACA	GCCCCCTTCT	CAGCAGCAGC	CACAGCAACA	GCCACAAAAG	GCTCTTCCTG	10980
CTCCTGTAAC	TACTGCAGCT	GCAGCCGTCA	GCGGCGCGGG	ACAGCCCGCC	TATGATCTGG	11040
ACTTGGAAGA	GGGCGAGGGA	CTGGCGCGTC	TGGGTGCACC	ATCGCCCGAG	CGGCACCCGC	11100
GGGTGCAACT	GAAAAAGGAT	TCTCGCGAGG	CGTACGTGCC	GCAGCAGAAC	CTGTTCAGGG	11160
ACAGGAGCGG	TGAGGAGCCG	GAGGAAATGC	GAGCTTCCCG	CTTTAACCGG	GGTCGCGAGC	11220
TGCGTCATGG	TCTGGACCGA	AGACGGGTGC	TGCGCGATGA	TGATTTTGAA	GTCGATGAAG	11280
TGACAGGGAT	AAGTCCTGCT	AGGGCACATG	TGGCTGCGGC	CAACCTAGTA	TCAGCCTACG	11340
AGCAGACCGT	GAAGGAGGAG	CGCAACTTTC	AAAAATCTTT	CAACAATCAT	GTGCGCACCC	11400
TGATTGCCCC	CGAGGAGGTG	ACACTGGGTC	TAATGCACCT	GTGGGACCTG	ATGGAAGCTA	11460
TTACCCAGAA	CCCCACCAGC	AAACCTCTGA	CCGCTCAGCT	GTTTCTAGTG	GTGCAACATA	11520
GCAGAGACAA	TGAGGCATTT	AGGGAGGCGC	TGTTGAACAT	CACTGAGCCC	GAGGGGAGAT	11580
GGTTGTATGA	TCTTATCAAT	ATTCTGCAAA	GTATCATAGT	GCAAGAACGT	AGCCTGGGTC	11640

58

TGGCTGAGAA	GGTGGCTGCT	ATTAAC TACT	CGGTCTTAAG	CCTGGGCAAG	CACTACGCTC	11700
GCAAGATCTA	TAAAACCCCA	TACGTACCTA	TAGACAAGGA	GGTTAAGATA	GATGGGTTTT	11760
ATATGCGCAT	GACTCTCAAG	GTGCTGACCT	TGAGTGACGA	TCTGGGAGTG	TACCGCAACG	11820
ACAGGATGCA	CCGTGCAGTG	AGCGCCAGCA	GAAGGCGTGA	GCTGAGCGAC	AGAGAACTTA	11880
TGCACAGCTT	GCAAAGAGCT	CTGACGGGGG	CTGGAACCGA	GGGGGAGAAC	TACTTTGACA	11940
TGGGAGCGGA	TTTGCAATGG	CAGCCCAGTC	GCAGGGCCCT	GGACGCAGCA	GGGTATGAGC	12000
TTCCTTACAT	AGAAGAGGCG	GATGAAGGCC	ATGACGAGGA	GGGCGAGTAC	CTGGAAGACT	12060
GATGGCGCGA	CCATCCATAT	TTTTGTTAGA	TGCAGCAACA	GCCACCTCCT	GATCCCGCAA	12120
TGCGGGCGGC	GCTGCAGAGC	CAGCCGTCCG	GCATTAACTC	CTCGGACGAT	TGGACCCAGG	12180
CCATGCAACG	CATCATGGCG	CTGACGACCC	GCAACCCCGA	AGCCTTTAGA	CAGCAACCCC	12240
AGGCCAACCG	CCTTTCTGCC	ATCCTGGAGG	CCGTAGTGCC	CTCCCGCTCC	AACCCACCCC	12300
ACGAGAAGGT	CCTGGCTATC	GTGAACGCGC	TGGTGGAGAA	CAAAGCCATA	CGTCCCGATG	12360
AGGCTGGACT	GGTATACAAT	GCCCTATTGG	AGCGCGTAGC	CCGTTACAAC	AGCAGCAACG	12420
TGCAGACCAA	CCTTGACCGG	ATGGTGACCG	ATGTGCGCGA	GGCTGTGTCT	CAGCGCGAGC	12480
GGTTCCAGCG	AGACTCCAAT	CTAGGGTCGC	TGGTGGCGTT	GAACGCCTTC	CTCAGCACCC	12540
AGCCTGCCAA	CGTGCCTCGC	GGCCAGCAAG	ACTACACAAA	CTTTCTAAGT	GCATTAAGAC	12600
TCATGGTGCG	CGAAGTCCCT	CAAAGTGAGG	TGTACCAGTC	CGGGCCAGAC	TACTTTTTCC	12660
AGACCAGCAG	ACAGGGCTTG	CAGACAGTGA	ACCTGAGCCA	GGCTTTTAAG	AACCTGAATG	12720
GTCTGTGGGG	AGTGCGTGCC	CCAGTAGGAG	ATCGGGCAAC	CGTGTCTAGC	TTGCTAACCC	12780
CCAACTCCCG	CCTACTACTG	CTCTTGGTAG	CCCCATTAC	TGACAGCGGT	AGCATCGACC	12840
GCAATTCTTA	CTTGGGCTAT	TTGTTGAACC	TGTATCGCGA	GGCCATAGGG	CAAATCAGG	12900
TAGATGAGCA	AACCTATCAA	GAAATTACCC	AAGTGAGCCG	CGCTCTGGGT	CAGGAAGACA	12960
CTGGCAGCTT	GGAAGCCACC	TTAAACTTCT	TGCTGACCAA	CCGGTCGCAG	AAGATCCCTC	13020
CTCAGTATGC	GCTTACCGCG	GAGGAGGAAC	GAATCCTGAG	ATACGTGCAG	CAGAGCGTGG	13080
GACTTTTCCT	AATGCAGGAG	GGGGCGACTC	CTACTGCTGC	GCTAGATATG	ACAGCCCGAA	13140
ACATGGAGCC	CAGCATGTAT	GCCAGTAACA	GGCCTTTTAT	CAATAAACTA	CTAGACTACT	13200
TACACAGGGC	GGCTGCTATG	AACTCTGATT	ATTTACCAA	TGCTATACTG	AACCCCATTT	13260
GGCTGCCCCC	ACCTGGGTTC	TATACGGGCG	AGTATGACAT	GCCCGACCCC	AATGACGGGT	13320
TTTTATGGGA	CGATGTGGAC	AGTAGTGTTC	TCTCCCGGCC	TCCTGGTTAT	AACACTTGGA	13380
AGAAGGAAGG	GGGCGATAGA	AGGCATTCTT	CCGTATCGCT	GTCCGGGGCA	ACGGGTGCTG	13440
TGCAGCGGT	GCCCGAGGCC	GCAAGTCCTT	TCCCTAGTTT	GCCATTTTCG	CTAAACAGTG	13500
TACGCAGCAG	TGAGCTGGGC	AGGATCACGC	GTCCGCGCTT	GATGGGCGAG	GAGGAGTACT	13560

TGAATGACTC	GCTGTTGAGG	CCAGAGCGGG	AGAAGAACTT	CCCCAATAAC	GGGATAGAGA	13620
GCCTGGTGGA	TAAGATGAGC	CGCTGGAAGA	CGTACGCGCA	CGAGCACAGG	GACGAGCCCC	13680
GAGCTAGCAG	CAGCGCCGGC	GCCCGTAGAC	GCCAGCGGCA	CGATAGGCAG	CGGGGACTTG	13740
TGTGGGACGA	TGAGGATTCC	GCCGACGACA	GCAGCGTGTT	GGACTTGGGT	GGGAGTGGTG	13800
GTGGTAACCC	GTTTGCTCAC	CTGCGCCCCC	GCGTTGGGCG	CCTGATGTAA	AAACCGAAAA	13860
TAAATGGTAC	TCACCAAGGC	CATGGCGACC	AGCGTGCGTT	CGTTTCTTCT	CTGTTGTATC	13920
TAGTATGATG	AGGCGAACCG	TGCTAGGAGG	AGCGGTGGTG	TATCCGGAGG	GTCCTCCTCC	13980
TTCGTATGAA	AGCGTGATGC	AGCAGGCGGC	GGCGGCGGCG	ATGCAGCCAC	CACTGGAGGC	14040
TCCCTTTGTC	CCCCCTCGGT	ACCTGGCACC	TACGGAGGGG	AGAAACAGCA	TTCGTTACTC	14100
GGAGCTGGCA	CCATTGTATG	ATACCACCCG	GTTGTATTTG	GTGGACAACA	AGTCGGCGGA	14160
CATCGCCTCA	CTGAACTATC	AGAACGACCA	CAGCAACTTC	CTCACCACGG	TGGTGCAAAA	14220
CAATGACTTT	ACCCCCACGG	AGGCCAGCAC	CCAGACAATC	AACTTTGACG	AGCGGTGCGG	14280
ATGGGGTGGT	CAGCTGAAGA	CTATCATGCA	CACCAACATG	CCCAACGTGA	ACGAGTACAT	14340
GTTTAGCAAC	AAGTTCAAAG	CTCGGGTGAT	GGTGTCCAGA	AAGGCTCCTG	AAGGTGTCAC	14400
AGTAGATGAC	AATTATGATC	ACAAGCAGGA	TATTTTGGAA	TATGAGTGGT	TTGAGTTTAC	14460
TCTACCGGAA	GGCAACTTCT	CAGCCACAAT	GACCATTGAC	CTAATGAACA	ATGCCATCAT	14520
TGATAATTAC	CTTGAAGTGG	GCAGACAGAA	TGGAGTGTTG	GAGAGTGACA	TTGGTGTTAA	14580
ATTTGACACC	AGGAACTTTA	AACTGGGTTG	GGATCCGGAA	ACTAAGTTGA	TTATGCCTGG	14640
GGTTTACACC	TATGAGGCAT	TCCATCCTGA	CATTGTATTG	TTGCCTGGTT	GTGGGGTTGA	14700
CTTTACTGAA	AGTCGCCTTA	GTAAGTTGCT	TGGTATCAGG	AAAAGACACC	CATTCCAGGA	14760
GGGTTTTAAG	ATCTTGATG	AGGATCTTGA	AGGGGGTAAT	ATCCCAGCCC	TTTTGGATGT	14820
AGAAGCCTAT	GAGAACAGTA	AGAAAGAACA	AGAAGCCAAA	ACAGAAGCCG	CTAAAGCTGC	14880
TGCTATTGCT	AAAGCCAATA	TAGTTGTCAG	CGACCCTGTC	AGGGTGGCTA	ATGCCGAAGA	14940
AGTCAGAGGA	GACAACTATA	CAGCTACATC	TGTTGCAACT	GAAGAATCGC	TATTGACTAC	15000
TGCTGCGACT	GGAACCAAAA	ATACAGAGAC	AGGACTCACT	ATCAAACCTG	TAGAAAAAGA	15060
TAGCAAGAGT	AGAAGTTACA	ATGTCTTGGA	AGATAAAGTT	AATACAGCCT	ACCGCAGCTG	15120
GTATCTGTCC	TACAACTATG	GCGACCCTGA	AAAAGGAGTC	CGTTCCTGGA	CACTGCTCAC	15180
CACCTCGGAT	GTCACCTGTG	GAGCAGAGCA	GGTGTAAGTG	TCACTTCCAG	ACATGATGCA	15240
GGACCCTGTC	ACATTCCGTT	CCACGAGACA	AGTCAGCAAC	TATCCAGTGG	TAGGTGCAGA	15300
GCTCATGCCA	GTCTTCTCAA	AAAGTTTCTA	CAACGAGCAA	GCCGTGTACT	CCCAGCAGCT	15360
TCGCCAGTCC	ACCTCGCTCA	CGCACGTCTT	CAACCGCTTC	CCTGAGAACC	AGATCCTCAT	15420
CGCCCCGCCA	GCGCCCCACCA	TTACCACCGT	CAGTGAAAAC	GTTCCCTGCTC	TCACAGATCA	15480

CGGGACCCTG	CCGTTGCGCA	GCAGTATCCG	GGGAGTCCAG	CGCGTGACCG	TTACTGACGC	15540
CAGACGCCGC	ACCTGCCCTT	ACGTCTACAA	GGCCCTGGGC	ATAGTCGCGC	CGCGCGTCTT	15600
TTCAAGCCGC	ACTTTCTAAA	AAAAAAAAAA	TGTCCATTCT	TATCTCACCT	AGTAATAACA	15660
CCGGTTGGGG	CCTGCGCGCG	CCAAGCAAGA	TGTACGGAGG	TGCTCGCAAA	CGCTCTACAC	15720
AGCACCTGT	GCGAGTGC	GGACACTTCC	GCGCTCCATG	GGGCGCCCTC	AAGGGCGGTA	15780
TCCGCACTAG	AACCACCGTC	GATGATGTGA	TCGACCAGGT	GGTGGCCGAT	GCTCGTAATT	15840
ATACTCCTAC	TGCACCTACA	TCTACTGTGG	ATGCAGTTAT	TGACAGCGTA	GTAGCTGACG	15900
CCCGCGCCTA	TGCTCGCCGG	AAGAGCAGGC	GGAGACGCAT	CGCCAGGCGC	CACCGGGCTA	15960
CTCCCGCTAT	GCGAGCAGCA	AGAGCTTTGC	TACGGAGAGC	CAAACGCGTG	GGGCGAAGAG	16020
CTATGCTTAG	AGCAGCCAGA	CGCGCGGCTT	CAGGTGCCAG	TGCTGGCAGG	TCCCGCAGGC	16080
GCGCAGCCAC	TGCAGCAGCA	GCGGCCATTG	CCAACATGGC	CCAACCGCGA	AGAGGCAATG	16140
TGTACTGGGT	GCGCGACGCC	ACCACCGGCC	AGCGCGTGCC	CGTGCGCACC	CGTCCCCCTC	16200
GCTCTTAGAA	GATACTGAGC	AGTCTCCGAT	GTTGTGTCCC	AGCGAGGATG	TCCAAGCGCA	16260
AATACAAGGA	AGAGATGCTC	CAGGTCATCG	CGCCTGAAAT	CTACGGTCCG	CCGGTGAAGG	16320
ATGAAAAAAA	GCCCCGCAAA	ATCAAGCGGG	TCAAAAAGGA	CAAAAAGGAA	GAAGATGGCG	16380
ATGATGGTCT	GGTGGAGTTT	GTGCGCGAGT	TCGCCCCAAG	GCGGCGTGTG	CAGTGGCGTG	16440
GACGCAAAGT	GCGGCCTGTG	CTGAGACCTG	GAACCACGGT	GGTCTTTACG	CCCGGCGAGC	16500
GCTCCAGCAC	TGCTTTTAAG	CGGTCCATATG	ATGAGGTGTA	TGGGGATGAT	GATATTCTGG	16560
AGCAGGCGGC	TGACCGCCTG	GGCGAGTTTG	CTTATGGCAA	GCGCTCCCGC	TCCAGTCCCA	16620
AGGAGGAGGC	GGTGTCCATT	CCCTTGGA	ATGGGAATCC	CACCCCTAGC	CTCAAGCCAG	16680
TCACCCTGCA	GCAAGTGCTG	CCCGTGCCCTC	CACGCAGAGG	CATCAAGCGA	GAGGGTGAGG	16740
ATCTGTATCC	CACTATGCAA	TTGATGGTGC	CCAAGCGCCA	GCGGCTGGAG	GACGTGCTGG	16800
AGAAAATGAA	AGTGGATCCC	GATATACAAC	CTGAGGTCAA	AGTGAGACCC	ATCAAGCAGG	16860
TGGCGCCAGG	TTTGGGAGTA	CAAACCGTAG	ACATCAAGAT	TCCAACCGAG	TCCATGGAAG	16920
TCCAACCGA	ACCTGCAAAG	CCCACAACCA	CCTCCATTGA	GGTACAAACG	GATCCCTGGA	16980
TGTCAGCACC	CGTTACAAC	CCAGCTGCCG	TCAACACCAC	TCGAAGATCC	CGGCGACAGT	17040
ACGGTCCAGC	AAGTTTGCTG	ATGCCAAATT	ATGCTCTGCA	CCCATCTATT	ATTCCAAC	17100
CGGGTTACCG	AGGCACTCGC	TACTACCGCA	GCCGGAGCAG	TACTTCCCGC	CGTCGCCGCA	17160
AAACACCTAC	AAGTCGTAGT	CACCGTCGTC	GCCGTCGCCC	CACCAGCAAT	CTGACTCCCC	17220
CTGCTCTGGT	GCGGAGAGTG	TATCGCGATG	GCCGCGCGGA	TCCCATGACG	TTGCCACGCG	17280
TACGCTACCA	CCCAAGCATC	ACAACCTAAC	GACTGTTGCC	GCTGCCTCCT	TGCAGATATG	17340
GCCCTCACTT	GCCGCCTTCG	TGTCCCCATT	ACTGGCTACC	GAGGAAGAAA	CTCGCGCCGT	17400

AGAAGAGGGA	TGTTGGGGCG	CGGGATGCGA	CGCCACAGGC	GGCGGCGCGC	TATCAGCAAG	17460
AGGCTGGGGG	GTGGCTTTCT	GCCTGCTCTG	ATCCCCATCA	TAGCCGCGGC	GATCGGGGCG	17520
ATACCAGGCA	TAGCTTCCGT	GGCGGTTTCT	GCCTCGCAGC	GCCACTGACA	TTGGAAAAAC	17580
TTATAAATAA	AACAGAATGG	ACTCTGATGC	TCCTGGTCCT	GTGACTATGT	TTTTGTAGAG	17640
ATGGAAGACA	TCAATTTTTT	ATCCCTGGCT	CCGCGACACG	GCACGAGGCC	GTACATGGGC	17700
ACCTGGAGCG	ACATCGGCAC	CAGCCAACTG	AACGGGGGCG	CCTTCAATTG	GAGCAGTATC	17760
TGGAGCGGGC	TTAAAAATTT	TGGCTCTACC	ATAAAAACCT	ATGGGAACAA	AGCTTGGAAC	17820
AGCAGCACAG	GGCAGGCACT	GAGAAATAAG	CTTAAAGAAC	AAAAC'TTCCA	ACAGAAGGTG	17880
GTTGATGGGA	TCGCCTCTGG	TATTAATGGG	GTGGTGGATC	TGGCCAACCA	GGCCGTGCAG	17940
AAACAGATAA	ACAGCCGCCT	GGACCCGCCG	CCGTCAGCCC	CGGGTGAAAT	GGAAGTGGAG	18000
GAAGATCTCC	CTCCCCTTGA	AAAACGGGGC	GACAAGCGTC	CGCGCCCCGA	TCTGGAGGAG	18060
ACACTAGTCA	CACGCTCAGA	CGACCCGCCC	TCCTACGAGG	AGGCAGTGAA	GCTTGGAATG	18120
CCCACCACCA	GGCCTGTAGC	CCCCATGGCT	ACCGGGGTGA	TGAAACCTTC	TCAGTCACAC	18180
CGACCCGCTA	CCTTGGACTT	GCCTCCTCCC	CCTGCTGCTG	CAGCGCCTGC	TCGCAAGCCT	18240
GTCGCTACCC	CGAAGCCAC	CACCGTACAG	CCCGTCGCCG	TAGCCAGACC	GCGTCCTGGG	18300
GGCGGCCAC	GACCGAATTC	AAACTGGCAG	AGTACTCTGA	ACAGCATCGT	TGGTCTGGGC	18360
GTGCAAAGTG	TAAACGCCG	TCGCTGCTTT	TAAATTAAAT	ATGGAGTAGC	GCTTAACTTG	18420
CCTGTCTGTG	TGTATGTGTC	ATCATCACGC	CGCTGCCGCA	GCAACAGCAG	AGGAGAAAGG	18480
AAGAGGTCGC	GCGCCGAGGC	TGAGTTGCTT	TCAAGATGGC	CACCCCATCG	ATGCTGCCCC	18540
AGTGGGCATA	CATGCACATC	GCCGGACAGG	ATGCTTCGGA	GTACCTGAGT	CCGGGTCTGG	18600
TGCAGTTTCG	CCGCGCCACA	GACACCTACT	TCAATCTGGG	GAACAAGTTT	AGGAACCCCA	18660
CCGTGGCGCC	CACCCATGAT	GTGACCACCG	ACCGCAGTCA	GCGGCTGATG	CTGCGCTTTG	18720
TACCCGTTGA	CCGGGAGGAC	AATACCTACT	CATACAAAGT	TCGATACACC	TTGGCTGTGG	18780
GCGACAACAG	AGTGCTGGAT	ATGGCCAGCA	CTTTCTTTGA	CATTGCGGGT	GTGTTGGATA	18840
GAGGCCCTAG	CTTCAAGCCA	TATTCTGGCT	CTGCTTACAA	CTCATTTGGCC	CCTAAGGGCG	18900
CTCCCAATAC	ATCTCAGTGG	CTTGATAAGG	GAGTCACAAC	CACTGATAAT	AATACTGAAA	18960
ACGGAGATGA	AGAAGATGAA	GTTGCCGAGG	AAGGGGAAGA	AGAAAAACAA	GCTACATACA	19020
CTTTTGGCAA	TGCGCCAGTA	AAAGCCGAAG	CTGAAATTAC	AAAAGAAGGA	CTGCCAATAG	19080
GTTTGGAAAGT	TCCATCTGAA	GGTGACCCTA	AACCCATTTA	TGCTGATAAA	CTGTATCAGC	19140
CAGAACCTCA	GGTGGGAGAG	GAATCTTGGA	CTGATACGGA	TGGCACAGAT	GAAAAATATG	19200
GAGGCAGAGC	ACTTAAACCT	GAAACTAAAA	TGAAACCCTG	CTACGGGTCT	TTTGCTAAAC	19260
CTACTAATGT	TAAAGGCGGC	CAAGCAAAAG	TGAAGAAAGT	AGAAGAAGGC	AAGGTTGAAT	19320

ATGACATTGA	CATGAACTTT	TTCGACCTAA	GATCACAAAA	GACTGGTCTC	AAGCCTAAAA	19380
TTGTAATGTA	TGCAGAAAAT	GTGGATCTAG	AAACTCCAGA	CACTCATGTG	GTGTACAAAC	19440
CTGGAGCTTC	AGATGCTAGT	TCTCATGCAA	ACCTTGGTCA	ACAGTCCATG	CCCAATAGAC	19500
CTAACTATAT	TGGCTTCAGG	GACAACTTCA	TCGGACTCAT	GTACTATAAC	AGTACTGGCA	19560
ACATGGGAGT	GCTGGCTGGA	CAAGCGTCTC	AGCTAAATGC	AGTGGTTGAC	TTGCAAGACA	19620
GAAACACAGA	ATTGTCATAT	CAACTCTTGC	TTGATTCTCT	GGGAGACAGA	ACCAGATATT	19680
TCAGCATGTG	GAATCAAGCA	GTGGATAGCT	ATGACCCAGA	TGTGCGTGTT	ATTGAAAACC	19740
ATGGTGTGGA	AGATGAACTT	CCCAACTATT	GTTTTCCATT	GGACGGTGTA	GGTCCGCGAA	19800
CAGACAGTTA	CAAGGGAATT	GAGACAAATG	GTGACGAAAA	CACTACTTGG	AAAGATTTAG	19860
ATCCAAATGG	CATAAGTGAA	CTTGCTAAGG	GAAATCCATT	TGCCATGGAA	ATCAACATCC	19920
AAGCTAATCT	CTGGAGAAGT	TTCTTTTATT	CCAACGTGGC	CCTCTATCTC	CCAGACTCGT	19980
ACAAATACAC	TCCAACCAAT	GTTACTCTCC	CAGAAAACAA	AAACACCTAT	GACTACATGA	20040
ATGGGCGGGT	GGTTCCCCCC	TCCCTGGTGG	ATACCTACGT	AAACATTGGC	GCCAGATGGT	20100
CTTTGGATGC	CATGGACAAC	GTCAACCCCT	TCAACCATCA	CCGCAACGCT	GGCCTGCGAT	20160
ACCGGTCCAT	GCTTCTGGGC	AATGGTCGCT	ACGTGCCTTT	CCACATTCAA	GTGCCTCAGA	20220
AATTCTTTGC	TGTGAAAAAC	CTGCTGCTTC	TACCTGGTTC	TTACACCTAC	GAGTGGAACT	20280
TCAGAAAGGA	TGTGAACATG	GTCCTGCAGA	GTTCCCTTGG	CAATGATCTC	CGAGTTGATG	20340
GCGCCAGCAT	CAGTTTTACC	AGCATCAATC	TCTATGCCAC	CTTCTTCCCC	ATGGCCCACA	20400
ACACTGCCTC	CACCCCTGAA	GCCATGCTGC	GCAACGACAC	CAATGATCAA	TCATTCAATG	20460
ACTACCTTTC	TGCAGCTAAC	ATGCTCTACC	CCATCCCTGC	CAATGCTACC	AACGTTCCCA	20520
TCTCCATTCC	CTCTCGCAAC	TGGGCCGCCT	TCAGGGGCTG	GTCCTTTACC	AGACTGAAAA	20580
CCAAGGAGAC	TCCCTCTTTG	GGATCAGGGT	TCGATCCCTA	CTTTGTTTAC	TCTGGTTCTA	20640
TACCCTACCT	GGATGGTACC	TTCTACCTCA	ACCACACTTT	CAAGAAAGTC	TCTATCATGT	20700
TTGACTCTTC	AGTCAGCTGG	CCTGGTAATG	ACAGATTGCT	AACTCCAAAC	GAGTTCGAAA	20760
TCAAGCGCAC	AGTTGATGGG	GAAGGCTACA	ATGTGGCCCA	ATGTAACATG	ACCAAAGACT	20820
GGTTTCTGGT	CCAGATGCTT	GCCAACTACA	ACATTGGATA	CCAGGGTTTC	TATGTTCTCTG	20880
AGGGTTACAA	GGATCGCATG	TATTCCTTCT	TCAGAAACTT	CCAGCCCATG	AGTAGACAGG	20940
TGGTTGATGA	GATTAACATC	AAAGACTATA	AAGCTGTGCG	CGTACCCTAC	CAGCATAATA	21000
ACTCTGGCTT	TGTGGGTAC	ATGGCTCCTA	CCATGCGTCA	GGGTCAAGCG	TACCCTGCTA	21060
ACTACCCATA	CCCCCTAATT	GGAACCACTG	CAGTAACCAG	TGTCACCCAG	AAAAAATTCC	21120
TGTGTGACAG	GACCATGTGG	CGCATCCCAT	TCTCTAGCAA	CTTCATGTCC	ATGGGTGCCC	21180
TTACAGACCT	GGGACAGAAC	TTGCTGTACG	CCAACCTCAGC	CCATGCGCTG	GACATGACTT	21240

TTGAGGTGGA	TCCCATGGAT	GAGCCCACCC	TGCTTTATCT	TCTTTTCGAA	GTATTCGACG	21300
TGGTCAGAGT	GCACCAACCA	CATCGCGGCG	TCATCGAGGC	CGTCTACCTG	CGCACACCGT	21360
TCTCGGCTGG	TAACGCCACC	ACATAAGAAA	CCTGCTTCTT	GCAAGGGGCA	GCCATGACCT	21420
GCGTGACCGG	AAACGGCTCC	AGCGAGCAAG	AGCTCAGAGC	CATCGTCCGA	GACCTTGGCT	21480
GTGGACCCTA	TTTTCTGGGA	ACCTTTGACA	AACGCTTCCC	GGGGTTTATG	GCTCCAGACA	21540
AGCTGGCCTG	CGCCATTGTC	AACACAGCCG	GTCGCGAGAC	GGGGGGAGAG	CACTGGTTGG	21600
CTTTTGGGTTG	GAACCCGCGC	TCCAACACAT	GCTACCTTTT	TGATCCATTT	GGATTCTCGG	21660
ATGACCGTCT	TAAGCAGATC	TACCAGTTTG	AATACGAGGG	GTTGCTGCGC	CGTAGCGCCC	21720
TTGCTACTAA	GGATCGCTGC	ATTACCCTGG	AAAAGTCCAC	CCAAACAGTG	CAGGGTCCGC	21780
GCTCCGCGCG	TTGTGGACTT	TTTGCTGCA	TGTTTCTCCA	TGCCTTTGTA	CACTGGCCAG	21840
ACCGTCCCAT	GGACGGTAAC	CCCACCATGA	AGTTGCTTAC	GGGAGTGCCC	AACAACATGC	21900
TCCAGTCACC	CCAAGTCCAG	CCCACCCTGC	GCAGGAACCA	GGAGGCGCTC	TACCATTTC	21960
TCAACACACA	TTCATCTTAC	TTTCGTTCTC	ACGCGGCACG	TATCGAAAGG	GCTACTGCGT	22020
TCGATCGTAT	GGGATAATAT	AAGTCATGTA	AAACCGTGTT	CAATAAACAG	AACTTTATTT	22080
TTTACATACA	CTGGTGGTTT	GCTCATTTAT	TCGCTCAGAA	GTCGAAGGGG	TTTTGGCGGG	22140
AATCAGAGTG	ACCCGCGGGC	AGGGATACGT	TTCGGAACTG	GAACTGAGCT	TGCCACTTGA	22200
ATTCGGGGAT	CACCAGCTTG	GGAAGTGGCA	GGTCAGGCAG	GATGTCGCTC	CACAGCTTCC	22260
GGGTTAGTTG	CAGGGCTCCC	AACAGGTCAG	GGGCTGAAAT	CTTAAAATCG	CAATTGGGAC	22320
CCGTGCTCTG	AGCGCGGGAG	TTGCGATACA	CAGGGTTGCA	ACACTGGAAC	ACCATAAGCG	22380
ACGGGTATTT	CACACTCGCC	AGCACAGTGG	GGTCGGTGAT	AATTCCCACA	TCCAGGTCTT	22440
CGGCATTGGC	CATGCTAAAG	GGGGTCATCT	TGCAAGTCTG	TCTGCCCATA	GTCGGTACCC	22500
AGCCTGGCTT	GTGGTTGCAA	TCGCAGCGCA	GAGGGATTAG	CATCATCTTG	GCCTGGTCCG	22560
ATCTCATACC	TGGATACACA	GCTTTCATGA	AAGCTTCATA	TTGTTTGAAA	GCCTGTTGGG	22620
CCTTGCTACC	CTCAGTGTAG	AACATCCCAC	ATGACTTGCT	AGAGAACTGG	TTGGCAGCAC	22680
ACCCGGCATC	ATTCACACAA	CAGCGAGCGT	CGTTGTTGGC	TATTTGTACC	ACACTCCTGC	22740
CCCAGCGGTT	CTGGGTGATC	TTGGTTCGCT	CAGGGTTCTC	CTTCAGCGCC	CGTTGACCGT	22800
TTTCGCTTGC	CACATCCATT	TCTATGATAT	GCTCCTTCTG	GATCATGATG	TTGCCATGCA	22860
AACACTTTAG	CTTGCCCTCA	TAATCATTAC	ATCCATGTGA	CCACAACGCG	CATCCCGTAC	22920
ACTCCAGTT	ATTGTGAGCG	ATCTCAGAAT	AGGAGTGCAC	CAACCCCTGC	AGGAATCTTC	22980
CCATCATGGT	TGAGAGGGTC	TGTTTACTGG	TGAAAGTCAA	CGGGACGCCT	CGATGCTCCT	23040
CATTACATA	CTGGTGGCAA	ATTCGCTTGT	ACTGTTTCATG	CTGCTCTGGC	ATAAGCTTGA	23100
AAGAGGTTCT	TAGGTCATTC	TCCAGCCTGT	ACTTCTCCAT	CAGCACAGCC	ATTACTTCCA	23160

TGCCCTTTTC	CCAGGCAGAA	ACCAGGGGTA	GGCTCATGGC	ATTTCTAACA	GAAATAGCAG	23220
CTACTTTAGC	CAGAGGGTCA	TCCTTGTCGA	TCTTCTCAAC	ACTTCTTTTG	CCATCCTTCT	23280
CAGTGATGCG	CACGGGTGGG	TAGCTGAAGC	CCACAGCCAC	CAGCTCCGCC	TCTTCTCTTT	23340
CTTCTTCGCT	GTCCTGACTG	ATGTCTTGTA	AAGGGACATG	CTTGGTCTTC	CTGGACTTCT	23400
TTTTGGGGGG	TATTGGCGGA	GGGCTGCTGC	TCCGCTCCGG	AGACATGGAG	GACCGCGAAG	23460
TTTCGCTCAC	CAGTACCACC	TGGCTCTCGG	TAGAAGAACC	GGACCCACAC	CGGCGGTAGG	23520
TGTTCCCTCT	CGGGGGCAGA	GGCGGAGGTG	ACTGCGATGG	GCTGCGGTCT	GGCCTGGGAG	23580
GCGGATGACT	GGCAGAGCCC	CTTCCGCGTT	CGGGGGTG TG	CTCCCGGTGG	CGGTGCGTTG	23640
ACTGATTTCC	TCCGCGGCTG	GCCATTGTGT	TCTCCTAGGC	AGAGAAAACA	ACAGACATGG	23700
AGACTCAGCC	ATCGCTGCCA	ACACCGCTGC	AAGCACCATC	ACACCTCGCC	TCCAGCGACG	23760
AGGAGGAGGA	ACAAAGCTTA	ACCGCCCCAC	CACCCAGTCC	CGCCACCACC	ACCTCTACCC	23820
TCGAGGATGA	GGAGGTCGAC	GCACCCAGG	AGATACAGGC	GCAGGATATG	AAGGATGAGA	23880
AAGCGGAAGA	GATTGAGGCA	GATATCGAGC	AGGACCCAGG	CTATGTGACA	CGGGCCGAGC	23940
ACGAGGAAGA	GCTGAGACGC	TTTCTAGAGA	AAGATGATGA	CAACCGTCCA	GAACAGCAAG	24000
CAGATGGCGA	TCAACAGAAG	GCTGGGCTCG	GTGGTCATGT	TGCCGACTAC	CTCACC GGCC	24060
TTGGTGGGGA	GGATGTGCTC	CTCAAACACC	TAGCAAGGCA	GTCGATCATA	ATCAAAGACG	24120
CACTGCTTGA	TCGCAGCGAA	GTGCCCATCA	GTGTGGAAGA	GCTCAGCCGC	GCCTACGAGC	24180
TCAATCTGTT	CTCGCCTCGG	GTACCCCCCA	AGCGTCAGCC	AAACGGCACC	TGCGAGCCCCA	24240
ACCCTCGCCT	CAACTTCTAT	CCCGCATTCA	CCGTCCCCGA	AGTGCTGGCC	ACCTACCACA	24300
TATTTTTTAA	AAACCAAAAA	ATCCCAATTT	CCTGCCGCGC	CAACCGAACT	CGCGCCGATG	24360
CCCTGTTCAA	CTTGGGACCT	GGCGCTTGCT	TACCTGATAT	AACTTCCTTG	GAAGAGGTCC	24420
CAAAGATCTT	CGAAGGTCTG	GGCAGTGATG	AGACTCGGGC	CGCAAATGCT	CTGCAACAGG	24480
GAGAGAGTGG	CATTGATGAA	CATCACAGCG	CTCTGGTGGA	GTTGGAGGGC	GATAATGCCC	24540
GACTTGCACT	ACTCAAGCGC	AGTATCGAAG	TGACCCATTT	TGCATACCCC	GCTGTCAACC	24600
TGCCCTCCAA	AGTCATGAGC	GCTGTCATGG	ATCAGATACT	CATTAAACGC	GCAAGTCCCC	24660
TATCAGAAAA	CATGCAGGAT	CCAGACGCCT	CGGATGAGGG	CAAACCACTG	GTCAGTGATG	24720
AACAGCTATC	TCGCTGGCTG	GGCACCAACT	CCCCACTAGA	CTTGGAAGAG	CGGCGCAAGC	24780
TCATGATGGC	CGTGGTGCTA	GTTACTGTGG	AAATGGAGTG	TCTTCGCCGC	TTCTTCACTG	24840
ACCCCGAGAC	ATTGCGCAAG	CTCGAGGAGA	ACCTGCACTA	CACTTTTAGA	CATGGATT TG	24900
TGCGACAGGC	ATGCAAGATC	TCCAACGTGG	AGCTTACGAA	CCTGGTTTCC	TACATGGGCA	24960
TTTTGCATGA	AAACAGACTC	GGACAGAGCG	TGTTGCACAC	CACCCTGAAG	GGTGAAGCCC	25020
GTCGCGACTA	CATCCGCGAC	ACTGTCTACC	TCTACCTCTG	CCATACCTGG	CAGACTGGTA	25080

TGGGTGTGTG	GCAGCAGTGT	TTGGAAGAAC	AGAACCTGAA	AGAGCTTGAC	AAGCTCTTAC	25140
AAAGATCCCT	CAAATCCTTG	TGGACGGGTT	TTGACGAGCG	CACAGTCGCC	TCTGATCTGG	25200
CAGATCTCAT	CTTCCCCGAG	CGTCTCAGGA	CCACTCTGCG	CAACGGGCTG	CCTGACTTCA	25260
TGAGCCAGAG	CATGCTTAAC	AAC TTTCGCT	CTTTCATCCT	GGAACGCTCC	GGTATCCTGC	25320
CCGCCACCTG	CTGTGCGCTA	CCATCCGACT	TTGTGCCTCT	GACCTACCGC	GAGTGCCAC	25380
CACCGCTATG	GAGCCACTGC	TACCTGTTCC	GCCTGGCCAA	CTACCTATCA	TACCACTCGG	25440
ATGTGATCGA	GGATGTGAGC	GGAGATGGCC	TGCTTGAGTG	CCACTGCCGC	TGTAATCTCT	25500
GCTCACCACA	TCGCTCCCTC	GTCTGTAACC	CCCAGCTGCT	TAGTGAAACC	CAAATTATCG	25560
GCACCTTCGA	ATTGCAGGGT	CCCAGCGGCG	AAGGCGATGG	GTCTTCTCCT	GGGCAAAGTT	25620
TGAAACTGAC	CCCGGGACTG	TGGACCTCCG	CCTACCTGCG	CAAGTTCTCC	CCCGAGGACT	25680
ACCACCCCTA	TGAGATCAGG	TTCTATGAGG	ACCAATCACA	GCCGCCCAA	GCCGAGCTAT	25740
CAGCATGCGT	CATCACCAG	GGGGCAATTT	TGGCCCAATT	GCAAGCCATC	CAAAAATCCC	25800
GCCAAGAATT	TTTGCTGAAA	AAGGGTAACG	GAGTCTACCT	CGACCCCCAG	ACTGGTGAGG	25860
AGCTCAACAC	AAGGTTTTCT	CAGGATGTCT	CAGCGCOGAG	GAAGCAAGAA	GTTGAAAGTG	25920
CAGCTGCCGC	CCCCAGAGGA	TATGGAGGAA	GACTGGGACA	GTCAGACAGA	GGAGATGGAA	25980
GATTGGGACA	GCCAGGCAGA	GGAGGAGGAG	GACAGCCTGG	AGGAAGACAG	TTTGGAGGAG	26040
GAAGACGAGG	AGGCAGAGGA	GGTGGAAGAA	GCAACCGCCG	CCAAACAGTT	GTCCTCGGCA	26100
GCGGAGACAA	GCAAGGCCAC	AGACAGTACC	ACAGCTACCA	TCTCCGCTCC	GGGTCGGGGG	26160
GCCCAGCACC	GTCCCAACAG	TAGATGGGAT	GAGACGGGGC	GACTCCCGAA	TGCGACCACC	26220
GCTTCTAAGA	CTGGTAAGGA	GCGGCAGGGA	TACAAGTCCT	GGCGGGGGCA	TAAGAACGCT	26280
ATCATATCCT	GCTTGATGA	ATGCGGGGGC	AACATATCCT	TCACCCGCCG	CTACCTGCTC	26340
TTCCACCACG	GGGTGAACTT	CCCCCGCAAT	GTCTTGCAAT	ACTACCGTCA	CCTCCACAGC	26400
CCCTATTACA	GCCCGCAAGT	CTCGGCAGAA	AAAGACAACA	GCAGCAAGGA	CCTCCAGCAG	26460
AAAACCAGCA	GCAGTTAGAA	AACCCACAGC	AGGTGCAGGA	GGACTGAGAA	TCACAGCGAA	26520
CGAGCCAGCG	CAGACCCGAG	AGCTGAGAAA	CCGGATTTTT	CCAACCTCT	ATGCCATCTT	26580
CCAACAGAGT	CGGGGGCAAG	AGCAGGAACT	GAAAGTAAAA	AACCGATCTT	TGCGCTCGCT	26640
CACCCGAAGT	TGTTTGTATC	ACAAGAGCGA	AGACCAACTT	CAGCGCACTC	TCGAGGACGC	26700
CGAGGCTCTC	TTCAACAAGT	ACTGCGCGCT	CACTCTTAAA	GAGTAGCCCG	CGCCCGCGCT	26760
ATCTCGAAAA	AGGCGGGAAT	TACGTCACCC	TTGGCGCCCG	TCCTTTGCCC	TCGTCATGAG	26820
TAAAGAAATT	CCCACGCCTT	ACATGTGGAG	TTATCAGCCC	CAAATGGGAC	TGGCAGCAGG	26880
CGCCTCCCAG	GACTACTCCA	CCCGTATGAA	TTGGCTCAGC	GCCGGTCCCT	CGATGATCTC	26940
ACGGGTTAAT	GATATACGAG	CTTATCGAAA	CCAATTACTC	CTAGAACAGT	CAGCACTTAC	27000

CACCACCCCC	AGACAACACC	TTAATCCCCG	AAATTGGCCC	GCCGCCCTGG	TGTACCAGGA	27060
AACCCCCGCT	CCCACCACCG	TACTACTTCC	TCGAGACGCC	CAGGCCGAAG	TTCAGATGAC	27120
TAACGCAGGT	GTACAGCTGG	CGGGCGGTTC	CGCCCTTTGT	CGTCACCGGC	CTCAACAGAG	27180
TATAAACGC	CTGGTGATCA	GAGGCCGAGG	TATCCAGCTC	AACGACGAGT	CGGTGAGCTC	27240
TTGCTTGGT	CTGCGACCAG	ACGGAGTCTT	CCAAATTGCC	GGCTGCGGGA	GATCTTCCTT	27300
CACTCCTCGT	CAGGCTGTAC	TGACTTTGGA	GAGTTCGTCC	TCACAGCCCC	GCTCGGGTGG	27360
CATCGGGACT	CTCCAGTTTG	TGGAGGAGTT	TACTCCCTCT	GTCTACTTCA	ACCCCTTCTC	27420
CGGATCTCCT	GGGCATTACC	CGGACGAGTT	CATACCAAAT	TTCGACGCAA	TCAGCGAGTC	27480
AGTGGATGGT	TATGATTGAT	GTCTAATGGT	GGCGCGGCTG	AGCTAGCTCG	ACTGCGACAT	27540
CTAGACCACT	GCCGCCGCTT	TCGCTGCTTT	GCCAGAGAAC	TCACCGAGTT	CATCTACTTC	27600
GAAATACCCG	AGGAGCACCC	TCAGGGACCG	GCCCACGGAG	TGCGTATTAC	CATCGAAGGG	27660
GGTATAGACT	CTCGCCTGCA	TCGAATCTTC	TGCCAGCGGC	CCGTGCTAAT	CGAGCGCGAC	27720
CAGGGAAACA	CCACAGTCTC	CATCTACTGC	ATCTGTAACC	ACCCCGGATT	GCATGAAAGC	27780
CTTTGCTGTC	TTATTTGTGC	TGAGTTTAAT	AAAAACTGAG	TTAAGACTCT	CCTACGGACT	27840
ACCAATTCTT	CAACCCGGAC	TTTATAACAA	TCAGACCCTC	CTACCAAGTC	AGAAGACCCC	27900
AACCCCTCCT	CTGATCCAGG	ACTCTAATTC	TACCTCCCCA	GCACCATACT	TTACTAGCCT	27960
TCCCGAAACT	AACAACCTCG	GAGCTAAACT	GCACCGCTTT	TCCAGAAGCC	TTCTCTCTGC	28020
CAATACTACC	ACTCCCAGAA	CCGGAGGTGA	GCTCCGTAGT	CTTCCTAATA	ACAACCCCTG	28080
GGTGGTAACT	GGGTTTGTA	CATTAGGTGT	AGTTGCGGGT	GGGCTTGTC	TTATCCTTTG	28140
CTACCTATAC	ACACCTTGCT	GTGCTTATTT	AGTAATCTTG	TGTTGCTGGT	TTAAGAAATG	28200
GGGGCCCTAC	TAGCCGCGCT	TGCTTTACTT	TCACTTTTTG	AGCCTGGCTC	TACTATGCTA	28260
GTTCAGCCTG	TACTATTTGA	TCCATGCCTC	AATTTTGATC	CAGACAACTG	CACACTCACT	28320
TTTGCTCCAG	AGGCTGGACG	CTGTGGAGTT	CTTATTAGGT	GCGGACGGGA	ATGCAGTCCC	28380
ATTGAAATAC	ACCACAATAA	CAAACCTTGG	AACAATACCT	TATTCACCAC	ATGGCAGCCA	28440
GGAGACCCTG	AGTGGTATAC	TGTCTCTGTC	CGTGGTCCTG	ACGGTTCCAT	CCGCACTGCT	28500
AATAACACTT	TTATTTTTGC	TGAGATGTGC	GATCTGACCA	TGTTCATGAG	CAAACAGTAT	28560
AACCTATGGC	CTCCAAGCAA	GGAGAACATT	GTGGCATTCT	CCCTTGCTTA	TTGCTTGTTG	28620
ACGTGTCTCA	TTACTGCTAT	TCTGTGTATC	TGCATACACT	TGCTTATTGC	CACTCGCCAC	28680
AGAAACAGCA	ATAAGGAAAA	AGAGAAAATG	CCTTGAGCTT	TTTCTCATCT	ATGTTTTTTT	28740
TTTTTGTTAC	AGACATGGCT	TCAGTTATAG	CTCTAATTAT	TGCCAGCATT	CTCACTGCCG	28800
CACACGGACA	AACAATTGTC	TATATTACCT	TAGGTCATAA	CCACACTCTT	ATAGGACCCC	28860
AAATTAGTTC	ACAGGTTATA	TGGACCAAAC	TTGGAAGTGT	TGATTATTTT	GACATAATCT	28920

GCAACAGAAC	TAAACCAATA	TTTGTAACT	GTAACAAACA	AAATCTCACC	TTAATCAATG	28980
TTAGCGAAAT	TTACAACGGT	TACTATTATG	GTTATGACAG	ACACAGCAGT	GAATATAAAA	29040
ATTACTTAGT	TCGCATAACT	CAACCCAAAA	CTACAAAAAT	GCCAAATATG	GCAAAAATTC	29100
AAATGGTTAG	CACATTAGAA	AATCTTTCAT	ATCCCACCAC	ACCCGATGAG	AAAAACATTC	29160
CAAATTCAAT	GATTGCCATT	ATTGCGGCGG	TGGCAGTGGG	AATGGCACTA	ATAATAATTT	29220
GTATGTTCCCT	ATATGCTTGT	TACTGTAGAA	AGTTTCACAA	ACAGGACCCC	CTACTAAATT	29280
TTTGACATTT	AATTTTTTAT	ACAGCTATGG	TTTCCACTAC	AGCCTTTTTT	ATTATCAGTA	29340
GCCTTGACAG	TGTCACCTAT	GGTCGCTCAC	ACCTCACTGT	AACGTGTTGGC	TCAACTTGTA	29400
CACTACAAGG	ACCCCAAGAA	GGGCATGTCA	GTTGGTGGAG	AATATATGAT	AGTGGATGGT	29460
TCATTAGGCC	ATGTGACCAG	CCTGGTAACA	AATTTCTCTG	CAACGGGAGA	GACCTGACCA	29520
TTATTAACAT	AACAGTAAAT	GACCAGGGCT	TCTATTATGG	AACTAACTAT	AAAAATAACT	29580
TAGATTACAA	CATTATCGTA	GTGCCAGCCA	CCACTCCAGC	TCCCCGCAA	ACCACTTTCT	29640
TTAGCAGCAG	TGCCAGTATT	TCTAAAAACAG	CTTCTGCAAT	CTTAAAGCTT	CAAAAAATCG	29700
CTTTAAGTAA	TTCCACAACC	TCTTCCACTA	ACACAACGTC	TAAATCAGTA	GTCGGCATCG	29760
CTGTTGCCGC	GGTAATGGGA	TTAATGATTA	TAACTTTGTG	CATAATCTAC	TACGCCTGCT	29820
GCTATAGAAA	ACATGAACAA	AAAAGCGATC	CCTTGCTGAA	TTTTGATATT	TAATTTTTTT	29880
TTATAGAATC	ATGAAAAAAC	TAATTATCCT	AGCTTTTATT	TTGTTTCAAT	CATATACCAC	29940
TAACACTACC	AATGTGCAGA	CTACTTTAAA	TCATAGTATG	GAAAACCACA	CTACCTCTTA	30000
TAAGCACACA	AACATCACTA	CCCATCAGCC	TAAATATGCT	ATGCAACTAG	AAATCACAAT	30060
ACTAATTGTG	ATTGCAATAC	TTATCATATC	TATCATTTTC	TATTTTACCC	TATGCCGCCA	30120
AATACCCAAT	ATTCATAGAA	AAAGACGTCC	CATTTATTGC	CCCATGATTA	GTCAACCCCA	30180
TATGACTCTA	AATGAAATCT	AAGATCTATT	CTTTCTCTTT	TTTACAGTAT	GGTGAACACC	30240
AATCATGATT	CCTAGAAAAT	TCTTCTTCAC	CATACTCATC	TGTGCTTTTA	ATGTCTGTGC	30300
CACCTTTACA	GCAGTAGCCA	CTACAAGCCC	CGACTGTATA	GGACCATTTG	CCTCATACAC	30360
ACTTTTTGCT	TTTGTCGCTT	GCACCTGCGT	GTGTAGCGTA	GTCTGCCTGG	TTATTAATTT	30420
TTTTCAACTT	GTAGACTGGA	TCTTTGTGAG	ACTTGCCTAT	CTGCGTCACC	ATCCCGAATA	30480
CCGCAATCAA	CATGTTGCGG	CACCTCTCAG	ACTTATTTAA	AACCATGCAG	GCTATACTAC	30540
CAGTCATTCT	GCTTCTGTTG	CTCCCCGCG	ATGCCTTAAC	CCCCGTCGCT	AATCGTACCC	30600
CACCTGAACA	ACTTAGAAAA	TGCAAATTCC	AACAACCATG	GACATTCCTT	GATTGCTATC	30660
GAGAAAAATC	TGATTTCCCC	ACATACTGGA	TTATGATCAT	TGGAATTGTT	AATCTAGTTT	30720
CTTGACACT	ATTCTCTTTC	CTTGTTTATC	ATTTTTTTGA	TTTTGGATGG	AATGCCCCCA	30780
ATGCACTCAC	TTACCCACAA	GAACCAGAGG	AACATATCCC	ACTACAGAAC	ATGCAACAGC	30840

CAATAGCTTT	AATAGATTAT	GACAATGAGC	CACAGCCCTC	GCTGCTTCCT	GCTATTAGTT	30900
ACTTCAACCT	AACCGGTGGA	GATGACTGAC	CCACTCGCCG	CCTCCACTGC	TGCCGAGGAA	30960
CTGCTTGATA	TGGACGGCCG	CACCTCAGAA	CAGCGACTCG	CCCAACTACG	CATACGCCAG	31020
CAGCAGGAAC	GTGCCGCCAA	GGAGCTCAGG	GATGCTATTG	AAATTCACCA	GTGCAAAAAA	31080
GGCATATTCT	GTCTGGTGAA	ACAAGCCAAG	ATTTCTTACG	AGATCACCAC	TACTGACCAT	31140
CGCCTCTCAT	ACGAGCTCGG	TCCGCAGCGG	CAAAAATTCA	CGTGTATGGT	GGGAATCAAC	31200
CCCATAGTCA	TTACCCAGCA	GGCTGGAGAT	ACTAAGGGTT	GCATCCACTG	TTCCTGCGGT	31260
TCCACCGAGT	GCATCTACAC	CCTACTTAAG	ACCCTCTGCG	GCCTTCGAGA	CATCCTACCC	31320
ATGAACTGAT	CAACTTTCCT	TCCCCCATT	CAAAAAACAA	TAATAAAAAAT	CACTTACTTG	31380
AAATCAGCAA	TCATGTCTCC	GTCCAAATTT	TCTCCTAGCA	GCACCTCACT	TCCCTCTTCC	31440
CAACTCTGGT	ACTCTAAACC	CCGCCTGGCA	GCATACTTTC	TCCACACTTT	AAATGGAATG	31500
TCAAATTTTA	GTTCTCTTTT	TCTACCCACA	ATCTTCATCT	CTTTATTCTC	CCCAGATGGC	31560
CAAACGAACT	CGGTTGAGCA	GCTCCTTCAA	CCCGGTCTAC	CCCTATGAAG	ATGAAAACAG	31620
CTCACACCCC	TTTATAAACC	CTGGTTTCAT	TTCCCCTAAT	GGGTTTACAC	AAAGCCCAGA	31680
CGGAGTTCTG	ACACTAAATT	GTGTTGCTCC	CCTTACAACC	GCTAATGGCG	CCCTAGATAT	31740
CAAAGTAGGA	GGAGGGCTTA	AAGTGAAGTC	AACTGATGGA	TTCTTAGAAG	AAAACATAAA	31800
CATCACATCA	CCACTTACAA	AGTCTAACCA	TTCTATAGGT	TTAGAATGGA	GCGATGGGTT	31860
ACAAACAAAC	GAAGCCAAGC	TCTGTGTCAA	ACTTGGAATA	GGTCTTGAT	TTGACTCTTC	31920
CAGTGCTATT	GCAATGGAAA	ATAACACTTT	GTGGACAGGT	GCAAAACCAA	GTGCCAACTG	31980
TGTAATTAAA	GAGGGAGAAG	ATTCCCCAGA	CTGTAAGCTC	ACTTTAGTTC	TAGTGAAGAA	32040
TGGAGGACTG	GTAAATGGAT	ACATAACATT	AATGGGAGAC	TCAGAATATA	CTAACACCTT	32100
GTTTAAAAAC	AAACAAGTTA	CAATAGATGT	AAACCTCGCA	TTTGATAATA	CCGGCCAAAT	32160
TATCACTTAC	CTATCATCTC	TTAAAAGTAA	CCTGAACCTT	AAAGACAACC	AAAACATGGC	32220
TACTGGAACC	ATAACCAGTG	CCAAAGGCTT	CATGCCCAGC	ACCACCGCCT	ATCCATTTAT	32280
AACATACGCC	ACTCAGTCCC	TAAATGAAGA	TTACATTTAT	GGAGAGTGTT	ACTACAAATC	32340
TACCAATGGA	ACTCTCTTTC	CACTAAAAGT	TACTGTCACA	CTAAACAGAC	GTATGTCAGC	32400
TTCTGGAATG	GCCTATGCTA	TGAACTTTTC	ATGGTCTCTA	AATGCAGAGG	AAGCCCCTGA	32460
AACTACCGAA	GTCACCTCTA	TTACCTCCCC	CTTCTTTTTT	TCTTATATCA	GAGAAGACGA	32520
CTGACAACAA	AAAATAAAGA	TTAACTTTTT	TATTGAAATC	AGTTTACAAG	ATTTCGAGTAG	32580
TTATTTTGCC	CCCCTCTTCC	CATTTTATAG	AATACACAAT	CCTCTCCCCA	CGCACAGCTT	32640
TGAACATTTG	AATTCCATTA	GAGATAGACA	TAGTTTTAGA	TTCCACATTC	CACACAGTTT	32700
CAGAGCGGGC	CAATCTTGGA	TCAGTGATAG	ATATAAAGCC	ATCGGAACAG	TCTTTCAAGG	32760

TGGTTTCACA	GTCCAACGTC	TGCGGCTGCG	GCTCCGGAGT	TTGGATTAGA	GTCATCTGGA	32820
AGAAGAACGA	TGGGAGTCAT	AATCCGAGAA	CGGGATCGGA	CGGTTGTGTC	TCAAACCTCG	32880
AAGCAGTCGC	TGTCTGCGCC	GCTCOGTGCG	ACTGCTGCTG	ATGGGATCAG	GATCCACAGT	32940
CTCTCTAAGC	ATGATTTTAA	TAGCCCTCAA	CATTAACATC	CTGGTGCGAT	GTGCACAACA	33000
ACGCATTCTA	ATCTCGCTTA	GCTCACTGCA	GTAGGTACAA	CACATTACCA	CAATGTTGTT	33060
TAACAGGCCA	TAATTAAAGG	TGCTCCAGCC	AAACTCATC	TCAGGGATAA	TCATGCCCCG	33120
GTGACCATCA	TACCAGATCT	TAATGTAAAT	CAAATGGCGC	CCCCTCCAGA	ACACACTGCC	33180
CACATACATA	ATCTCCTTGG	GCATATGCAT	GTTCAACAATC	TCTCTGTACC	ATGGACAGCG	33240
CTGGTTAATC	ATACAGCCCC	TAATAACCTT	CCGGAACCAA	ATAGCCAGCA	CTGCTCCCCC	33300
AGCAATACAT	TGAAGAGAAC	CCGGCTGTTT	ACAGTGACAA	TGAAGAACCC	ACTTCTCTCG	33360
CCCATGGATC	ACTTGAGAAT	GAAATATATC	TATAGTGGCA	CAACACAAAC	ATAAATGCAT	33420
GCATCTTTTC	ATAACCCCTA	ACTCTTCGGG	GGTTAGAAAC	ATATCCCAGG	GAATGGGAAG	33480
CTCTTGCAAA	ACAGTAAAGC	TGGCAGAACA	AGGAAGACCG	CGAACATAAC	TTACACTGTG	33540
CATGGTCAGG	GTATTACAAT	CTGGTAACAG	TGGATGGTCT	TCAGTCATAG	AAGCTCTGGT	33600
TTCATTTTCC	TCACAGCGTG	GTAAAGGGGC	CCTCAAATGA	GGGTCCATGA	TGTACGGATG	33660
ATGTCTGTGG	CATGACGTCG	ATCGTGCACG	CGACCTCGTT	GTAATGGAGC	TGCTTCCTGA	33720
CATTCTCGTA	TTTTGCGATG	CAAAACCTAG	CCTTAGCACA	ACACACTTCT	CTTCGCCTTC	33780
TATCCCGTCG	CCTAACGCAT	TCAGTGTGGT	AATTGAAGTA	CAGCCATTCC	CGTAGATTGG	33840
TCAAAGTTTC	CTCGGCTTCA	GTTGTTATGA	AAACTCCATC	ATGTCTGATC	GCTCTGATAA	33900
AATCATTAC	TGTAGAATGG	GCAATACCCA	ACCATGCAAT	ACAATTAGCT	TGAGTTTTAA	33960
TCAAAGGAGG	GGGAGGAAGA	CATGGAAGAA	CCATAATTAA	TTTTTTATTC	CAGACGATCT	34020
CGCAGTATTT	CTAAATGAAG	ATCACGAAGA	TGGCACCTCT	CGCCCCACT	GTGTTGATGA	34080
AAAATAACAG	CTAAGTCAAA	CACGATGCGA	TTCTCAAGAT	GCTCAATGGT	GGCTTCAAGC	34140
AAAGCCTCCA	CGCGCACATC	CAAAAACAAA	AGAACAGCAA	AAGAAGGGGC	ATGTTCTAAT	34200
TCCTCAATCA	TCATATTACA	TTCCTGTACC	ATTCCCAGAT	AATTTTCATC	TTTCCAGCCT	34260
TGAATTAATC	GTGTCATTTT	TTCTTGTAAG	TCCAATCCAC	ACATGAAAAA	CAGCTCTCGG	34320
AGGGCACCCCT	CCACCACCAT	CCTTAAGCAC	ACCCTCATAA	TGACAAAATA	TCTTGCTCCT	34380
GTGTCACCTG	CAGCAAAATTG	AGAATGGCAA	CATCAAACGA	CATGCCATTG	TCTCTAAGCT	34440
CTTCTCTAAG	TTCAAGTTGT	AAAACTCCT	TCAAATCATC	GCCAAACTGC	TTGGCCATAG	34500
GTCCGCCAGG	AATAAGAGCG	GGGGACGCTA	CTGTACAGAA	CAAACGGAGA	CCGCCCCAAT	34560
GGGATCCAGC	AAAAGTGAGG	TTACAATAAG	CATACTGAGA	ACCTCCAGTG	ATATCATCCA	34620
GAGTGCTGGA	AACATAATCA	GGCAGAGTTT	CTCGTATAAA	ATTAATAAAA	GAAAATTCTG	34680

70

CCAGATGAAC	ATTTAAAAATT	TCTGGAATAC	AGATGCAATA	AGTTACCGCG	CTGCGCTCCA	34740
ACATTGTTAG	TACGATTAGT	CTGTAAAAAA	ACAGCACAAA	AGTTATTACA	TCATGCTAGC	34800
CTGGCGAACG	GATGGATAAA	TCACTCTCTC	CAACACCAGG	CAGGCTACAG	GGTCTCCAAC	34860
ACGACCCTCG	TAAAACCTGT	CAGTATGATT	AAAAAGCATC	ACCGAAAGAG	GCTGTTGATG	34920
AGCAGCAAAT	ATTATTTGCG	ATGAAGCATA	CAATCCAGAA	GTGTTAGTAT	CAGTTAAAGA	34980
AAAAAAACGT	CCAATATAGC	ATCTGGGAAC	AATTATGCTC	AATCTCAAAT	GCAGCAAAGC	35040
GACACCTCTG	GGATGCAAAG	TAAAATCCAC	AGGAGCATAA	AAAATGTAAT	TATTCCTCTC	35100
TTGCACAGGC	AGCCTAGCTC	CCGGCCCCCTC	CAAAATCACA	TACAAAACCTT	CAGCCATAGC	35160
TTACCGCACA	AATCAGGCAG	AGCAGACAGG	AGAACTATAA	ACTGACTGCC	GCCTGTGCGC	35220
AATATATAGT	CAACCTATAC	ACTGACGTAA	TCGGATAAAG	TCTAAAAAAT	CCCGCCAAAA	35280
CCAGCACACG	CCCAGAAACT	GTGTCATCCG	CGAGAAAATT	TCACTTCCGC	ATTTTATTCC	35340
GGAAAAACGT	CACTTCCTCT	TTCCCACGAA	TCGTCACTTC	CGGTAATCTT	GTAACGTCAC	35400
CTTCCCGCCC	CGCCCCTAAC	GGTCGCGGTC	CCCACAGCCA	ATCACCTTTC	ACCCTCCCCA	35460
AATTCAAACG	CCTCATTTGC	ATATTAACAC	GCACCAAAAG	TTTAAGGTAT	ATTATTGATG	35520
ATGG						35524

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36519 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCATCTTCAA	TAATATACCT	CAAACCTTTT	GTGCGCGTTA	ATATGCAAAT	GAGGCGTTTG	60
AATTTGGGGA	GGAAGGGCGG	TGATTGGTCG	AGGGATGAGC	GACCGTTAGG	GGCGGGGCGA	120
GTGACGTTTT	GATGACGTGG	TTGCGAGGAG	GAGCCAGTTT	GCAAGTTCTC	GTGGGAAAAG	180
TGACGTCAAA	CGAGGTGTGG	TTTGAACACG	GAAATACTCA	ATTTTCCCGC	GCTCTCTGAC	240
AGGAAATGAG	GTGTTTCTGG	GCGGATGCAA	GTGAAAACGG	GCCATTTTCG	CGCGAAAACCT	300
GAATGAGGAA	GTGAAAATCT	GAGTAATTTT	GCGTTTATGG	CAGGGAGGAG	TATTTGCCGA	360
GGGCCGAGTA	GACTTTGACC	GATTACGTGG	GGGTTTCGAT	TACCGTGTTT	TTCACCTAAA	420
TTTCCGCGTA	CGGTGTCAAA	GTCCGGTGTT	TTTACGTAGG	TGTCAGCTGA	TCGCCAGGGT	480
ATTTAAACCT	GCGCTCTCCA	GTCAAGAGGC	CACCTTTGAG	TGCCAGCGAG	AAGAGTTTTT	540
TCCTCCGCGC	CGCGAGTCAG	ATCTACACTT	TGAAAGATGA	GGCACCTGAG	AGACCTGCCC	600

GATGAGAAAA	TCATCATCGC	TTCCGGGAAC	GAGATTCTGG	AACTGGTGGT	AAATGCCATG	660
ATGGGCGACG	ACCCTCCGGA	GGCCCCCACC	CCATTTGAGA	CACCTTCGCT	GCACGATTTG	720
TATGATCTGG	AGGTGGATGT	GGCCGAGGAC	GATCCCAATG	AGGAGGCGGT	AAATGATTTT	780
TTTAGCGATG	CCGCGCTGCT	AGCTGCCGAG	GAGGCTTCGA	GCTCTAGCTC	AGACAGCGAC	840
TCTTCACTGC	ATACCCCTAG	ACCGGCAGAG	GGTGAGAAAA	AGATCCCCGA	GCTTAAAGGG	900
GAAGAGATGG	ACTTGCGCTG	CTATGAGGAA	TGCTTGCCCC	CGAGCGATGA	TGAGGACGAG	960
CAGGCGATCC	AGAACGCAGC	GAGCCAGGGA	GTGCAAGCCG	CCAGCGAGAG	CTTTGCGCTG	1020
GACTGCCCCG	CTCTGCCCGG	ACACGGCTGT	AAGTCTTGTG	AATTTTCATCG	CATGAATACT	1080
GGAGATAAAG	CTGTGTTGTG	TGCACTTTGC	TATATGAGAG	CTTACAACCA	TTGTGTTTAC	1140
AGTAAGTGTG	ATTAAGTTGA	ACTTTAGAGG	GAGGCAGAGA	GCAGGGTGAC	TGGGCGATGA	1200
CTGGTTTATT	TATGTATATA	TGTTCTTTAT	ATAGGTCCCG	TCTCTGACGC	AGATGATGAG	1260
ACCCCCACTA	CAAAGTCCAC	TTCGTCACCC	CCAGAAATTG	GCACATCTCC	ACCTGAGAAT	1320
ATTGTTAGAC	CAGTTCCTGT	TAGAGCCACT	GGGAGGAGAG	CAGCTGTGGA	ATGTTTGGAT	1380
GACTTGCTAC	AGGGTGGGGT	TGAACCTTTG	GACTTGTGTA	CCCGGAAACG	CCCCAGGCAC	1440
TAAGTGCCAC	ACATGTGTGT	TTACTTGAGG	TGATGTCAGT	ATTTATAGGG	TGTGGAGTGC	1500
AATAAAAAAT	GTGTTGACTT	TAAGTGCGTG	GTTTATGACT	CAGGGGTGGG	GACTGTGAGT	1560
ATATAAGCAG	GTGCAGACCT	GTGTGGTTAG	CTCAGAGCGG	CATGGAGATT	TGGACGGTCT	1620
TGGAAGACTT	TCACAAGACT	AGACAGCTGC	TAGAGAACGC	CTCGAACGGA	GTCTCTTACC	1680
TGTGGAGATT	CTGCTTCGGT	GGCGACCTAG	CTAGGCTAGT	CTACAGGGCC	AAACAGGATT	1740
ATAGTGAACA	ATTTGAGGTT	ATTTTGAGAG	AGTGTTCCTG	TCTTTTGTGAC	GCTCTTAACT	1800
TGGGCCATCA	GTCTCACTTT	AACCAGAGGA	TTTCGAGAGC	CCTTGATTTT	ACTACTCCTG	1860
GCAGAACCA	TGCAGCAGTA	GCCTTTTTTG	CTTTTATTCT	TGACAAATGG	AGTCAAGAAA	1920
CCCATTTTCA	GAGGGATTAC	CAGCTGGATT	TCTTAGCAGT	AGCTTTGTGG	AGAACATGGA	1980
AGTGCCAGCG	CCTGAATGCA	ATCTCCGGCT	ACTTGCCGGT	ACAGCCGCTA	GACACTCTGA	2040
GGATCCTGAA	TCTCCAGGAG	AGTCCCAGGG	CACGCCAACG	TCGCCAGCAG	CAGCAGCAGG	2100
AGGAGGATCA	AGAAGAGAAC	CCGAGAGCCG	GCCTGGACCC	TCCGGCGGAG	GAGGAGGAGT	2160
AGCTGACCTG	TTTCCTGAAC	TGCGCCGGGT	GCTGACTAGG	TCTTCGAGTG	GTCGGGAGAG	2220
GGGGATTAAG	CGGGAGAGGC	ATGATGAGAC	TAATCACAGA	ACTGAACTGA	CTGTGGGTCT	2280
GATGAGTCGC	AAGCGCCCAG	AAACAGTGTG	GTGGCATGAG	GTGCAGTCGA	CTGGCACAGA	2340
TGAGGTGTCT	GTGATGCATG	AGAGGTTTTT	TCTAGAACAA	GTCAAGACTT	GTTGGTTAGA	2400
GCCTGAGGAT	GATTGGGAGG	TAGCCATCAG	GAATTATGCC	AAGCTGGCTC	TGAGGCCAGA	2460
CAAGAAGTAC	AAGATTACTA	AGCTGATAAA	TATCAGAAAT	GCCTGCTACA	TCTCAGGGAA	2520

TGGGGCTGAA	GTGGAGATCT	GTCTCCAGGA	AAGGGTGGCT	TTCAGATGCT	GCATGATGAA	2580
TATGTACCCG	GGAGTGGTGG	GCATGGATGG	GGTTACCTTT	ATGAACATGA	GGTTCAGGGG	2640
AGATGGGTAT	AATGGCACGG	TCTTTATGGC	CAATACCAAG	CTGACAGTCC	ATGGCTGCTC	2700
CTTCTTTGGG	TTTAATAACA	CCTGCATCGA	GGCCTGGGGT	CAGGTCCGTG	TGAGGGGCTG	2760
CAGTTTTTCA	GCCAACTGGA	TGGGGGTCGT	GGGCAGGACC	AAGAGTATGC	TGTCCGTGAA	2820
GAAATGCTTG	TTTGAGAGGT	GCCACCTGGG	GGTGATGAGC	GAGGGCGAAG	CCAGAATCCG	2880
CCACTGCGCC	TCTACCGAGA	CGGGCTGCTT	TGTGCTGTGC	AAGGGCAATG	CTAAGATCAA	2940
GCATAATATG	ATCTGTGGAG	CCTCGGACGA	GCGCGGCTAC	CAGATGCTGA	CCTGCGCCGG	3000
CGGGAACAGC	CATATGCTGG	CCACCGTACA	TGTGGCTTCC	CATGCTCGCA	AGCCCTGGCC	3060
CGAGTTCGAG	CACAATGTCA	TGACCAGGTG	CAATATGCAT	CTGGGGTCCC	GCCGAGGCAT	3120
GTTCATGCCC	TACCAGTGCA	ACCTGAATTA	TGTGAAGGTG	CTGCTGGAGC	CCGATGCCAT	3180
GTCCAGAGTG	AGCCTGACGG	GGGTGTTTGA	CATGAATGTG	GAGGTGTGGA	AGATTCTGAG	3240
ATATGATGAA	TCCAAGACCA	GGTGCCGAGC	CTGCGAGTGC	GGAGGGAAGC	ATGCCAGGTT	3300
CCAGCCCGTG	TGTGTGGATG	TGACGGAGGA	CCTGCGACCC	GATCATTGTTG	TGTTGCCCTG	3360
CACCGGGACG	GAGTTCGGTT	CCAGCGGGGA	AGAATCTGAC	TAGAGTGAGT	AGTGTCTGTTG	3420
GGCGGGGGAG	GACCTGCATG	AGGGCCAGAA	TAAGTGAAT	CTGTGCTTTT	CTGTGTGTTG	3480
CAGCAGCATG	AGCGGAAGCG	GCTCCTTTGA	GGGAGGGGTA	TTCAGCCCTT	ATCTGACGGG	3540
GCGTCTCCCC	TCCTGGGCGG	GAGTGCGTCA	GAATGTGATG	GGATCCACGG	TGGACGGCCG	3600
GCCCGTGCGAG	CCCGCGAACT	CTTCAACCCT	GACCTATGCA	ACCCTGAGCT	CTTCGTCGTT	3660
GGACGCAGCT	GCCGCCGCAG	CTGCTGCATC	TGCCGCCAGC	GCCGTGCGCG	GAATGGCCAT	3720
GGGCGCCGGC	TACTACGGCA	CTCTGGTGGC	CAACTCGAGT	TCCACCAATA	ATCCCGCCAG	3780
CCTGAACGAG	GAGAAGCTGT	TGCTGCTGAT	GGCCAGCTC	GAGGCCTTGA	CCCAGCGCCT	3840
GGGCGAGCTG	ACCCAGCAGG	TGGCTCAGCT	GCAGGAGCAG	ACGCGGGCCG	CGGTTGCCAC	3900
GGTGAAATCC	AAATAAAAAA	TGAATCAATA	AATAAACGGA	GACGGTTGTT	GATTTTAACA	3960
CAGAGTCTGA	ATCTTTATTT	GATTTTTCGC	GCGCGGTAGG	CCCTGGACCA	CCGGTCTCGA	4020
TCATTGAGCA	CCCGGTGGAT	CTTTTCCAGG	ACCCGGTAGA	GGTGGGCTTG	GATGTTGAGG	4080
TACATGGGCA	TGAGCCCGTC	CCGGGGGTGG	AGGTAGCTCC	ATTGCAGGGC	CTCGTGCTCG	4140
GGGGTGGTGT	TGTAAATCAC	CCAGTCATAG	CAGGGGCGCA	GGGCATGGTG	TTGCACAATA	4200
TCTTTGAGGA	GGAGACTGAT	GGCCACGGGC	AGCCCTTTGG	TGTAGGTGTT	TACAAATCTG	4260
TTGAGCTGGG	AGGGATGCAT	GCGGGGGGAG	ATGAGGTGCA	TCTTGGCCTG	GATCTTGAGA	4320
TTGGCGATGT	TACCGCCCAG	ATCCCGCCTG	GGGTTTCATGT	TGTGCAGGAC	CACCAGCACG	4380
GTGTATCCGG	TGCACTTGGG	GAATTTATCA	TGCAACTTGG	AAGGGAAGGC	GTGAAAGAAT	4440

TTGGCGACGC	CTTTGTGCCC	GCCCAGGTTT	TCCATGCACT	CATCCATGAT	GATGGCGATG	4500
GGCCCGTGGG	CGGCGGCCTG	GGCAAAGACG	TTTCGGGGGT	CGGACACATC	ATAGTTGTGG	4560
TCCTGGGTGA	GGTCATCATA	GGCCATTTTA	ATGAATTTGG	GGCGGAGGGT	GCCGGACTGG	4620
GGGACAAAGG	TACCCTCGAT	CCCGGGGGCG	TAGTTCCCCT	CACAGATCTG	CATCTCCCAG	4680
GCTTTGAGCT	CGGAGGGGGG	GATCATGTCC	ACCTGCGGGG	CGATAAAGAA	CACGGTTTCC	4740
GGGGCGGGGG	AGATGAGCTG	GGCCGAAAGC	AAGTTCCGGA	GCAGCTGGGA	CTTGCCGCAG	4800
CCGGTGGGGC	CGTAGATGAC	CCCGATGACC	GGCTGCAGGT	GGTAGTTGAG	GGAGAGACAG	4860
CTGCCGTCTT	CCCGGAGGAG	GGGGGCCACC	TCGTTCATCA	TCTCGCGCAC	GTGCATGTTC	4920
TCGCGCACCA	GTTCCGCCAG	GAGGCGCTCT	CCCCCAGGG	ATAGGAGCTC	CTGGAGCGAG	4980
GCGAAGTTTT	TCAGCGGCTT	GAGTCCGTCG	GCCATGGGCA	TTTTGGAGAG	GGTTTGTTC	5040
AAGAGTTCCA	GGCGGTCCCA	GAGCTCGGTG	ATGTGCTCTA	CGGCATCTCG	ATCCAGCAGA	5100
CCTCCTCGTT	TCGCGGGTTG	GGACGGCTGC	GGGAGTAGGG	CACCAGACGA	TGGGCGTCCA	5160
GCGCAGCCAG	GGTCCGGTCC	TTCCAGGGTC	GCAGCGTCCG	CGTCAGGGTG	GTCTCCGTCA	5220
CGGTGAAGGG	GTGCGCGCCG	GGCTGGGCGC	TTGCGAGGGT	GCGCTTCAGG	CTCATCCGGC	5280
TGGTCGAAAA	CCGCTCCCGA	TCGGCGCCCT	GCGCGTCGGC	CAGGTAGCAA	TTGACCATGA	5340
GTTTCGTAGTT	GAGCGCCTCG	GCCGCGTGGC	CTTTGGCGCG	GAGCTTACCT	TTGGAAGTCT	5400
GCCCCGAGGC	GGGACAGAGG	AGGGACTTGA	GGGCGTAGAG	CTTGGGGGCG	AGGAAGACGG	5460
ACTCGGGGGC	GTAGGCGTCC	GCGCCGCAGT	GGGCGCAGAC	GGTCTCGCAC	TCCACGAGCC	5520
AGGTGAGGTC	GGGCTGGTCG	GGGTCAAAAA	CCAGTTTCCC	GCCGTTCTTT	TTGATGCGTT	5580
TCTTACCTTT	GGTCTCCATG	AGCTCGTGTC	CCCGCTGGGT	GACAAAGAGG	CTGTCCGTGT	5640
CCCCGTAGAC	CGACTTTATG	GGCCGGTCCT	CGAGCGGTGT	GCCGCGGTCC	TCCTCGTAGA	5700
GGAACCCCGC	CCACTCCGAG	ACGAAAGCCC	GGGTCCAGGC	CAGCACGAAG	GAGGCCACGT	5760
GGGACGGGTA	GCGGTCGTTG	TCCACCAGCG	GGTCCACCTT	TTCCAGGGTA	TGCAAACACA	5820
TGTCCCCCTC	GTCCACATCC	AGGAAGGTGA	TTGGCTTGTA	AGGTAGGCC	ACGTGACCGG	5880
GGGTCCCGGC	CGGGGGGGTA	TAAAAGGGTG	CGGGTCCCTG	CTCGTCCTCA	CTGTCTTCCG	5940
GATCGCTGTC	CAGGAGCGCC	AGCTGTTGGG	GTAGGTATTC	CCTCTCGAAG	GCGGGCATGA	6000
CCTCGGCACT	CAGGTTGTCA	GTTTCTAGAA	ACGAGGAGGA	TTTGATATTG	ACGGTGCCGG	6060
CGGAGATGCC	TTTCAAGAGC	CCCTCGTCCA	TCTGGTCAGA	AAAGACGATC	TTTTTGTGTG	6120
CGAGCTTGGT	GGCGAAGGAG	CCGTAGAGGG	CGTTGGAGAG	GAGCTTGGCG	ATGGAGCGCA	6180
TGGTCTGGTT	TTTTTCCTTG	TCGGCGCGCT	CCTTGGCGGC	GATGTTGAGC	TGCACGTACT	6240
CGCGCGCCAC	GCACTTCCAT	TCGGGGAAGA	CGGTGGTCAG	CTCGTCGGGC	ACGATTCTGA	6300
CCTGCCAGCC	CCGATTATGC	AGGGTGATGA	GGTCCACACT	GGTGGCCACC	TCGCCGCGCA	6360

GGGGCTCATT	AGTCCAGCAG	AGGCGTCCGC	CCTTGCGCGA	GCAGAAGGGG	GGCAGGGGGT	6420
CCAGCATGAC	CTCGTCGGGG	GGGTCGGCAT	CGATGGTGAA	GATGCCGGGC	AGGAGGTCGG	6480
GGTCAAAGTA	GCTGATGGAA	GTGGCCAGAT	CGTCCAGGGC	AGCTTGCCAT	TCGCGCACGG	6540
CCAGCGCGCG	CTCGTAGGGA	CTGAGGGGCG	TGCCCCAGGG	CATGGGATGG	GTAAGCGCGG	6600
AGGCGTACAT	GCCGCAGATG	TCGTAGACGT	AGAGGGGCTC	CTCGAGGATG	CCGATGTAGG	6660
TGGGGTAGCA	GCGCCCCCCG	CGGATGCTGG	CGCGCACGTA	GTCATACAGC	TCGTGCGAGG	6720
GGGCGAGGAG	CCCCGGGCCC	AGGTTGGTGC	GACTGGGCTT	TTCGGCGCGG	TAGACGATCT	6780
GGCGGAAAAT	GGCATGCGAG	TTGGAGGAGA	TGGTGGGCCT	TTGGAAGATG	TTGAAGTGGG	6840
CGTGGGGCAG	TCCGACCGAG	TCGCGGATGA	AGTGGGCGTA	GGAGTCTTGC	AGCTTGCGCA	6900
CGAGCTCGGC	GGTGACTAGG	ACGTCCAGAG	CGCAGTAGTC	GAGGGTCTCC	TGGATGATGT	6960
CATACTTGAG	CTGTCCCTTT	TGTTCCACA	GCTCGCGGTT	GAGAAGGAAC	TCTTCGCGGT	7020
CCTTCCAGTA	CTCTTCGAGG	GGGAACCCGT	CCTGATCTGC	ACGGTAAGAG	CCTAGCATGT	7080
AGAACTGGTT	GACGGCCTTG	TAGGCGCAGC	AGCCCTTCTC	CACGGGGAGG	GCGTAGGCCT	7140
GGGCGGCCCT	GCGCAGGGAG	GTGTGCGTGA	GGGCGAAAGT	GTCCCTGACC	ATGACCTTGA	7200
GGAACTGGTG	CTTGAAGTCG	ATATCGTOGC	AGCCCCCTG	CTCCAGAGC	TGGAAGTCCG	7260
TGCGCTTCTT	GTAGGCGGGG	TTGGGCAAAG	CGAAAGTAAC	ATCGTTGAAG	AGGATCTTGC	7320
CCGCGCGGGG	CATAAAGTTG	CGAGTGATGC	GGAAAGGTTG	GGGCACCTCG	GCCCGGTTGT	7380
TGATGACCTG	GGCGGCGAGC	ACGATCTCGT	CGAAGCCGTT	GATGTTGTGG	CCCACGATGT	7440
AGAGTTCCAC	GAATCGCGGA	CGGCCCTTGA	CGTGGGGCAG	TTTCTTGAGC	TCCTCGTAGG	7500
TGAGCTCGTC	GGGGTCGCTG	AGCCCGTGCT	GCTCGAGCGC	CCAGTCGGCG	AGATGGGGGT	7560
TGGCGCGGAG	GAAGGAAGTC	CAGAGATCCA	CGGCCAGGGC	GGTTTGACAG	CGGTCCCCGT	7620
ACTGACGGAA	CTGCTGCCCC	ACGGCCATTT	TTTCGGGGGT	GACGCAGTAG	AAGGTGCGGG	7680
GGTCCCCGTG	CCAGCGATCC	CATTTGAGCT	GGAGGGCGAG	ATCGAGGGCG	AGCTCGACGA	7740
GCCGGTCGTC	CCCGGAGAGT	TTCATGACCA	GCATGAAGGG	GACGAGCTGC	TTGCCGAAGG	7800
ACCCCATCCA	GGTGTAGGTT	TCCACATCGT	AGGTGAGGAA	GAGCCTTTCG	GTGCGAGGAT	7860
GCGAGCCGAT	GGGGAAGAAC	TGGATCTCCT	GCCACCAATT	GGAGGAATGG	CTGTTGATGT	7920
GATGGAAGTA	GAAATGCCGA	CGGCGCGCCG	AACACTCGTG	CTTGTGTTTA	TACAAGCGGC	7980
CACAGTGCTC	GCAACGCTGC	ACGGGATGCA	CGTGCTGCAC	GAGCTGTACC	TGAGTTCCTT	8040
TGACGAGGAA	TTTCAGTGGG	AAGTGGAGTC	GTGGCGCCTG	CATCTCGTGC	TGTACTACGT	8100
CGTGGTGGTC	GGCCTGGCCC	TCTTCTGCCT	CGATGGTGGT	CATGCTGACG	AGCCCGCGCG	8160
GGAGGCAGGT	CCAGACCTCG	GCGCGAGCGG	GTCGGAGAGC	GAGGACGAGG	GCGCGCAGGC	8220
CGGAGCTGTC	CAGGGTCCTG	AGACGCTGCG	GAGTCAGGTC	AGTGGGCAGC	GGCGGCGCGC	8280

GGTTGACTTG	CAGGAGTTTT	TCCAGGGCGC	GCGGGAGGTC	CAGATGGTAC	TTGATCTCCA	8340
CCGCGCCATT	GGTGGCGACG	TCGATGGCTT	GCAGGGTCCC	GTGCCCCTGG	GGTGTGACCA	8400
CCGTCCCCCG	TTTCTTCTTG	GGCGGCTGGG	GCGACGGGGG	CGGTGCCTCT	TCCATGGTTA	8460
GAAGCGGCGG	CGAGGACGCG	CGCCGGGCGG	CAGGGGCGGC	TCGGGGCCCC	GAGGCAGGGG	8520
CGGCAGGGGC	ACGTCGGCGC	CGCGCGCGGG	TAGGTTCTGG	TACTGCGCCC	GGAGAAGACT	8580
GGCGTGAGCG	ACGACGCGAC	GGTTGACGTC	CTGGATCTGA	CGCCTCTGGG	TGAAGGCCAC	8640
GGGACCCGTG	AGTTTGAACC	TGAAAGAGAG	TTGACAGAA	TCAATCTCGG	TATCGTTGAC	8700
GGCGGCCTGC	CGCAGGATCT	CTTGACGTC	GCCCGAGTTG	TCCTGGTAGG	CGATCTCGGT	8760
CATGAACTGC	TCGATCTCCT	CCTCTTGAAG	GTCTCCGCGG	CCGGCGCGCT	CCACGGTGGC	8820
CGCGAGGTCG	TTGGAGATGC	GGCCCATGAG	CTGCGAGAAG	GCGTTCATGC	CCGCCTCGTT	8880
CCAGACGCGG	CTGTAGACCA	CGACGCCCTC	GGGATCGCCG	GCGCGCATGA	CCACCTGGGC	8940
GAGGTTGAGC	TCCACGTGGC	GCGTGAAGAC	CGCGTAGTTG	CAGAGGCGCT	GGTAGAGGTA	9000
GTTGAGCGTG	GTGGCGATGT	GCTCGGTGAC	GAAGAAATAC	ATGATCCAGC	GGCGGAGCGG	9060
CATCTCGCTG	ACGTCGCCCA	GCGCCTCCAA	ACGTTCCATG	GCCTCGTAAA	AGTCCACGGC	9120
GAAGTTGAAA	AACTGGGAGT	TGCGCGCCGA	GACGGTCAAC	TCCTCCTCCA	GAAGACGGAT	9180
GAGCTCGGCG	ATGGTGGCGC	GCACCTCGCG	CTCGAAGGCC	CCCGGGAGTT	CCTCCACTTC	9240
CTCTTCTTCC	TCCTCCACTA	ACATCTCTTC	TACTTCCTCC	TCAGGCGGCA	GTGGTGGCGG	9300
GGGAGGGGGC	CTGCGTCGCC	GGCGGCGCAC	GGGCAGACGG	TCGATGAAGC	GCTCGATGGT	9360
CTCGCCGCGC	CGGCGTCGCA	TGGTCTCGGT	GACGGCGCGC	CCGTCTCTCG	GGGGCCGCAG	9420
CGTGAAGACG	CCGCCGCGCA	TCTCCAGGTG	GCGGGGGGGG	TCCCCGTTGG	GCAGGGAGAG	9480
GGCGCTGACG	ATGCATCTTA	TCAATTGCCC	CGTAGGGACT	CCGCGCAAGG	ACCTGAGCGT	9540
CTCGAGATCC	ACGGGATCTG	AAAACCGCTG	AACGAAGGCT	TCGAGCCAGT	CGCAGTCGCA	9600
AGGTAGGCTG	AGCACGGTTT	CTTCTGGCGG	GTCATGTTGG	TTGGGAGCGG	GGCGGGCGAT	9660
GCTGCTGGTG	ATGAAGTTGA	AATAGGCGGT	TCTGAGACGG	CGGATGGTGG	CGAGGAGCAC	9720
CAGGTCTTTG	GGCCCGGCTT	GCTGGATGCG	CAGACGGTCG	GCCATGCCCC	AGGCGTGGTC	9780
CTGACACCTG	GCCAGGTCCT	TGTAGTAGTC	CTGCATGAGC	CGCTCCACGG	GCACCTCCTC	9840
CTCGCCCGCG	CGGCCGTGCA	TGCGCGTGAG	CCCGAAGCCG	CGCTGGGGCT	GGACGAGCGC	9900
CAGGTGCGCG	ACGACGCGCT	CGGCGAGGAT	GGCTTGCTGG	ATCTGGGTGA	GGGTGGTCTG	9960
GAAGTCATCA	AAGTCGACGA	AGCGGTGGTA	GGCTCCGGTG	TTGATGGTGT	AGGAGCAGTT	10020
GGCCATGACG	GACCAGTTGA	CGGTCTGGTG	GCCCGGACGC	ACGAGCTCGT	GGTACTTGAG	10080
GCGCGAGTAG	GCGCGCGTGT	CGAAGATGTA	GTCGTTGCAG	GTGCGCACCA	GGTACTGGTA	10140
GCCGATGAGG	AAGTGC GGCG	GCGGCTGGCG	GTAGAGCGGC	CATCGCTCGG	TGGCGGGGGC	10200

GCCGGGCGCG	AGGTCCTCGA	GCATGGTGCG	GTGGTAGCCG	TAGATGTACC	TGGACATCCA	10260
GGTGATGCCG	GCGGCGGTGG	TGGAGGCGCG	CGGGAACCTG	CGGACGCGGT	TCCAGATGTT	10320
GCGCAGCGGC	AGGAAGTAGT	TCATGGTGGG	CACGGTCTGG	CCCCTGAGGC	GCGCGCAGTC	10380
GTGGATGCTC	TATACGGGCA	AAAACGAAAG	CGGTCAGCGG	CTCGACTCCG	TGGCCTGGAG	10440
GCTAAGCGAA	CGGGTTGGGC	TGCGCGTGTA	CCCCGGTTCG	AATCTCGAAT	CAGGCTGGAG	10500
CCGCAGCTAA	CGTGGTATTG	GCACTCCCGT	CTCGACCCAA	GCCTGCACCA	ACCCTCCAGG	10560
ATACGGAGGC	GGGTCGTTTT	GCAACTTTTT	TTTGGAGGCC	GGATGAGACT	AGTAAGCGCG	10620
GAAAGCGGCC	GACCGCGATG	GCTCGCTGCC	GTAGTCTGGA	GAAGAATCGC	CAGGGTTGCG	10680
TTGCGGTGTG	CCCCGGTTCG	AGGCCGGCCG	GATTCCGCGG	CTAACGAGGG	CGTGGCTGCC	10740
CCGTCGTTTC	CAAGACCCCA	TAGCCAGCCG	ACTTCTCCAG	TTACGGAGCG	AGCCCCTCTT	10800
TTGTTTTGTT	TGTTTTTGCC	AGATGCATCC	CGTACTGCGG	CAGATGCGCC	CCCACCACCC	10860
TCCACCGCAA	CAACAGCCCC	CTCCACAGCC	GGCGTTCTG	CCCCCGCCCC	AGCAGCAACT	10920
TCCAGCCACG	ACCGCCGCGG	CCGCCGTGAG	CGGGGCTGGA	CAGAGTTATG	ATCACCAGCT	10980
GGCCTTGGA	GAGGGCGAGG	GGCTGGCGCG	CCTGGGGGCG	TCGTCGCCGG	AGCGGCACCC	11040
GCGCGTGCAG	ATGAAAAGGG	ACGCTCGCGA	GGCCTACGTG	CCCAAGCAGA	ACCTGTTTCTAG	11100
AGACAGGAGC	GGCGAGGAGC	CCGAGGAGAT	GCGCGCGGCC	CGGTTCCACG	CGGGGCGGGA	11160
GCTGCGGCGC	GGCCTGGACC	GAAAGAGGGT	GCTGAGGGAC	GAGGATTTCTG	AGGCGGACGA	11220
GCTGACGGGG	ATCAGCCCCG	CGCGCGCGCA	CGTGGCCGCG	GCCAACCTGG	TCACGGCGTA	11280
CGAGCAGACC	GTGAAGGAGG	AGAGCAACTT	CCAAAATCC	TTCAACAACC	ACGTGCGCAC	11340
CCTGATCGCG	CGCGAGGAGG	TGACCCTGGG	CCTGATGCAC	CTGTGGGACC	TGCTGGAGGC	11400
CATCGTGCAG	AACCCACCA	GCAAGCCGCT	GACGGCGCAG	CTGTTCTTGG	TGGTGCAGCA	11460
TAGTCGGGAC	AACGAAGCGT	TCAGGGAGGC	GCTGCTGAAT	ATCACCGAGC	CCGAGGGCCG	11520
CTGGCTCCTG	GACCTGGTGA	ACATTCTGCA	GAGCATCGTG	GTGCAGGAGC	GCGGGCTGCC	11580
GCTGTCCGAG	AAGCTGGCGG	CCATCAACTT	CTCGGTGCTG	AGTTTGGGCA	AGTACTACGC	11640
TAGGAAGATC	TACAAGACCC	CGTACGTGCC	CATAGACAAG	GAGGTGAAGA	TCGACGGGTT	11700
TTACATGCGC	ATGACCCTGA	AAGTGCTGAC	CCTGAGCGAC	GATCTGGGGG	TGTACCGCAA	11760
CGACAGGATG	CACCGTGCGG	TGAGCGCCAG	CAGGCGGCGC	GAGCTGAGCG	ACCAGGAGCT	11820
GATGCATAGT	CTGCAGCGGG	CCCTGACCGG	GGCCGGGACC	GAGGGGGAGA	GCTACTTTGA	11880
CATGGGCGCG	GACCTGCACT	GGCAGCCCAG	CCGCCGGGCC	TTGGAGGCGG	CGGCAGGACC	11940
CTACGTAGAA	GAGGTGGACG	ATGAGGTGGA	CGAGGAGGGC	GAGTACCTGG	AAGACTGATG	12000
GCGCGACCGT	ATTTTGTGTA	GATGCAACAA	CAACAGCCAC	CTCCTGATCC	CGCGATGCGG	12060
GCGGCGCTGC	AGAGCCAGCC	GTCCGGCATT	AACTCCTCGG	ACGATTGGAC	CCAGGCCATG	12120

CAACGCATCA	TGGCGCTGAC	GACCCGCAAC	CCCGAAGCCT	TTAGACAGCA	GCCCCAGGCC	12180
AACCGGCTCT	CGGCCATCCT	GGAGGCCGTG	GTGCCCTCGC	GCTCCAACCC	CACGCACGAG	12240
AAGGTCCTGG	CCATCGTGAA	CGCGCTGGTG	GAGAACAAGG	CCATCCGCGG	CGACGAGGCC	12300
GGCCTGGTGT	ACAACGCGCT	GCTGGAGCGC	GTGGCCCGCT	ACAACAGCAC	CAACGTGCAG	12360
ACCAACCTGG	ACCGCATGGT	GACCGACGTG	CGCGAGGCCG	TGGCCCAGCG	CGAGCGGTTC	12420
CACCGCGAGT	CCAACCTGGG	ATCCATGGTG	GCGCTGAACG	CCTTCCTCAG	CACCCAGCCC	12480
GCCAACGTGC	CCCGGGGCCA	GGAGGACTAC	ACCAACTTCA	TCAGCGCCCT	GCGCCTGATG	12540
GTGACCGAGG	TGCCCCAGAG	CGAGGTGTAC	CAGTCCGGGC	CGGACTACTT	CTTCCAGACC	12600
AGTCGCCAGG	GCTTGCAGAC	CGTGAACCTG	AGCCAGGCTT	TCAAGAACTT	GCAGGGCCTG	12660
TGGGGCGTGC	AGGCCCGGGT	CGGGGACCGC	GCGACGGTGT	CGAGCCTGCT	GACGCCGAAC	12720
TCGCGCCTGC	TGCTGCTGCT	GGTGGCCCCC	TTCACGGACA	GCGGCAGCAT	CAACCGCAAC	12780
TCGTACCTGG	GCTACCTGAT	TAACCTGTAC	CGCGAGGCCA	TCGGCCAGGC	GCACGTGGAC	12840
GAGCAGACCT	ACCAGGAGAT	CACCCACGTG	AGCCGCGCCC	TGGGCCAGGA	CGACCCGGGC	12900
AACCTGGAAG	CCACCCTGAA	CTTTTGTCTG	ACCAACCGGT	CGCAGAAGAT	CCCGCCCCAG	12960
TACGCGCTCA	GCACCGAGGA	GGAGCGCATC	CTGCGTTACG	TGCAGCAGAG	CGTGGGCCTG	13020
TTCCTGATGC	AGGAGGGGGC	CACCCCCAGC	GCCGCGCTCG	ACATGACCGC	GCGCAACATG	13080
GAGCCCAGCA	TGTACGCCAG	CAACCGCCCG	TTCATCAATA	AACTGATGGA	CTACTTGCAT	13140
CGGGCGGCCG	CCATGAACTC	TGACTATTTT	ACCAACGCCA	TCCTGAATCC	CCACTGGCTC	13200
CGGCCGCGG	GGTTCTACAC	GGGCGAGTAC	GACATGCCCC	ACCCCAATGA	CGGGTTCCTG	13260
TGGGACGATG	TGGACAGCAG	CGTGTTCTCC	CCCCGACCGG	GTGCTAACGA	GCGCCCCCTG	13320
TGGAAGAAGG	AAGGCAGCGA	CCGACGCCCC	TCCTCGGCGC	TGTCCGGCCG	CGAGGGTGCT	13380
GCCGCGGCGG	TGCCCCAGGC	CGCCAGTCCT	TTCCCGAGCT	TGCCCTTCTC	GCTGAACAGT	13440
ATCCGCAGCA	GCGAGCTGGG	CAGGATCACG	CGCCGCGCCT	TGCTGGGCGA	AGAGGAGTAC	13500
TTGAATGACT	CGCTGTTGAG	ACCCGAGCGG	GAGAAGAACT	TCCCCAATAA	CGGGATAGAA	13560
AGCCTGGTGG	ACAAGATGAG	CCGCTGGAAG	ACGTATGCGC	AGGAGCACAG	GGACGATCCC	13620
CGGGCGTTCG	AGGGGGCCAC	GAGCCGGGGC	AGCGCCGCCC	GTAAACGCCG	GTGGCACGAC	13680
AGGCAGCGGG	GACAGATGTG	GGACGATGAG	GACTCGCCCG	ACGACAGCAG	CGTGTGAGAC	13740
TTGGGTGGGA	GTGGTAACCC	GTTGCTCAC	CTGCGCCCCC	GTATCGGGCG	CATGATGTAA	13800
GAGAAACCGA	AAATAAATGA	TACTCACCAA	GGCCATGGCG	ACCAGCGTGC	GTTTCGTTTCT	13860
TCTCTGTTGT	TGTTGTATCT	AGTATGATGA	GGCGTGCGTA	CCCGGAGGGT	CCTCCTCCCT	13920
CGTACGAGAG	CGTGATGCAG	CAGGCGATGG	CGGCGGCGGC	GATGCAGCCC	CCGCTGGAGG	13980
CTCCTTACGT	GCCCCGCGG	TACCTGGCGC	CTACGGAGGG	GCGGAACAGC	ATTCGTTACT	14040

CGGAGCTGGC	ACCCTTGTAC	GATACCACCC	GGTTGTACCT	GGTGGACAAC	AAGTCGGCGG	14100
ACATCGCCTC	GCTGAACTAC	CAGAACGACC	ACAGCAACTT	CCTGACCACC	GTGGTGACAGA	14160
ACAATGACTT	CACCCCCACG	GAGGCCAGCA	CCCAGACCAT	CAACTTTGAC	GAGCGCTCGC	14220
GGTGGGGCGG	CCAGCTGAAA	ACCATCATGC	ACACCAACAT	GCCCAACGTG	AACGAGTTCA	14280
TGTACAGCAA	CAAGTTCAAG	GCGCGGGTGA	TGGTCTCCCG	CAAGACCCCC	AATGGGGTGA	14340
CAGTGACAGA	GGATTATGAT	GGTAGTCAGG	ATGAGCTGAA	GTATGAATGG	GTGGAATTTG	14400
AGCTGCCCGA	AGGCAACTTC	TCGGTGACCA	TGACCATCGA	CCTGATGAAC	AACGCCATCA	14460
TCGACAATTA	CTTGCGGGTG	GGGCGGCAGA	ACGGGGTGCT	GGAGAGCGAC	ATCGGCGTGA	14520
AGTTCGACAC	TAGGAACTTC	AGGCTGGGCT	GGGACCCCGT	GACCGAGCTG	GTCATGCCCG	14580
GGGTGTACAC	CAACGAGGCT	TTCCATCCCG	ATATTGTCTT	GCTGCCCGGC	TGCGGGGTGG	14640
ACTTCACCGA	GAGCGGCCTC	AGCAACCTGC	TGGGCATTTC	CAAGAGGCAG	CCCTTCCAGG	14700
AAGGCTTCCA	GATCATGTAC	GAGGATCTGG	AGGGGGGCAA	CATCCCCGCG	CTCCTGGATG	14760
TCGACGCCTA	TGAGAAAAGC	AAGGAGGATG	CAGCAGCTGA	AGCAACTGCA	GCCGTAGCTA	14820
CCGCCTCTAC	CGAGGTCAGG	GGCGATAATT	TTGCAAGCGC	CGCAGCAGTG	GCAGCGGCCG	14880
AGGCGGCTGA	AACCGAAAGT	AAGATAGTCA	TTCAGCCGGT	GGAGAAGGAT	AGCAAGAACA	14940
GGAGCTACAA	CGTACTACCG	GACAAGATAA	ACACCGCCTA	CCGCAGCTGG	TACCTAGCCT	15000
ACAACATATG	CGACCCCGAG	AAGGGCGTGC	GCTCCTGGAC	GCTGCTCACC	ACCTCGGACG	15060
TCACCTGCGG	CGTGGAGCAA	GTCTACTGGT	CGCTGCCCGA	CATGATGCAA	GACCCGGTCA	15120
CCTTCOGCTC	CACGCGTCAA	GTTAGCAACT	ACCCGGTGGT	GGGCGCCGAG	CTCCTGCCCG	15180
TCTACTCCAA	GAGCTTCTTC	AACGAGCAGG	CGTCTACTC	GCAGCAGCTG	CGCGCCTTCA	15240
CCTCGCTTAC	GCACGTCTTC	AACCGCTTCC	CCGAGAACCA	GATCCTCGTC	CGCCCGCCCG	15300
CGCCCACCAT	TACCACCGTC	AGTGAAAACG	TTCCTGCTCT	CACAGATCAC	GGGACCCTGC	15360
CGCTGCGCAG	CAGTATCCGG	GGAGTCCAGC	GCGTGACCGT	TACTGACGCC	AGACGCCGCA	15420
CCTGCCCCCTA	CGTCTACAAG	GCCCTGGGCA	TAGTCGCGCC	GCGCGTCCTC	TCGAGCCGCA	15480
CCTTCTAAAT	GTCCATTCTC	ATCTCGCCCA	GTAATAACAC	CGGTTGGGGC	CTGCGCGCGC	15540
CCAGCAAGAT	GTACGGAGGC	GCTCGCCAAC	GCTCCACGCA	ACACCCCGTG	CGCGTGCGCG	15600
GGCACTTCCG	CGCTCCCTGG	GGCGCCCTCA	AGGGCCGCGT	GCGGTCGCGC	ACCACCGTCG	15660
ACGACGTGAT	CGACCAGGTG	GTGGCCGACG	CGCGCAACTA	CACCCCGGCC	GCCGCGCCCG	15720
TCTCCACCGT	GGACGCCGTC	ATCGACAGCG	TGGTGGCGGA	CGCGCGCCGG	TACGCCCGCG	15780
CCAAGAGCCG	GCGGCGGCGC	ATCGCCCGGC	GGCACCAGGAG	CACCCCGGCC	ATGCGCGCGG	15840
CGCGAGCCTT	GCTGCGCAGG	GCCAGGCGCA	CGGGACGCAG	GGCCATGCTC	AGGGCGGCCA	15900
GACGCGCGGC	TTCAGGCGCC	AGCGCCGGCA	GGACCCGGAG	ACGCGCGGCC	ACGGCGGCGG	15960

CAGCGGCCAT	CGCCAGCATG	TCCCGCCCGC	GGCGAGGGAA	CGTGTACTGG	GTGCGCGACG	16020
CCGCCACCGG	TGTGCGCGTG	CCCGTGCGCA	CCCGCCCCCC	TCGCACTTGA	AGATGTTTAC	16080
TTCGCGATGT	TGATGTGTCC	CAGCGGCGAG	GAGGATGTCC	AAGCGCAAAT	TCAAGGAAGA	16140
GATGCTCCAG	GTCATCGCGC	CTGAGATCTA	CGGCCCTGCG	GTGGTGAAGG	AGGAAAGAAA	16200
GCCCCGCAAA	ATCAAGCGGG	TCAAAAAGGA	CAAAAAGGAA	GAAGAAAGTG	ATGTGGACGG	16260
ATTGGTGGAG	TTTGTGCGCG	AGTTCGCCCC	CCGGCGGCGC	GTGCAGTGGC	GCGGGCGGAA	16320
GGTGCAACCG	GTGCTGAGAC	CCGGCACCAC	CGTGGTCTTC	ACGCCCGGCG	AGCGCTCCGG	16380
CACCGCTTCC	AAGCGCTCCT	ACGACGAGGT	GTACGGGGAT	GATGATATTC	TGGAGCAGGC	16440
GGCCGAGCGC	CTGGGCGAGT	TTGCTTACGG	CAAGCGCAGC	CGTTCCGCAC	CGAAGGAAGA	16500
GGCGGTGTCC	ATCCCGCTGG	ACCACGGCAA	CCCCACGCCG	AGCCTCAAGC	CCGTGACCTT	16560
GCAGCAGGTG	CTGCCGACCG	CGGCGCCGCG	CCGGGGGTTC	AAGCGCGAGG	GCGAGGATCT	16620
GTACCCACC	ATGCAGCTGA	TGGTGCCCAA	GCGCCAGAAG	CTGGAAGACG	TGCTGGAGAC	16680
CATGAAGGTG	GACCCGGACG	TGCAGCCCGA	GGTCAAGGTG	CGGCCCATCA	AGCAGGTGGC	16740
CCCGGGCCTG	GGCGTGACGA	CCGTGGACAT	CAAGATTCCC	ACGGAGCCCA	TGGAAACGCA	16800
GACCGAGCCC	ATGATCAAGC	CCAGCACCAG	CACCATGGAG	GTGCAGACGG	ATCCCTGGAT	16860
GCCATCGGCT	CCTAGTCGAA	GACCCCGGCG	CAAGTACGGC	GCGGCCAGCC	TGCTGATGCC	16920
CAACTACGCG	CTGCATCCTT	CCATCATCCC	CAOGCCGGGC	TACCGCGGCA	CGCGCTTCTA	16980
CCGCGGTCAT	ACCAGCAGCC	GCCGCCGCAA	GACCACCACT	CGCCGCCGCC	GTGCCCGCAC	17040
CGCCGCTGCA	ACCACCCCTG	CCGCCCTGGT	GCGGAGAGTG	TACCGCCGCG	GCCGCGCACC	17100
TCTGACCCTG	CCGCGCGCGC	GCTACCACCC	GAGCATCGCC	ATTTAACTT	TCGCCAGCTT	17160
TGCAGATCAA	TGGCCCTCAC	ATGCCGCCTT	CGCGTTCCCA	TTACGGGCTA	CCGAGGAAGA	17220
AAACCGCGCC	GTAGAAGGCT	GGCGGGGAAC	GGGATGCGTC	GCCACCACCA	CCGGCGGCGG	17280
CGCGCCATCA	GCAAGCGGTT	GGGGGGAGGC	TTCCTGCCCG	CGCTGATCCC	CATCATCGCC	17340
GCGGCGATCG	GGGCGATCCC	CGGCATTGCT	TCCGTGGCGG	TGCAGGCCTC	TCAGCGCCAC	17400
TGAGACACAC	TTGGAAACAT	CTTGTAATAA	ACCCATGGAC	TCTGACGCTC	CTGGTCCTGT	17460
GATGTGTTTT	CGTAGACAGA	TGGAAGACAT	CAATTTTTTC	TCCCTGGCTC	CGCGACACGG	17520
CACGCGGCCG	TTCATGGGCA	CCTGGAGCGA	CATCGGCACC	AGCCAACTGA	ACGGGGGCGC	17580
CTTCAATTGG	AGCAGTCTCT	GGAGCGGGCT	TAAGAAATTC	GGGTCCACGC	TTAAAACCTA	17640
TGGCAGCAAG	GCGTGGAACA	GCACCACAGG	GCAGGCGCTG	AGGGATAAGC	TGAAAGAGCA	17700
GAACCTCCAG	CAGAAGGTGG	TCGATGGGCT	CGCCTCGGGC	ATCAACGGGG	TGGTGGACCT	17760
GGCCAACCAG	GCCGTGCAGC	GGCAGATCAA	CAGCCGCCTG	GACCCGGTGC	CGCCCGCCGG	17820
CTCCGTGGAG	ATGCCGCAGG	TGGAGGAGGA	GCTGCCTCCC	CTGGACAAGC	GGGGCGAGAA	17880

GCGACCCCGC	CCCGATGCGG	AGGAGACGCT	GCTGACGCAC	ACGGACGAGC	CGCCCCCGTA	17940
CGAGGAGGCG	GTGAAACTGG	GTCTGCCCAC	CACGCGGCCC	ATCGOGCCCC	TGGCCACCGG	18000
GGTGCTGAAA	CCCGAAAAGC	CCGCGACCCT	GGACTTGCTT	CCTCCCCAGC	CTTCCCGCCC	18060
CTCTACAGTG	GCTAAGCCCC	TGCCGCGGGT	GGCCGTGGCC	CGCGCGCGAC	CGGGGGGCAC	18120
CGCCCGCCCT	CATGCGAACT	GGCAGAGCAC	TCTGAACAGC	ATCGTGCGTC	TGGGAGTGCA	18180
GAGTGTGAAG	CGCCGCGGCT	GCTATTAAAC	CTACCGTAGC	GCTTAACTTG	CTTGTCTGTG	18240
TGTGTATGTA	TTATGTCGCC	GCCGCGGCTG	TCCACCAGAA	GGAGGAGTGA	AGAGGCGCGT	18300
CGCCGAGTTG	CAAGATGGCC	ACCCCATCGA	TGCTGCCCCA	GTGGGCGTAC	ATGCACATCG	18360
CCGGACAGGA	CGCTTCGGAG	TACCTGAGTC	CGGGTCTGGT	GCAGTTTGCC	CGCGCCACAG	18420
ACACCTACTT	CAGTCTGGGG	AACAAGTTTA	GGAACCCAC	GGTGGCGCCC	ACGCACGATG	18480
TGACCACCGA	CCGCAGCCAG	CGGCTGACGC	TGCGCTTCGT	GCCCGTGGAC	CGCGAGGACA	18540
ACACCTACTC	GTACAAAGTG	CGCTACACGC	TGGCCGTGGG	CGACAACCGC	GTGCTGGACA	18600
TGGCCAGCAC	CTACTTTGAC	ATCCGCGGCG	TGCTGGATCG	GGGCCCTAGC	TTCAAACCTT	18660
ACTCCGGCAC	CGCCTACAAC	AGTCTGGCCC	CCAAGGGAGC	ACCCAACACT	TGTCAGTGGA	18720
CATATAAAGC	CGATGGTGAA	ACTGCCACAG	AAAAAACCTA	TACATATGGA	AATGCACCCG	18780
TGCAGGGCAT	TAACATCACA	AAAGATGGTA	TTCAACTTGG	AACTGACACC	GATGATCAGC	18840
CAATCTACGC	AGATAAAACC	TATCAGCCTG	AACCTCAAGT	GGGTGATGCT	GAATGGCATG	18900
ACATCACTGG	TACTGATGAA	AAGTATGGAG	GCAGAGCTCT	TAAGCCTGAT	ACCAAAATGA	18960
AGCCTTGTTA	TGGTTCTTTT	GCCAAGCCTA	CTAATAAAGA	AGGAGGTCAG	GCAAATGTGA	19020
AAACAGGAAC	AGGCACTACT	AAAGAATATG	ACATAGACAT	GGCTTTCTTT	GACAACAGAA	19080
GTGCGGCTGC	TGCTGGCCTA	GCTCCAGAAA	TTGTTTTGTA	TACTGAAAAT	GTGGATTTGG	19140
AAACTCCAGA	TACCCATATT	GTATACAAAG	CAGGCACAGA	TGACAGCAGC	TCTTCTATTA	19200
ATTTGGGTCA	GCAAGCCATG	CCCAACAGAC	CTAACTACAT	TGGTTTCAGA	GACAACTTTA	19260
TCGGGCTCAT	GTAATAAAC	AGCACTGGCA	ATATGGGGGT	GCTGGCCGGT	CAGGCTTCTC	19320
AGCTGAATGC	TGTGGTTGAC	TTGCAAGACA	GAAACACCGA	GCTGTCCTAC	CAGCTCTTGC	19380
TTGACTCTCT	GGGTGACAGA	ACCCGGTATT	TCAGTATGTG	GAATCAGGCG	GTGGACAGCT	19440
ATGATCCTGA	TGTGCGCATT	ATTGAAAATC	ATGGTGTGGA	GGATGAACTT	CCCAACTATT	19500
GTTTCCCTCT	GGATGCTGTT	GGCAGAACAG	ATACTTATCA	GGAATTAAG	GCTAATGGAA	19560
CTGATCAAAC	CACATGGACC	AAAGATGACA	GTGTCAATGA	TGCTAATGAG	ATAGGCAAGG	19620
GTAATCCATT	CGCCATGGAA	ATCAACATCC	AAGCCAACCT	GTGGAGGAAC	TTCCTCTACG	19680
CCAACGTGGC	CCTGTACCTG	CCCGACTCTT	ACAAGTACAC	GCCGGCCAAT	GTTACCCTGC	19740
CCACCAACAC	CAACACCTAC	GATTACATGA	ACGGCCGGGT	GGTGGCGCCC	TCGCTGGTGG	19800

ACTCCTACAT	CAACATCGGG	GCGCGCTGGT	CGCTGGATCC	CATGGACAAC	GTGAACCCCT	19860
TCAACCACCA	CCGCAATGCG	GGGCTGCGCT	ACCGCTCCAT	GCTCCTGGGC	AACGGGCGCT	19920
ACGTGCCCTT	CCACATCCAG	GTGCCCCAGA	AATTTTTCGC	CATCAAGAGC	CTCCTGCTCC	19980
TGCCCCGGTC	CTACACCTAC	GAGTGGAAC	TCCGCAAGGA	CGTCAACATG	ATCCTGCAGA	20040
GCTCCCTCGG	CAACGACCTG	CGCACGGACG	GGGCCTCCAT	CTCCTTCACC	AGCATCAACC	20100
TCTACGCCAC	CTTCTTCCCC	ATGGCGCACA	ACACGGCCTC	CACGCTCGAG	GCCATGCTGC	20160
GCAACGACAC	CAACGACCAG	TCCTTCAACG	ACTACCTCTC	GGCGGCCAAC	ATGCTCTACC	20220
CCATCCCGGC	CAACGCCACC	AACGTGCCCC	TCTCCATCCC	CTCGCGCAAC	TGGGCCGCGT	20280
TCCGCGGCTG	GTCCTTCACG	CGTCTCAAGA	CCAAGGAGAC	GCCCTCGCTG	GGCTCCGGGT	20340
TCGACCCCTA	CTTCGTCTAC	TCGGGCTCCA	TCCCCTACCT	CGACGGCACC	TTCTACCTCA	20400
ACCACACCTT	CAAGAAGGTC	TCCATCACCT	TCGACTCCTC	CGTCAGCTGG	CCCGGCAACG	20460
ACCGGCTCCT	GACGCCCAAC	GAGTTCGAAA	TCAAGCGCAC	CGTCGACGGC	GAGGGCTACA	20520
ACGTGGCCCA	GTGCAACATG	ACCAAGGACT	GGTTCCTGGT	CCAGATGCTG	GCCCCACTACA	20580
ACATCGGCTA	CCAGGGCTTC	TACGTGCCCC	AGGGCTACAA	GGACCGCATG	TACTCCTTCT	20640
TCCGCAACTT	CCAGCCCATG	AGCCGCCAGG	TGGTGGACGA	GGTCAACTAC	AAGGACTACC	20700
AGGCCGTCAC	CCTGGCCTAC	CAGCACAACA	ACTCGGGCTT	CGTCGGCTAC	CTCGCGCCCCA	20760
CCATGCGCCA	GGGCCAGCCC	TACCCCGCCA	ACTACCCCTA	CCCGCTCATC	GGCAAGAGCG	20820
CCGTCACCAG	CGTCACCCAG	AAAAAGTTCC	TCTGCGACAG	GGTCATGTGG	CGCATCCCCT	20880
TCTCCAGCAA	CTTCATGTCC	ATGGGCGCGC	TCACCGACCT	CGGCCAGAAC	ATGCTCTATG	20940
CCAACTCCGC	CCACGCGCTA	GACATGAATT	TCGAAGTCGA	CCCCATGGAT	GAGTCCACCC	21000
TTCTCTATGT	TGTCTTCGAA	GTCTTCGACG	TCGTCCGAGT	GCACCAGCCC	CACCGCGGCG	21060
TCATCGAGGC	CGTCTACCTG	CGCACCCCCT	TCTCGGCCGG	TAACGCCACC	ACCTAAGCTC	21120
TTGCTTCTTG	CAAGCCATGG	CCGCGGGCTC	CGGCGAGCAG	GAGCTCAGGG	CCATCATCCG	21180
CGACCTGGGC	TGCGGGCCCT	ACTTCCTGGG	CACCTTCGAT	AAGCGCTTCC	CGGGATTCTAT	21240
GGCCCCGCAC	AAGCTGGCCT	GCGCCATCGT	CAACACGGCC	GGCCGCGAGA	CCGGGGGCGA	21300
GCACTGGCTG	GCCTTCGCCT	GGAACCCGCG	CTCGAACACC	TGCTACCTCT	TCGACCCCTT	21360
CGGGTTCTCG	GACGAGCGCC	TCAAGCAGAT	CTACCAGTTC	GAGTACGAGG	GCCTGCTGCG	21420
CCGCAGCGCC	CTGGCCACCG	AGGACCGCTG	CGTCACCCTG	GAAAAGTCCA	CCCAGACCGT	21480
GCAGGGTCCG	CGCTCGGCCG	CCTGCGGGCT	CTTCTGCTGC	ATGTTCTCTG	ACGCCTTCGT	21540
GCACTGGCCC	GACCGCCCCA	TGGACAAGAA	CCCCACCATG	AACTTGCTGA	CGGGGGTGCC	21600
CAACGGCATG	CTCCAGTCGC	CCCAGGTGGA	ACCCACCCTG	CGCCGCAACC	AGGAGGCGCT	21660
CTACCGCTTC	CTCAACTCCC	ACTCCGCCCTA	CTTTCGCTCC	CACCGCGCGC	GCATCGAGAA	21720

GGCCACCGCC	TTCGACCGCA	TGAATCAAGA	CATGTAAACC	GTGTGTGTAT	GTTAAATGTC	21780
TTTAATAAAC	AGCACTTTCA	TGTTACACAT	GCATCTGAGA	TGATTTATTT	AGAAATCGAA	21840
AGGGTTCTGC	CGGGTCTCGG	CATGGCCCGC	GGGCAGGGAC	ACGTTGCGGA	ACTGGTACTT	21900
GGCCAGCCAC	TTGAACTCGG	GGATCAGCAG	TTTGGGCAGC	GGGGTGTCTG	GGAAGGAGTC	21960
GGTCCACAGC	TTCCGCGTCA	GTTGCAGGGC	GCCCAGCAGG	TCGGGCGCGG	AGATCTTGAA	22020
ATCGCAGTTG	GGACCCGCGT	TCTGCGCGCG	GGAGTTGCGG	TACACGGGGT	TGCAGCACTG	22080
GAACACCATC	AGGGCCGGGT	GCTTCACGCT	CGCCAGCACC	GTCGCGTCGG	TGATGCTCTC	22140
CACGTCGAGG	TCCTCGGCGT	TGGCCATCCC	GAAGGGGGTC	ATCTTGAGG	TCTGCCTTCC	22200
CATGGTGGGC	ACGCACCCGG	GCTTGTGGTT	GCAATCGCAG	TGCAGGGGGA	TCAGCATCAT	22260
CTGGGCCTGG	TCGGCGTTCA	TCCCGGGTA	CATGGCCTTC	ATGAAAGCCT	CCAATTGCCT	22320
GAACGCCTGC	TGGGCCTTGG	CTCCCTCGGT	GAAGAAGACC	CCGCAGGACT	TGCTAGAGAA	22380
CTGGTTGGTG	GCGCACCCGG	CGTCGTGCAC	GCAGCAGCGC	GCGTCGTTGT	TGGCCAGCTG	22440
CACCACGCTG	CGCCCCCAGC	GGTCTGCGGT	GATCTTGGCC	CGGTCGGGGT	TCTCCTTCAG	22500
CGCGCGCTGC	CCGTTCTCGC	TCGCCACATC	CATCTCGATC	ATGTGCTCCT	TCTGGATCAT	22560
GGTGGTCCCG	TGCAGGCACC	GCAGCTTGCC	CTCGGCCTCG	GTGCACCCGT	GCAGCCACAG	22620
CGCGCACCCG	GTGCACTCCC	AGTTCTTGTT	GGCGATCTGG	GAATGCGCGT	GCACGAAGCC	22680
CTGCAGGAAG	CGGCCCATCA	TGGTGGTCAG	GGTCTTGTTG	CTAGTGAAGG	TCAGCGGAAT	22740
GCCGCGGTGC	TCCTCGTTGA	TGTACAGGTG	GCAGATGCGG	CGGTACACCT	CGCCCTGCTC	22800
GGGCATCAGC	TGGAAGTTGG	CTTTCAGGTC	GGTCTCCACG	CGGTAGCGGT	CCATCAGCAT	22860
AGTCATGATT	TCCATACCCT	TCTCCCAGGC	CGAGACGATG	GGCAGGCTCA	TAGGGTTCTT	22920
CACCATCATC	TTAGCGCTAG	CAGCCGCGGC	CAGGGGGTCG	CTCTCGTCCA	GGGTCTCAAA	22980
GCTCCGCTTG	CCGTCTTCT	CGGTGATCCG	CACCGGGGGG	TAGCTGAAGC	CCACGGCCGC	23040
CAGCTCCTCC	TCGGCCTGTC	TTTCGTCTC	GCTGTCTTGG	CTGACGTCCT	GCAGGACCAC	23100
ATGCTTGGTC	TTGCGGGGTT	TCTTCTTGGG	CGGCAGCGGC	GGCGGAGATG	TTGGAGATGG	23160
CGAGGGGGAG	CGCGAGTTCT	CGCTCACCAC	TACTATCTCT	TCCTCTTCTT	GGTCCGAGGC	23220
CACGCGGCGG	TAGGTATGTC	TCTTCGGGGG	CAGAGGCGGA	GGCGACGGGC	TCTCGCCGCC	23280
GCGACTTGGC	GGATGGCTGG	CAGAGCCCCT	TCCGCGTTTC	GGGGTGCCT	CCCGGCGGCG	23340
CTCTGACTGA	CTTCCTCCGC	GGCCGGCCAT	TGTGTTCTCC	TAGGGAGGAA	CAACAAGCAT	23400
GGAGACTCAG	CCATCGCCAA	CCTCGCCATC	TGCCCCCACC	GCCGACGAGA	AGCAGCAGCA	23460
GCAGAATGAA	AGCTTAACCG	CCCCGCCGCC	CAGCCCCGCC	ACCTCCGACG	CGGCCGTCCC	23520
AGACATGCAA	GAGATGGAGG	AATCCATCGA	GATTGACCTG	GGCTATGTGA	CGCCCGCGGA	23580
GCACGAGGAG	GAGCTGGCAG	TGCGCTTTTC	ACAAGAAGAG	ATACACCAAG	AACAGCCAGA	23640

GCAGGAAGCA	GAGAATGAGC	AGAGTCAGGC	TGGGCTCGAG	CATGACGGCG	ACTACCTCCA	23700
CCTGAGCGGG	GGGGAGGACG	CGCTCATCAA	GCATCTGGCC	CGGCAGGCCA	CCATCGTCAA	23760
GGATGCGCTG	CTCGACCGCA	CCGAGGTGCC	CCTCAGCGTG	GAGGAGCTCA	GCCGCGCCTA	23820
CGAGTTGAAC	CTCTTCTCGC	CGCGCGTGCC	CCCCAAGCGC	CAGCCCAATG	GCACCTGCGA	23880
GCCCAACCCG	CGCCTCAACT	TCTACCCGGT	CTTCGCGGTG	CCCGAGGCCC	TGGCCACCTA	23940
CCACATCTTT	TTCAAGAACC	AAAAGATCCC	CGTCTCCTGC	CGCGCCAACC	GCACCCGCGC	24000
CGACGCCCTT	TTCAACCTGG	GTCCCGGCGC	CCGCCACCT	GATATCGCCT	CCTTGGAAGA	24060
GGTTCCCAAG	ATCTTCGAGG	GTCTGGGCAG	CGACGAGACT	CGGGCCGCGA	ACGCTCTGCA	24120
AGGAGAAGGA	GGAGAGCATG	AGCACCACAG	CGCCCTGGTC	GAGTTGGAAG	GCGACAACGC	24180
GCGGCTGGCG	GTGCTCAAAC	GCACGGTCGA	GCTGACCCAT	TTCGCCTACC	CGGCTCTGAA	24240
CCTGCCCCCC	AAAGTCATGA	GCGCGGTCAT	GGACCAGGTG	CTCATCAAGC	GCGCGTCGCC	24300
CATCTCCGAG	GACGAGGGCA	TGCAAGACTC	CGAGGAGGGC	AAGCCCGTGG	TCAGCGACGA	24360
GCAGCTGGCC	CGGTGGCTGG	GTCCTAATGC	TAGTCCCCAG	AGTTTGGAAG	AGCGGCGCAA	24420
ACTCATGATG	GCCGTGGTCC	TGGTGACCGT	GGAGCTGGAG	TGCCTGCGCC	GCTTCTTCGC	24480
CGACGCGGAG	ACCCTGCGCA	AGGTCGAGGA	GAACCTGCAC	TACCTCTTCA	GGCACGGGTT	24540
CGTGCGCCAG	GCCTGCAAGA	TCTCCAACGT	GGAGCTGACC	AACCTGGTCT	CCTACATGGG	24600
CATCTTGAC	GAGAACC GCC	TGGGGCAGAA	CGTGCTGCAC	ACCACCCTGC	GCGGGGAGGC	24660
CCGGCGCGAC	TACATCCGCG	ACTGCGTCTA	CCTCTACCTC	TGCCACACCT	GGCAGACGGG	24720
CATGGGCGTG	TGGCAGCAGT	GTCTGGAGGA	GCAGAACCTG	AAAGAGCTCT	GCAAGCTCCT	24780
GCAGAAGAAC	CTCAAGGGTC	TGTGGACCGG	GTTGACGAG	CGCACCACCG	CCTCGGACCT	24840
GGCCGACCTC	ATTTTCCCCG	AGCGCCTCAG	GCTGACGCTG	CGCAACGGCC	TGCCCCACTT	24900
TATGAGCCAA	AGCATGTTGC	AAAAC TTTCG	CTCTTTTCATC	CTCGAACGCT	CCGGAATCCT	24960
GCCCGCCACC	TGCTCCGCGC	TGCCCTCGGA	CTTCGTGCCG	CTGACCTTCC	GCGAGTGCCC	25020
CCCGCCGCTG	TGGAGCCACT	GCTACCTGCT	GCGCCTGGCC	AACTACCTGG	CCTACCACTC	25080
GGACGTGATC	GAGGACGTCA	GCGGCGAGGG	CCTGCTCGAG	TGCCACTGCC	GCTGCAACCT	25140
CTGCACGCCG	CACCGCTCCC	TGGCCTGCAA	CCCCCAGCTG	CTGAGCGAGA	CCCAGATCAT	25200
CGGCACCTTC	GAGTTGCAAG	GGCCCAGCGA	AGGCGAGGGT	TCAGCCGCCA	AGGGGGGTCT	25260
GAAACTCACC	CCGGGGCTGT	GGACCTCGGC	CTACTTGCGC	AAGTTCGTGC	CCGAGGACTA	25320
CCATCCCTTC	GAGATCAGGT	TCTACGAGGA	CCAATCCCAT	CCGCCCAAGG	CCGAGCTGTC	25380
GGCCTGCGTC	ATCACCAGG	GGGCGATCCT	GGCCCAATTG	CAAGCCATCC	AGAAATCCCG	25440
CCAAGAATTC	TTGCTGAAAA	AGGGCCGCGG	GGTCTACCTC	GACCCCCAGA	CCGGTGAGGA	25500
GCTCAACCCC	GGCTTCCCCC	AGGATGCCCC	GAGGAAACAA	GAAGCTGAAA	GTGGAGCTGC	25560

CGCCCGTGGA	GGATTTGGAG	GAAGACTGGG	AGAACAGCAG	TCAGGCAGAG	GAGGAGGAGA	25620
TGGAGGAAGA	CTGGGACAGC	ACTCAGGCAG	AGGAGGACAG	CCTGCAAGAC	AGTCTGGAGG	25680
AAGACGAGGA	GGAGGCAGAG	GAGGAGGTGG	AAGAAGCAGC	CGCCGCCAGA	CGTCTGTCCT	25740
CGGCGGGGGA	GAAAGCAAGC	AGCACGGATA	CCATCTCCGC	TCCGGGTCGG	GGTCCCGCTC	25800
GACCACACAG	TAGATGGGAC	GAGACCGGAC	GATTCCCGAA	CCCCACCACC	CAGACCGGTA	25860
AGAAGGAGCG	GCAGGGATAC	AAGTCCTGGC	GGGGGCACAA	AAACGCCATC	GTCTCCTGCT	25920
TGCAGGCCTG	CGGGGGCAAC	ATCTCCTTCA	CCCGGCGCTA	CCTGCTCTTC	CACCGCGGGG	25980
TGAACTTTCC	CCGCAACATC	TTGCATTACT	ACCGTCACCT	CCACAGCCCC	TACTACTTCC	26040
AAGAAGAGGC	AGCAGCAGCA	GAAAAAGACC	AGCAGAAAAC	CAGCAGCTAG	AAAATCCACA	26100
GCGGCGGCAG	CAGGTGGACT	GAGGATCGCG	GCGAACGAGC	CGGCGCAAAC	CCGGGAGCTG	26160
AGGAACCGGA	TCTTTCCAC	CCTCTATGCC	ATCTTCCAGC	AGAGTCGGGG	GCAGGAGCAG	26220
GAAGTGAAG	TCAAGAACCG	TTCTCTGCGC	TCGCTCACCC	GCAGTTGTCT	GTATCACAAG	26280
AGCGAAGACC	AACTTCAGCG	CACTCTCGAG	GACGCCGAGG	CTCTCTTCAA	CAAGTACTGC	26340
GCGCTCACTC	TTAAAGAGTA	GCCCGCGCCC	GCCAGTCGC	AGAAAAAGGC	GGGAATTACG	26400
TCACCTGTGC	CCTTCGCCCT	AGCCGCCTCC	ACCCATCATC	ATGAGCAAAG	AGATTCCCAC	26460
GCCTTACATG	TGGAGCTACC	AGCCCCAGAT	GGGCCTGGCC	GCCGGTGCCG	CCCAGGACTA	26520
CTCCACCCGC	ATGAATTGGC	TCAGCGCCGG	GCCCGCGATG	ATCTCACGGG	TGAATGACAT	26580
CCGCGCCAC	CGAAACCAGA	TACTCCTAGA	ACAGTCAGCG	CTCACCGCCA	CGCCCCGCAA	26640
TCACCTCAAT	CCGCGTAATT	GGCCCGCCGC	CCTGGTGTAC	CAGGAAATTC	CCCAGCCCAC	26700
GACCGTACTA	CTTCGCGGAG	ACGCCCAGGC	CGAAGTCCAG	CTGACTAACT	CAGGTGTCCA	26760
GCTGGCGGGC	GGCGCCACCC	TGTGTCGTCA	CCGCCCGCT	CAGGGTATAA	AGCGGCTGGT	26820
GATCCGGGGC	AGAGGCACAC	AGCTCAACGA	CGAGGTGGTG	AGCTCTTCGC	TGGGTCTGCG	26880
ACCTGACGGA	GTCTTCCAAC	TCGCCGGATC	GGGGAGATCT	TCCTTCACGC	CTCGTCAGGC	26940
CGTCCTGACT	TTGGAGAGTT	CGTCCTCGCA	GCCCGGCTCG	GGTGGCATCG	GCACTCTCCA	27000
GTTCGTGGAG	GAGTTCACTC	CCTCGGTCTA	CTTCAACCCC	TTCTCCGGCT	CCCCCGGCCA	27060
CTACCCGGAC	GAGTTCATCC	CGAACTTGA	CGCCATCAGC	GAGTCGGTGG	ACGGCTACGA	27120
TTGAATGTCC	CATGGTGGCG	CAGCTGACCT	AGCTCGGCTT	CGACACCTGG	ACCACTGCCG	27180
CCGCTTCCGC	TGCTTCGCTC	GGGATCTCGC	CGAGTTTGCC	TACTTTGAGC	TGCCCAGGGA	27240
GCACCCCTCAG	GGCCCGGCCC	ACGGAGTGCG	GATCGTCGTC	GAAGGGGGCC	TCGACTCCCA	27300
CCTGCTTCGG	ATCTTCAGCC	AGCGTCCGAT	CCTGGTCGAG	CGCGAGCAAG	GACAGACCCT	27360
TCTGACTCTG	TACTGCATCT	GCAACCACCC	CGGCCTGCAT	GAAAGTCTTT	GTTGTCTGCT	27420
GTGTACTGAG	TATAATAAAA	GCTGAGATCA	GCGACTACTC	CGGACTTCCG	TGTGTTCCCTG	27480

AATCCATCAA	CCAGTCTTTG	TTCTTCACCG	GGAACGAGAC	CGAGCTCCAG	CTCCAGTGTA	27540
AGCCCCACAA	GAAGTACCTC	ACCTGGCTGT	TCCAGGGGCTC	CCCGATCGCC	GTTGTCAACC	27600
ACTGCGACAA	CGACGGAGTC	CTGCTGAGCG	GCCCTGCCAA	CCTTACTTTT	TCCACCCGCA	27660
GAAGCAAGCT	CCAGCTCTTC	CAACCCTTCC	TCCCCGGGAC	CTATCAGTGC	GTCTCGGGAC	27720
CCTGCCATCA	CACCTTCCAC	CTGATCCCGA	ATACCACAGC	GTCGCTCCCC	GCTACTAACA	27780
ACCAAATAA	CCTCCACCAA	CGCCACCGTC	GCGACCTTTC	TGAATCTAAT	ACTACCACCC	27840
ACACCGGAGG	TGAGCTCCGA	GGTCAACCAA	CCTCTGGGAT	TTACTACGGC	CCCTGGGAGG	27900
TGGTTGGGTT	AATAGCGCTA	GGCCTAGTTG	CGGGTGGGCT	TTTGGTTCTC	TGCTACCTAT	27960
ACCTCCCTTG	CTGTTCGTAC	TTAGTGGTGC	TGTGTTGCTG	GTTTAAGAAA	TGGGGAAGAT	28020
CACCCTAGTG	AGCTGCGGTG	CGCTGGTGGC	GGTGTGCTT	TCGATTGTGG	GACTGGGCGG	28080
TGCGGCTGTA	GTGAAGGAGA	AGGCCGATCC	CTGCTTGCA	TTCAATCCCA	ACAAATGCCA	28140
GCTGAGTTTT	CAGCCCGATG	GCAATCGGTG	CGCGTACTG	ATCAAGTGGG	GATGGGAATG	28200
CGAGAACGTG	AGAATCGAGT	ACAATAACAA	GACTCGGAAC	AATACTCTCG	CGTCCGTGTG	28260
GCAGCCCGGG	GACCCCGAGT	GGTACACCGT	CTCTGTCCCC	GGTGCTGACG	GCTCCCCGCG	28320
CACCGTGAAT	AATACTTTCA	TTTTTGCGCA	CATGTGCGAC	ACGGTCATGT	GGATGAGCAA	28380
GCAGTACGAT	ATGTGGCCCC	CCACGAAGGA	GAACATCGTG	GTCTTCTCCA	TCGCTTACAG	28440
CCTGTGCACG	GCGCTAATCA	CCGCTATCGT	GTGCCTGAGC	ATTCACATGC	TCATCGCTAT	28500
TCGCCCCAGA	AATAATGCCG	AAAAAGAAAA	ACAGCCATAA	CGTTTTTTTT	CACACCTTTT	28560
TCAGACCATG	GCCTCTGTTA	AATTTTTGCT	TTTATTTGCC	AGTCTCATTG	CCGTCATTCA	28620
TGGAATGAGT	AATGAGAAAA	TTACTATTTA	CACTGGCACT	AATCACACAT	TGAAAGGTCC	28680
AGAAAAAGCC	ACAGAAGTTT	CATGGTATTG	TTATTTTAAT	GAATCAGATG	TATCTACTGA	28740
ACTCTGTGGA	AACAATAACA	AAAAAATGA	GAGCATTACT	CTCATCAAGT	TTCAATGTGG	28800
ATCTGACTTA	ACCCTAATTA	ACATCACTAG	AGACTATGTA	GGTATGTATT	ATGGAACCTAC	28860
AGCAGGCATT	TCGGACATGG	AATTTTATCA	AGTTTCTGTG	TCTGAACCCA	CCACGCCTAG	28920
AATGACCACA	ACCACAAAAA	CTACACCTGT	TACCACTATG	CAGCTCACTA	CCAATAACAT	28980
TTTTGCCATG	CGTCAAATGG	TCAACAATAG	CACTCAACCC	ACCCACCCA	GTGAGGAAAT	29040
TCCCAAATCC	ATGATTGGCA	TTATTGTTGC	TGTAGTGGTG	TGCATGTTGA	TCATCGCCTT	29100
GTGCATGGTG	TACTATGCCT	TCTGCTACAG	AAAGCACAGA	CTGAACGACA	AGCTGGAACA	29160
CTTACTAAGT	GTTGAATTTT	AATTTTTTAG	AACCATGAAG	ATCCTAGGCC	TTTTAATTTT	29220
TTCTATCATT	ACCTCTGCTC	TATGCAATTC	TGACAATGAG	GACGTTACTG	TCGTTGTCGG	29280
ATCAAATTAT	ACACTGAAAG	GTCCAGCGAA	GGGTATGCTT	TCGTGGTATT	GCTATTTTGG	29340
ATCTGACACT	ACAGAACTG	AATTATGCAA	TCTTAAGAAT	GGCAAAATTC	AAAATTCTAA	29400

AATTAACAAT	TATATATGCA	ATGGTACTGA	TCTGATACTC	CTCAATATCA	CGAAATCATA	29460
TGCTGGCAGT	TACACCTGCC	CTGGAGATGA	TGCTGACAGT	ATGATTTTTT	ACAAAAGTAAC	29520
TGTTGTTGAT	CCCACTACTC	CACCTCCACC	CACCACAACT	ACTCACACCA	CACACACAGA	29580
TCAAACCGCA	GCAGAGGAGG	CAGCAAAGTT	AGCCTTGCAG	GTCCAAGACA	GTTCAATTGT	29640
TGGCATTACC	CCTACACCTG	ATCAGCGGTG	TCCGGGGCTG	CTAGTCAGCG	GCATTGTCCG	29700
TGTGCTTTCG	GGATTAGCAG	TCATAATCAT	CTGCATGTTT	ATTTTTGCTT	GCTGCTATAG	29760
AAGGCTTTAC	CGACAAAAAT	CAGACCCACT	GCTGAACCTC	TATGTTTAAT	TTTTTCCAGA	29820
GTCATGAAGG	CAGTTAGCGC	TCTAGTTTTT	TGTTCTTTGA	TTGGCATTGT	TTTTTGCAAT	29880
CCTATTCCCTA	AAGTTAGCTT	TATTAAAGAT	GTGAATGTTA	CTGAGGGGGG	CAATGTGACA	29940
CTGGTAGGTG	TAGAGGGTGC	TGAAAACACC	ACCTGGACAA	AATACCACCT	CAATGGGTGG	30000
AAAGATATTT	GCAATTGGAG	TGTATTAGTT	TATACATGTG	AGGGAGTTAA	TCTTACCATT	30060
GTCAATGCCA	CCTCAGCTCA	AAATGGTAGA	ATTCAAGGAC	AAAGTGTGAG	TGTATCTAAT	30120
GGGTATTTTA	CCCAACATAC	TTTTATCTAT	GACGTTAAAG	TCATACCACT	GCCTACGCCT	30180
AGCCACCTA	GCACTACCAC	ACAGACAACC	CACACTACAC	AGACAACCAC	ATACAGTACA	30240
TTAAATCAGC	CTACCACCAC	TACAGCAGCA	GAGGTGCGCA	GCTCGTCTGG	GGTCCGAGTG	30300
GCATTTTTGA	TGTGGGCCCC	ATCTAGCAGT	CCCACTGCTA	GTACCAATGA	GCAGACTACT	30360
GAATTTTTGT	CCACTGTGCA	GAGCCACACC	ACAGCTACCT	CCAGTGCCTT	CTCTAGCACC	30420
GCCAATCTCT	CCTCGCTTTC	CTCTACACCA	ATCAGTCCCG	CTACTACTCC	TAGCCCCGCT	30480
CCTCTTCCCA	CTCCCCTGAA	GCAAACAGAC	GGCGGCATGC	AATGGCAGAT	CACCCTGCTC	30540
ATTGTGATCG	GGTTGGTCAT	CCTGGCCGTG	TTGCTCTACT	ACATCTTCTG	CCGCCGCATT	30600
CCCAACGCGC	ACCGCAAGCC	GGTCTACAAG	CCCATCATTG	TCGGGCAGCC	GGAGCCGCTT	30660
CAGGTGGAAG	GGGGTCTAAG	GAATCTTCTC	TTCTCTTTTA	CAGTATGGTG	ATTGAACTAT	30720
GATTCCTAGA	CAATTCTTGA	TCACTATTCT	TATCTGECTC	CTCCAAGTCT	GTGCCACCCCT	30780
CGCTCTGGTG	GCCAACGCCA	GTCCAGACTG	TATTGGGCCC	TTCGCCTCCT	ACGTGCTCTT	30840
TGCCTTCACC	ACCTGCATCT	GCTGCTGTAG	CATAGTCTGC	CTGCTTATCA	CCTTCTTCCA	30900
GTTCAATTGAC	TGGATCTTTG	TGCGCATCGC	CTACCTGCGC	CACCACCCCC	AGTACCGCGA	30960
CCAGCGAGTG	GCGCGGCTGC	TCAGGCTCCT	CTGATAAGCA	TGCGGGCTCT	GCTACTTCTC	31020
GCGCTTCTGC	TGTTAGTGCT	CCCCCGTCCC	GTCGACCCCC	GGTCCCCCAC	CCAGTCCCCC	31080
GAGGAGGTCC	GCAAATGCAA	ATTCCAAGAA	CCCTGGAAAT	TCCTCAAATG	CTACCGCCAA	31140
AAATCAGACA	TGCATCCCAG	CTGGATCATG	ATCATTGGGA	TCGTGAACAT	TCTGGCCTGC	31200
ACCCTCATCT	CCTTTGTGAT	TTACCCCTGC	TTTGACTTTG	GTTGGAACTC	GCCAGAGGCG	31260
CTCTATCTCC	CGCCTGAACC	TGACACACCA	CCACAGCAAC	CTCAGGCACA	CGCACTACCA	31320

CCACTACAGC	CTAGGCCACA	ATACATGCCC	ATATTAGACT	ATGAGGCCGA	GCCACAGCGA	31380
CCCATGCTCC	COGCTATTAG	TTACTTCAAT	CTAACCGGCG	GAGATGACTG	ACCCACTGGC	31440
CAACAACAAC	GTCAACGACC	TTCTCCTGGA	CATGGACGGC	CGCGCCTCGG	AGCAGCGACT	31500
CGCCCAACTT	CGCATTTCGCC	AGCAGCAGGA	GAGAGCCGTC	AAGGAGCTGC	AGGATGCGGT	31560
GGCCATCCAC	CAGTGCAAGA	GAGGCATCTT	CTGCCTGGTG	AAACAGGCCA	AGATCTCCTA	31620
CGAGGTCACT	CCAAACGACC	ATCGCCTCTC	CTACGAGCTC	CTGCAGCAGC	GCCAGAAGTT	31680
CACCTGCCTG	GTCGGAGTCA	ACCCCATCGT	CATCACCAG	CAGTCTGGCG	ATACCAAGGG	31740
GTGCATCCAC	TGCTCCTGCG	ACTCCCCCGA	CTGCGTCCAC	ACTCTGATCA	AGACCCTCTG	31800
CGGCCTCCGC	GACCTCCTCC	CCATGAACTA	ATCACCCTCT	TATCCAGTGA	AATAAAGATC	31860
ATATTGATGA	TGATTTTACA	GAAATAAAAA	ATAATCATTT	GATTTGAAAT	AAAGATACAA	31920
TCATATTGAT	GATTTGAGTT	TAACAAAAAA	ATAAAGAATC	ACTTACTTGA	AATCTGATAC	31980
CAGGTCTCTG	TCCATGTTTT	CTGCCAACAC	CACCTTCACTC	CCCTCTTCCC	AGCTCTGGTA	32040
CTGCAGGCCC	CGGCGGGCTG	CAAAC'TTCCT	CCACACGCTG	AAGGGGATGT	CAAATTCCTC	32100
CTGTCCCTCA	ATCTTCATTT	TATCTTCTAT	CAGATGTCCA	AAAAGCGCGT	CCGGGTGGAT	32160
GATGACTTCG	ACCCCGTCTA	CCCCTACGAT	GCAGACAACG	CACCGACCGT	GCCCTTCATC	32220
AACCCCCCCT	TCGTCTCTTC	AGATGGATTTC	CAAGAGAAGC	CCCTGGGGGT	GTTGTCCCTG	32280
CGACTGGCCG	ACCCCGTCAC	CACCAAGAAC	GGGGAAATCA	CCCTCAAGCT	GGGAGAGGGG	32340
GTGGACCTCG	ATTCTCTCGG	AAAAC'TCATC	TCCAACACGG	CCACCAAGGC	CGCCGCCCCCT	32400
CTCAGTTTTT	CCAACAACAC	CATTTCCCTT	AACATGGATC	ACCCCTTTTA	CACTAAAGAT	32460
GGAAAATTAT	CCTTACAAGT	TTCTCCACCA	TTAAATATAC	TGAGAACAAG	CATTCTAAAC	32520
ACACTAGCTT	TAGGTTTTGG	ATCAGGTTTA	GGACTCCGTG	GCTCTGCCTT	GGCAGTACAG	32580
TTAGTCTCTC	CACCTACATT	TGATACTGAT	GGAAACATAA	AGCTTACCTT	AGACAGAGGT	32640
TTGCATGTTA	CAACAGGAGA	TGCAATTGAA	AGCAACATAA	GCTGGGCTAA	AGGTTTAAAA	32700
TTTGAAGATG	GAGCCATAGC	AACCAACATT	GGAAATGGGT	TAGAGTTTGG	AAGCAGTAGT	32760
ACAGAAACAG	GTGTTGATGA	TGCTTACCCA	ATCCAAGTTA	AACTTGATC	TGGCCTTAGC	32820
TTTGACAGTA	CAGGAGCCAT	AATGGCTGGT	AACAAAGAAG	ACGATAAACT	CAC'TTTGTGG	32880
ACAACACCTG	ATCCATCACC	AAACTGTCAA	ATACTCGCAG	AAAATGATGC	AAAAC'TAACA	32940
CTTTGCTTGA	CTAAATGTGG	TAGTCAAATA	CTGGCCACTG	TGTCAGTCTT	AGTTGTAGGA	33000
AGTGGAACCC	TAAACCCCAT	TACTGGCACC	GTAAGCAGTG	CTCAGGTGTT	TCTACGTTTT	33060
GATGCAAACG	GTGTTCTTTT	AACAGAACAT	TCTACACTAA	AAAAATACTG	GGGGTATAGG	33120
CAGGGAGATA	GCATAGATGG	CACTCCATAT	ACCAATGCTG	TAGGATTAT	GCCCAATTTA	33180
AAAGCTTATC	CAAAGTCACA	AAGTTCTACT	ACTAAAAATA	ATATAGTAGG	GCAAGTATAC	33240

ATGAATGGAG	ATGTTTCAAA	ACCTATGCTT	CTCACTATAA	CCCTCAATGG	TACTGATGAC	33300
AGCAACAGTA	CATATTCAAT	GTCATTTTCA	TACACCTGGA	CTAATGGAAG	CTATGTTGGA	33360
GCAACATTTG	GGGCTAACTC	TTATACCTTC	TCATACATCG	CCCAAGAATG	AACACTGTAT	33420
CCCACCCTGC	ATGCCAACCC	TTCCCACCCC	ACTCTGTGGA	ACAAACTCTG	AAACACAAAA	33480
TAAAATAAAG	TTCAAGTGTT	TTATTGATTC	AACAGTTTTA	CAGGATTCTG	GCAGTTATTT	33540
TTCTCTCCACC	CTCCCAGGAC	ATGGAATACA	CCACCCTCTC	CCCCCGCACA	GCCTTGAACA	33600
TCTGAATGCC	ATTGGTGATG	GACATGCTTT	TGGTCTCCAC	GTTCCACACA	GTTTCAGAGC	33660
GAGCCAGTCT	CGGGTCGGTC	AGGGAGATGA	AACCCTCCGG	GCACTCCCGC	ATCTGCACCT	33720
CACAGCTCAA	CAGCTGAGGA	TTGTCTCTCG	TGGTCGGGAT	CACGGTTATC	TGGAAGAAGC	33780
AGAAGAGCGG	CGGTGGGAAT	CATAGTCCGC	GAACGGGATC	GGCCGGTGGT	GTCGCATCAG	33840
GCCCCGCAGC	AGTCGCTGCC	GCCGCCGCTC	CGTCAAGCTG	CTGCTCAGGG	GGTCCGGGTC	33900
CAGGGACTCC	CTCAGCATGA	TGCCCACGGC	CCTCAGCATC	AGTCGTCTGG	TGCGGCGGGC	33960
GCAGCAGCGC	ATGCGGATCT	CGCTCAGGTC	GCTGCAGTAC	GTGCAACACA	GAACCACCAG	34020
GTTGTTCAAC	AGTCCATAGT	TCAACACGCT	CCAGCCGAAA	CTCATCGCGG	GAAGGATGCT	34080
ACCCACGTGG	CCGTCTGACC	AGATCCTCAG	GTAAATCAAG	TGGTGCCCCC	TCCAGAACAC	34140
GCTGCCCACG	TACATGATCT	CCTTGGGCAT	GTGGCGGTTT	ACCACCTCCC	GGTACCACAT	34200
CACCCTCTGG	TTGAACATGC	AGCCCCGGAT	GATCCTGCGG	AACCACAGGG	CCAGCACCCG	34260
CCCGCCCGCC	ATGCAGCGAA	GAGACCCCGG	GTCCCGGCAA	TGGCAATGGA	GGACCCACCG	34320
CTCGTACCCG	TGGATCATCT	GGGAGCTGAA	CAAGTCTATG	TTGGCACAGC	ACAGGCATAT	34380
GCTCATGCAT	CTCTTCAGCA	CTCTCAACTC	CTCGGGGGTC	AAAACCATAT	CCCAGGGCAC	34440
GGGGAACCTT	TGCAGGACAG	CGAACCCCGC	AGAACAGGGC	AATCCTCGCA	CAGAACTTAC	34500
ATTGTGCATG	GACAGGGTAT	CGCAATCAGG	CAGCACCGGG	TGATCCTCCA	CCAGAGAAGC	34560
GCGGGTCTCG	GTCTCCTCAC	AGCGTGGTAA	GGGGGCCCGC	CGATACGGGT	GATGGCGGGA	34620
CGCGGCTGAT	CGTGTTCCGG	ACCGTGTCAT	GATGCAGTTG	CTTTCGGACA	TTTTCGTACT	34680
TGCTGTAGCA	GAACCTGGTC	CGGGCGCTGC	ACACCGATCG	CCGGCGGCGG	TCTCGGCGCT	34740
TGGAACGCTC	GGTGTGAAA	TTGTAAAACA	GCCACTCTCT	CAGACCGTGC	AGCAGATCTA	34800
GGGCCTCAGG	AGTGATGAAG	ATCCCATCAT	GCCTGATGGC	TCTGATCACA	TCGACCACCG	34860
TGGAATGGGC	CAGACCCAGC	CAGATGATGC	AATTTTGTG	GGTTTCGGTG	ACGGCGGGGG	34920
AGGGAAGAAC	AGGAAGAACC	ATGATTAAC	TTTAATCCAA	ACGGTCTCGG	AGTACTTCAA	34980
AATGAAGATC	GCGGAGATGG	CACCTCTCGC	CCCCGCTGTG	TTGGTGAAA	ATAACAGCCA	35040
GGTCAAAGGT	GATACGGTTC	TCGAGATGTT	CCACGGTGCG	TTCCAGCAAA	GCCTCCACGC	35100
GCACATCCAG	AAACAAGACA	ATAGCGAAAG	CGGGAGGGTT	CTCTAATTCC	TCAATCATCA	35160

TGTTACACTC	CTGCACCATC	CCCAGATAAT	TTTCATTTTT	CCAGCCTTGA	ATGATTCGAA	35220
CTAGTTCGTG	AGGTAAATCC	AAGCCAGCCA	TGATAAAGAG	CTCGCGCAGA	GCGCCCTCCA	35280
CCGGCATTCT	TAAGCACACC	CTCATAATTC	CAAGATATTC	TGCTCCTGGT	TCACCTGCAG	35340
CAGATTGACA	AGCGGAATAT	CAAAATCTCT	GCCGCGATCC	CTGAGCTCCT	CCCTCAGCAA	35400
TAAGTGTAAG	TACTCTTTCA	TATCCTCTCC	GAAATTTTTA	GCCATAGGAC	CACCAGGAAT	35460
AAGATTAGGG	CAAGCCACAG	TACAGATAAA	CCGAAGTCCT	CCCCAGTGAG	CATTGCCAAA	35520
TGCAAGACTG	CTATAAGCAT	GCTGGCTAGA	CCCGGTGATA	TCTTCCAGAT	AACTGGACAG	35580
AAAATCGCCC	AGGCAATTTT	TAAGAAAATC	AACAAAAGAA	AAATCCTCCA	GGTGGACGTT	35640
TAGAGCCTCG	GGAACAACGA	TGAAGTAAAT	GCAAGCGGTG	CGTTCCAGCA	TGGTTAGTTA	35700
GCTGATCTGT	AGAAAAACA	AAAATGAACA	TTAAACCATG	CTAGCCTGGC	GAACAGGTGG	35760
GTAAATCGTT	CTCTCCAGCA	CCAGGCAGGC	CACGGGGTCT	CCGGCGCGAC	CCTCGTAAAA	35820
ATTGTGCGTA	TGATTGAAAA	CCATCACAGA	GAGACGTTC	CGGTGGCCGG	CGTGAATGAT	35880
TCGACAAGAT	GAATACACCC	CCGGAACATT	GGCGTCCGCG	AGTGAAAAAA	AGCGCCCAGAG	35940
GAAGCAATAA	GGCACTACAA	TGCTCAGTCT	CAAGTCCAGC	AAAGCGATGC	CATGCGGATG	36000
AAGCACAAAA	TTCTCAGGTG	CGTACAAAAT	GTAATTACTC	CCCTCCTGCA	CAGGCAGCAA	36060
AGCCCCCGAT	CCCTCCAGGT	ACACATACAA	AGCCTCAGCG	TCCATAGCTT	ACCGAGCAGC	36120
AGCACACAAC	AGGCGCAAGA	GTCAGAGAAA	GGCTGAGCTC	TAACCTGTCC	ACCCGCTCTC	36180
TGCTCAATAT	ATAGCCCAGA	TCTACACTGA	CGTAAAGGCC	AAAGTCTAAA	AATACCCGCC	36240
AAATAATCAC	ACACGCCCAG	CACACGCCCA	GAAACCGGTG	ACACACTCAA	AAAAATACGC	36300
GCACTTCCTC	AAACGCCCAA	AACTGCCGTC	ATTTCCGGGT	TCCCACGCTA	CGTCATCAAA	36360
ACACGACTTT	CAAATTCCGT	CGACCGTTAA	AAACGTCACC	CGCCCCGCCC	CTAACGGTGC	36420
CCCGTCTCTC	AGCCAATCAG	CGCCCCGCAT	CCCCAAATTC	AAACACCTCA	TTTGCATATT	36480
AACGCGCACA	AAAAGTTTGA	GGTATATTAT	TGATGATGG			36519

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8299 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCCCAATACG	CAAACCGCCT	CTCCCCGCGC	GTTGGCCGAT	TCATTAATGC	AGCTGCGCGC	60
TCGCTCGCTC	ACTGAGGCCG	CCCGGGCAAA	GCCCCGGCGT	CGGGCGACCT	TTGGTCGCCC	120

GGCCTCAGTG	AGCGAGCGAG	CGCGCAGAGA	GGGAGTGGCC	AACTCCATCA	CTAGGGGTTC	180
CTTGTAAGTTA	ATGATTAACC	CGCCATGCTA	CTTATCTACA	TCATCGATGA	ATTCGAGCTT	240
GCATGCCTGC	AGGTCGTTAC	ATAACTTACG	GTAAATGGCC	CGCCTGGCTG	ACCGCCCAAC	300
GACCCCCGCC	CATTGACGTC	AATAATGACG	TATGTTCCCA	TAGTAACGCC	AATAGGGACT	360
TTCCATTGAC	GTCAATGGGT	GGAGTATTTA	CGGTAAACTG	CCCACTTGGC	AGTACATCAA	420
GTGTATCATA	TGCCAAGTAC	GCCCCCTATT	GACGTCAATG	ACGGTAAATG	GCCCGCCTGG	480
CATTATGCCC	AGTACATGAC	CTTATGGGAC	TTTCCTACTT	GGCAGTACAT	CTACGTATTA	540
GTCATCGCTA	TTACCATGGT	GATGCGGTTT	TGGCAGTACA	TCAATGGGCG	TGGATAGCGG	600
TTTGACTCAC	GGGGATTTCC	AAGTCTCCAC	CCCATTGACG	TCAATGGGAG	TTTGTTTTGG	660
CACCAAAATC	AACGGGACTT	TCCAAAATGT	CGTAACAAC	CCGCCCCATT	GACGCAAATG	720
GGCGGTAGGC	GTGTACGGTG	GGAGGTCTAT	ATAAGCAGAG	CTCGTTTAGT	GAACCGTCAG	780
ATCGCCTGGA	GACGCCATCC	ACGCTGTTTT	GACCTCCATA	GAAGACACCG	GGACCGATCC	840
AGCCTCCGGA	CTCTAGAGGA	TCCGGTACTC	GACCCGAGCT	CGGATCCACT	AGTAACGGCC	900
GCCAGTGTGC	TGGAATTCTG	CACTCCAGGC	TGCCCCGGTT	TGCATGCTGC	TGCTGCTGCT	960
GCTGCTGGGC	CTGAGGCTAC	AGCTCTCCCT	GGGCATCATC	CTAGTTGAGG	AGGAGAACCC	1020
GGACTTCTGG	AACCGCGAGG	CAGCCGAGGC	CCTGGGTGCC	GCCAAGAAGC	TGCAGCCTGC	1080
ACAGACAGCC	GCCAAGAACC	TCATCATCTT	CCTGGGCGAT	GGGATGGGGG	TGTCTACGGT	1140
GACAGCTGCC	AGGATCCTAA	AAGGGCAGAA	GAAGGACAAA	CTGGGGCCTG	AGATACCCCT	1200
GGCCATGGAC	CGCTTCCCAT	ATGTGGCTCT	GTCCAAGACA	TACAATGTAG	ACAAACATGT	1260
GCCAGACAGT	GGAGCCACAG	CCACGGCCTA	CCTGTGCGGG	GTCAAGGGCA	ACTTCCAGAC	1320
CATTGGCTTG	AGTGCAGCCG	CCCGCTTTAA	CCAGTGCAAC	ACGACACGCG	GCAACGAGGT	1380
CATCTCCGTG	ATGAATCGGG	CCAAGAAAGC	AGGGAAGTCA	GTGGGAGTGG	TAACCACCAC	1440
ACGAGTGCAG	CACGCCTCGC	CAGCCGGCAC	CTACGCCCAC	ACGGTGAACC	GCAACTGGTA	1500
CTCGGACGCC	GACGTGCCTG	CCTCGGCCCG	CCAGGAGGGG	TGCCAGGACA	TCGCTACGCA	1560
GCTCATCTCC	AACATGGACA	TTGATGTGAT	CCTAGGTGGA	GGCCGAAAGT	ACATGTTTCG	1620
CATGGGAACC	CCAGACCCTG	AGTACCCAGA	TGACTACAGC	CAAGGTGGGA	CCAGGCTGGA	1680
CGGGAAGAAT	CTGGTGCAGG	AATGGCTCGG	CGAACGCCAG	GGTGCCCGGT	ACGTGTGGAA	1740
CCGCACTGAG	CTCATGCAGG	CTTCCCTGGA	CCCGTCTGTG	ACCCATCTCA	TGGGTCTCTT	1800
TGAGCCTGGA	GACATGAAAT	ACGAGATCCA	CCGAGACTCC	ACACTGGACC	CCTCCCTGAT	1860
GGAGATGACA	GAGGCTGCCC	TGCGCCTGCT	GAGCAGACAC	CCCCGCGGCT	TCTTCCTCTT	1920
CGTGAGAGGT	GGTCGCATCG	ACCATGGTCA	TCATGAAAGC	AGGGCTTACC	GGGCACTGAC	1980
TGAGACGATC	ATGTTGACG	ACGCCATTGA	GAGGGCGGGC	CAGCTCACCA	GCGAGGAGGA	2040

CACGCTGAGC	CTCGTCACTG	CCGACCACTC	CCACGTCTTC	TCCTTCGGAG	GCTACCCCT	2100
GCGAGGGAGC	TCCTTCATCG	GGCTGGCCGC	TGGCAAGGCC	CGGGACAGGA	AGGCCTACAC	2160
GGTCCTCCTA	TACGGAAACG	GTCCAGGCTA	TGTGCTCAAG	GACGGCGCCC	GGCCGGATGT	2220
TACCGAGAGC	GAGAGCGGGA	GCCCCGAGTA	TCGGCAGCAG	TCAGCAGTGC	CCCTGGACGA	2280
AGAGACCCAC	GCAGGCGAGG	ACGTGGCGGT	GTTCGCGCGC	GGCCCGCAGG	CGCACCTGGT	2340
TCACGGCGTG	CAGGAGCAGA	CCTTCATAGC	GCACGTCATG	GCCTTCGCCG	CCTGCCTGGA	2400
GCCCTACACC	GCCTGCGACC	TGGCGCCCCC	CGCCGGCACC	ACCGACGCCG	CGCACCCGGG	2460
GCGGTCCGTG	GTCCCCGCGT	TGCTTCCTCT	GCTGGCCGGG	ACCCTGCTGC	TGCTGGAGAC	2520
GGCCACTGCT	CCCTGAGTGT	CCCGTCCCTG	GGGCTCCTGC	TTCCCCATCC	CGGAGTTCTC	2580
CTGCTCCCCA	CCTCCTGTCT	TCCTGCCTGG	CCTCCAGCCC	GAGTCGTCAT	CCCCGGAGTC	2640
CCTATACAGA	GGTCTTGCCA	TGGAACCTTC	CCCTCCCCGT	GCGCTCTGGG	GACTGAGCCC	2700
ATGACACCAA	ACCTGCCCCCT	TGGCTGCTCT	CGGACTCCCT	ACCCCAACCC	CAGGGACTGC	2760
AGGTTGTGCC	CTGTGGCTGC	CTGCACCCCA	GGAAAGGAGG	GGGCTCAGGC	CATCCAGCCA	2820
CCACCTACAG	CCCAGTGGGG	TCGAGACAGA	TGGTCAGTCT	GGAGGATGAC	GTGGCGTGAA	2880
GCTGGCCGCG	GGGATCCAGA	CATGATAAGA	TACATTGATG	AGTTTGACA	AACCACAACT	2940
AGAATGCAGT	GAAAAAATG	CTTTATTTGT	GAAATTTGTG	ATGCTATTGC	TTTATTTGTA	3000
ACCATTATAA	GCTGCAATAA	ACAAGTTAAC	AACAACAATT	GCATTCAATT	TATGTTTCAG	3060
GTTTCAGGGG	AGGTGTGGGA	GGTTTTTTCG	GATCCTCTAG	AGTCGACTCT	AGANNNNNNN	3120
NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	3180
NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	3240
NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	3300
NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	3360
NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNGGATCCC	CATGACTACG	TCCGGCGTTC	3420
CATTTGGCAT	GACACTACGA	CCAACACGAT	CTCGGTTGTC	TCGGCGCACT	CCGTACAGTA	3480
GGGATCGTCT	ACCTCCTTTT	GAGACAGAAA	CCCGCGCTAC	CATACTGGAG	GATCATCCGC	3540
TGCTGCCCCG	ATGTAACACT	TTGACAATGC	ACAACGTGAG	TTACGTGCGA	GGTCTTCCCT	3600
GCAGTGTGGG	ATTTACGCTG	ATTCAGGAAT	GGGTTGTTCC	CTGGGATATG	GTTCTAACGC	3660
GGGAGGAGCT	TGTAATCCTG	AGGAAGTGTA	TGCACGTGTG	CCTGTGTTGT	GCCAACATTG	3720
ATATCATGAC	GAGCATGATG	ATCCATGGTT	ACGAGTCCTG	GGCTCTCCAC	TGTCATTGTT	3780
CCAGTCCCGG	TTCCCTGCAG	TGTATAGCCG	GCGGGCAGGT	TTTGCCAGC	TGGTTTAGGA	3840
TGGTGGTGGA	TGGCGCCATG	TTTAATCAGA	GGTTTATATG	GTACCGGGAG	GTGGTGAATT	3900
ACAACATGCC	AAAAGAGGTA	ATGTTTATGT	CCAGCGTGTT	TATGAGGGGT	CGCCACTTAA	3960

TCTACCTGCG	CTTGTGGTAT	GATGGCCACG	TGGGTTCTGT	GGTCCCCGCC	ATGAGCTTTG	4020
GATACAGCGC	CTTGCACTGT	GGGATTTTGA	ACAATATTGT	GGTGCTGTGC	TGCAGTTACT	4080
GTGCTGATTT	AAGTGAGATC	AGGGTGCGCT	GCTGTGCCCC	GAGGACAAGG	CGCCTTATGC	4140
TGCGGGCGGT	GCGAATCATC	GCTGAGGAGA	CCACTGCCAT	GTTGTATTCC	TGCAGGACGG	4200
AGCGGCGGCG	GCAGCAGTTT	ATTGCGCGCG	TGCTGCAGCA	CCACCGCCCT	ATCCTGATGC	4260
ACGATTATGA	CTCTACCCCC	ATGTAGGGAT	CCCCATCACT	AGTGCGGCCG	CGGGGATCCA	4320
GACATGATAA	GATACATTGA	TGAGTTTGGA	CAAACCACAA	CTAGAATGCA	GTGAAAAAAA	4380
TGCTTTATTT	GTGAAATTTG	TGATGCTATT	GCTTTATTTG	TAACCATTAT	AAGCTGCAAT	4440
AAACAAGTTA	ACAACAACAA	TTGCATTTCAT	TTTATGTTTC	AGGTTTCAGG	GGAGGTGTGG	4500
GAGGTTTTTT	CGGATCCTCT	AGAGTCGACC	TGCAGGCATG	CAAGCTGTAG	ATAAGTAGCA	4560
TGGCGGGTTA	ATCATTAACT	ACAAGGAACC	CCTAGTGATG	GAGTTGGCCA	CTCCCTCTCT	4620
GCGCGCTCGC	TCGCTCACTG	AGGCCGGGCG	ACCAAAGGTC	GCCCCACGCC	CGGGCTTTGC	4680
CCGGGCGGCC	TCAGTGAGCG	AGCGAGCGCG	CAGCTGGCGT	AATAGCGAAG	AGGCCCGCAC	4740
CGATCGCCCT	TCCCAACAGT	TGCGCAGCCT	GAATGGCGAA	TGGAANTTCC	AGACGATTGA	4800
GCGTCAAAAT	GTAGGTATTT	CCATGAGCGT	TTTTCTGTGT	GCAATGGCTG	GCGGTAATAT	4860
TGTTCTGGAT	ATTACCAGCA	AGGCCGATAG	TTTGAGTTCT	TCTACTCAGG	CAAGTGATGT	4920
TATTACTAAT	CAAAGAAGTA	TTGCGACAAC	GGTTAATTTG	CGTGATGGAC	AGACTCTTTT	4980
ACTCGGTGGC	CTCACTGATT	ATAAAAACAC	TTCTCAGGAT	TCTGGCGTAC	CGTTCCTGTC	5040
TAAAATCCCT	TTAATCGGCC	TCCTGTTTAG	CTCCCCTCT	GATTCTAACG	AGGAAAGCAC	5100
GTTATACGTG	CTCGTCAAAG	CAACCATAGT	ACGCGCCCTG	TAGCGGCGCA	TTAAGCGCGG	5160
CGGGTGTTGG	GGTTACGCGC	AGCGTGACCG	CTACACTTGC	CAGCGCCCTA	GCGCCCGCTC	5220
CTTTCGCTTT	CTTCCCTTCC	TTTCTCGCCA	CGTTGCGCCG	CTTTCCTCCG	CAAGCTCTAA	5280
ATCGGGGGCT	CCCTTTAGGG	TTCCGATTTA	GTGCTTTACG	GCACCTCGAC	CCCCAAAAAC	5340
TTGATTAGGG	TGATGGTTCA	CGTAGTGGGC	CATCGCCCTG	ATAGACGGTT	TTTCGCCCTT	5400
TGACGTTGGA	GTCCACGTTT	TTTAATAGTG	GACTCTTGTT	CCAAACTGGA	ACAACACTCA	5460
ACCCTATCTC	GGTCTATTCT	TTTGATTAT	AAGGGATTTT	GCCGATTTTC	GCCTATTGGT	5520
TAAAAATGA	GCTGATTTAA	CAAAAATTTA	ACGCGAATTT	TAACAAAATA	TTACGTTTAA	5580
CAATTTAAAT	ATTTGCTTAT	ACAATCTTCC	TGTTTTTGGG	GCTTTTCTGA	TTATCAACCG	5640
GGGTACATAT	GATTGACATG	CTAGTTTTAC	GATTACCGTT	CATCGATTCT	CTTGTTTGCT	5700
CCAGACTCTC	AGGCAATGAC	CTGATAGCCT	TTGTAGAGAC	CTCTCAAAAA	TAGCTACCCT	5760
CTCCGGCATG	AATTTATCAG	CTAGAACGGT	TGAATATCAT	ATTGATGGTG	ATTTGACTGT	5820
CTCCGGCCTT	TCTCACCCTG	TTGAATCTTT	ACCTACACAT	TACTCAGGCA	TTGCATTTAA	5880

AATATATGAG	GGTTCATAAA	ATTTTTATCC	TTGCGTTGAA	ATAAAGGCTT	CTCCCGCAAA	5940
AGTATTACAG	GGTCATAATG	TTTTTG GTAC	AACCGATTTA	GCTTTATGCT	CTGAGGCTTT	6000
ATTGCTTAAT	TTTGCTAATT	CTTTGCCTTG	CCTGTATGAT	TTATTGGATG	TTGGAANTTC	6060
CTGATGCGGT	ATTTTCTCCT	TACGCATCTG	TGCGGTATTT	CACACCGCAT	ATGGTGCACT	6120
CTCAGTACAA	TCTGCTCTGA	TGCCGCATAG	TTAAGCCAGC	CCCGACACCC	GCCAACACCC	6180
GCTGACGCGC	CCTGACGGGC	TTGTCTGCTC	CCGGCATCCG	CTTACAGACA	AGCTGTGACC	6240
GTCTCCGGGA	GCTGCATGTG	TCAGAGGTTT	TCACCGTCAT	CACCGAAACG	CGCGAGACGA	6300
AAGGGCCTCG	TGATACGCCT	ATTTTTATAG	GTTAATGTCA	TGATAATAAT	GGTTTCTTAG	6360
ACGTCAGGTG	GCACTTTTCG	GGGAAATGTG	CGCGGAACCC	CTATTGTGTT	ATTTTTCTAA	6420
ATACATTCAA	ATATGTATCC	GCTCATGAGA	CAATAACCCT	GATAAATGCT	TCAATAATAT	6480
TGAAAAAGGA	AGAGTATGAG	TATTCAACAT	TTCCGTGTCG	CCCTTATTCC	CTTTTTTGCG	6540
GCATTTTGCC	TTCCTGTTTT	TGCTCACCCA	GAAACGCTGG	TGAAAGTAAA	AGATGCTGAA	6600
GATCAGTTGG	GTGCACGAGT	GGGTTACATC	GAACCTGGATC	TCAACAGCGG	TAAGATCCCT	6660
GAGAGTTTTC	GCCCCGAAGA	ACGTTTTCCA	ATGATGAGCA	CTTTTAAAGT	TCTGCTATGT	6720
GGCGCGGTAT	TATCCCGTAT	TGACGCCGGG	CAAGAGCAAC	TCGGTCGCCG	CATACACTAT	6780
TCTCAGAATG	ACTTG GTTG	GTACTCACCA	GTCACAGAAA	AGCATCTTAC	GGATGGCATG	6840
ACAGTAAGAG	AATTATGCAG	TGCTGCCATA	ACCATGAGTG	ATAACACTGC	GGCCAACTTA	6900
CTTCTGACAA	CGATCGGAGG	ACCGAAGGAG	CTAACCCTT	TTTTGCACAA	CATGGGGGAT	6960
CATGTAATC	GCCTTGATCG	TTGGGAACCG	GAGCTGAATG	AAGCCATACC	AAACGACGAG	7020
CGTGACACCA	CGATGCCCTGT	AGCAATGGCA	ACAACGTTGC	GCAAACTATT	AACTGGCGAA	7080
CTACTTACTC	TAGCTTCCCG	GCAACAATTA	ATAGACTGGA	TGGAGGCGGA	TAAAGTTGCA	7140
GGACCACTTC	TGCGCTCGGC	CCTTCCGGCT	GGCTGGTTTA	TTGCTGATAA	ATCTGGAGCC	7200
GGTGAGCGTG	GGTCTCGCGG	TATCATTGCA	GCACTGGGGC	CAGATGGTAA	GCCCTCCCGT	7260
ATCGTAGTTA	TCTACACGAC	GGGGAGTCAG	GCAACTATGG	ATGAACGAAA	TAGACAGATC	7320
GCTGAGATAG	GTGCCTCACT	GATTAAGCAT	TGGTAACTGT	CAGACCAAGT	TTACTCATAT	7380
ATACTTTAGA	TTGATTTAAA	ACTTCATTTT	TAATTTAAAA	GGATCTAGGT	GAAGATCCTT	7440
TTTGATAATC	TCATGACCAA	AATCCCTTAA	CGTGAGTTTT	CGTTCCACTG	AGCGTCAGAC	7500
CCCGTAGAAA	AGATCAAAGG	ATCTTCTTGA	GATCCTTTTT	TTCTGCGCGT	AATCTGCTGC	7560
TTGCAAACAA	AAAAACCACC	GCTACCAGCG	GTGGTTTGTT	TGCCGGATCA	AGAGCTACCA	7620
ACTCTTTTTC	CGAAGGTAAC	TGGCTTCAGC	AGAGCGCAGA	TACCAAAATAC	TGTCCTTCTA	7680
GTGTAGCCGT	AGTTAGGCCA	CCACTTCAAG	AACTCTGTAG	CACCGCCTAC	ATACCTCGCT	7740
CTGCTAATCC	TGTTACCAGT	GGCTGCTGCC	AGTGGCGATA	AGTCGTGTCT	TACCGGGTTG	7800

94

GACTCAAGAC GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC	7860
ACACAGCCCA GCTTGGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCTA	7920
TGAGAAAGCG CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG	7980
GTCGGAACAG GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA TCTTTATAGT	8040
CCTGTCGGGT TCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC GTCAGGGGGG	8100
CGGAGCCTAT GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTGTCTGG	8160
CCTTTTGCTC ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC	8220
GCCTTTGAGT GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG	8280
AGCGAGGAAG CGGAAGAGC	8299

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCAGGTACCG CGAGTCAGAT CTACAC

26

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTGTCTGAGC TAGAGCTC

18

WHAT IS CLAIMED IS:

1. A vector comprising a chimpanzee adenovirus DNA sequence and a selected heterologous gene operatively linked to regulatory sequences which direct expression of said gene in a heterologous host cell.
2. The vector according to claim 1 wherein said chimpanzee adenovirus sequence comprises at least 5' and 3' cis-elements necessary for replication and virion encapsidation, said cis-elements flanking said selected gene and regulatory sequences.
3. The vector according to claim 1 wherein said chimpanzee adenovirus sequence has a deletion in all or a part of the E1 gene.
4. The vector according to claim 1 wherein said chimpanzee adenovirus sequence comprises the sequence of SEQ ID NO: 1 or a fragment thereof.
5. The vector according to claim 1 wherein said chimpanzee adenovirus sequence comprises the sequence of SEQ ID NO: 2 or a fragment thereof.
6. A host cell transfected with the vector of claim 1.
7. A human cell that expresses a selected gene introduced therein through transduction of the vector of claim 1.
8. A non-simian mammalian cell line that expresses a chimpanzee adenovirus gene.

9. The cell line according to claim 8 wherein said gene is an adenovirus E1 gene or a functional fragment of said E1 gene.

10. The cell line according to claim 8 wherein said chimpanzee adenovirus gene is obtained from the sequence of SEQ ID NO: 1.

11. The cell line according to claim 8 wherein said chimpanzee adenovirus gene is obtained from the sequence of SEQ ID NO: 2.

12. A pharmaceutical composition comprising a recombinant adenovirus vector in a pharmaceutically acceptable carrier, said vector comprising a chimpanzee adenovirus DNA sequence and a selected heterologous gene operatively linked to regulatory sequences which direct expression of said gene in a host cell.

13. A method for delivering a heterologous gene to a mammalian cell comprising introducing into said cell an effective amount of the vector of claim 1.

14. A method for producing a selected gene product comprising infecting a mammalian cell with the vector of claim 1, culturing said cell under suitable conditions and isolating and recovering from said cell culture the expressed gene product.

15. The use of a vector comprising a chimpanzee adenovirus DNA sequence and a selected heterologous gene encoding an antigen of an infective agent operatively linked to regulatory sequences which direct expression of said gene in the production of a medicament for eliciting an immune response in a mammalian host against said infective agent.

16. The use of a vector comprising a chimpanzee adenovirus DNA sequence and a selected heterologous therapeutic gene operatively linked to regulatory sequences which direct expression of said gene in the production of a medicament for treating a patient having an acquired or inherited genetic defect.

C-1 CLONES





Fig. 1B





Fig. 1C



Human Serotype			Ad-4		Ad-5		Ad-7		Ad-12		Ad-40	
Sub-group			E		C		B		A		F	
Chimp Virus			C1 vs C68		C1 C68		C1 C68		C1 C68		C1 C68	
Protein C1/C68 aa												
E1 and pIX regions												
E1A 6/11K	58/101	26 ^a	41	52 ^a	29	14 ^a	81	26 ^a	12	NH ^a	NH	NH ^a
E1A 25K	231/226	55	56	91	33	26	82	60	36	37	36	39
E1A 28K	262/257	57	57	92	34	34	83	61	37	40	34	40
E1B 21K	181/186	60	49	68 ^b	48	46	94	61	39	38	43	42
E1B 55K	495/498	74			53	57	88	73	46	46	46	47
E1B 8.3K	91/102	54			21	29	85	53	21	25	27	30
pIX	139/143	80			52	48	96	80	56	51	52	53
E2 and IVa2 Regions												
E2A DBP	516/513	78	76	93	53	53	86	76	45	49	46	47
E2B pTP	643/628	91	90	94	81	80	96	90	75	76	73	73
E2B pol	1121/1125	90	83	92	75	76	96	90	72	72	68	69
IVa2	448/448	93			82	82	96	92	76	77	80	80
E3 Region												
E3A#1	106/106	78			52	58	96	78	66	70	NH	NH
E3A#2	146/209	33 ^a			NH	NH	80	34	NH	NH	NH	NH
E3A#3	172/176	60			38	32	75	60	NH	NH	NH	NH
E3Hyp	184/204	26			NH	NH	73	34	NH	NH	NH	NH
E3Hyp	188/204	31			NH	NH	82	31	NH	NH	NH	NH
E3Hyp	103/295	NH			NH	NH	48 ^a	NH	NH	NH	NH	NH
E3B#4	91/ 91	71			47	48	92	77	44	41	37	36
E3B#5	134/143	54			34	32	75	49	27	25	26	22
E3B#6	135/135	79			52	54	91	80	52	52	46	48
E4 Region												
E4	123/124	orf-1 70			42	45			44	50	NH	NH
E4	129/129	orf-2 64			32 ^c	31 ^c			30	31	32	35
E4	117/117	orf-3 84			49	52			65	67	60	59
E4	124/121	orf-4 62			45	56			40	45	39	38
E4	303/301	orf-6 76			57	63			50	51	47	47
E4	83/ 64	orf-7 60			42	55			49	42	36	31
Late Region												
L1 16.6K	139/139	AgnoP 76			45	47	88	74	28	25	38	36
L1 52/55K	389/391	85			69	69			71	70	77	75
L1 IIIa	586/592	85			76	79			75	66	73	65
L2 III	564/534	Penton 82			70	72	85	83 ^d	72	76	72	76
L2 pVII	192/193	91	87	96	73	70			76	74	73	72
L2 pV	353/343	M. Core 84			58	61			63	67	60	61
L2 pVI	76/ 77	91			69	73			65	64	72	65
L3 pVI	250/242	79			65	68			66	58	57	49
L3 II	956/933	Heron 86	85	88	79	78	86	85	76	79	77	79
L3 23K	207/206	EndoPr 89	78	88	75	76	93	87	79	80	78	82
L4 100K	828/804	80			62	65			61	64	59	62
L4 22K	197/188	Morph 72			43	40			36	38	39	44
L4 33K	231/222	76			44	44			NH	NH	41	41
L4 pVIII	227/227	Hex AS 92	95	90 ^a	79	79	86	78 ^e	78	79	80	80
L5 IV	322/425	Fiber 24 ^a	27 ^a	90	19 ^a	36 ^a	66	26 ^a	18 ^a	28 ^a	17 ^a	23 ^a

Fig. 2

C-68 CLONES





Fig. 3B




Fig. 3C





Fig 3E




Fig. 4B





Fig. 4A

C68 E1 Expression Plasmid



C1 E1 Expression Plasmid

Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6D




Fig. 6E




Fig. 6F






Fig. 6G



CONSTRUCTION OF C-1 EXPRESSION VECTOR



CONSTRUCTION OF C-68 EXPRESSION VECTOR




Fig. 8





Fig. 8B



50




Fig. 8C




Fig. 8C




Fig. 8D




Fig. 8H




Fig. 81




Fig. 02




Fig. 8





Fig. 8.2

CONSTRUCTION OF GFP EXPRESSION VECTORS



GENERATION OF RECOMBINANT C68-CMV-GFP VIRUS BY HOMOLOGOUS RECOMBINATION

Fig. 10B




Fig. 10C






Fig. 10A



**Transfect E1 Cell Line
Agar Overlay
2 Weeks
Isolate plaques**

Fig. 10D



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15694

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N5/10 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 26914 A (RHÔNE-POULENC RORER S.A.) 24 November 1994 see page 2, line 33 - page 3, line 26 ---	1-3,6-9, 12-16
Y	A.H.KIDD ET AL.: "Human and simian adenoviruses: Phylogenetic interferences from analysis of VA RNA genes" VIROLOGY, vol. 207, no. 1, 20 February 1995, ORLANDO US, pages 32-45, XP002052836 see table 2 --- -/--	1-3,6-9, 12-16

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

21 January 1998

Date of mailing of the international search report

11.02.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentkan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15694

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>R. WIGAND ET AL.: "Chimpanzee adenoviruses are related to four subgenera of human adenoviruses" INTERVIROLOGY, vol. 30, no. 1, January 1989 - February 1989, pages 1-9, XP002052837 cited in the application see page 1; table 4 -----</p>	1-16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/15694

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claim 13, insofar as an in vivo method is concerned, is directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the vector.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/15694

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9426914 A	24-11-94	FR 2705361 A	25-11-94
		AU 6787894 A	12-12-94
		BR 9406720 A	06-02-96
		CA 2163256 A	24-11-94
		CN 1124040 A	05-06-96
		CZ 9503028 A	14-02-96
		EP 0698108 A	28-02-96
		FI 955552 A	27-12-95
		HU 73465 A	28-08-96
		JP 8510122 T	29-10-96
		NO 954466 A	07-11-95
		PL 311660 A	04-03-96
		SK 144795 A	03-04-96
		ZA 9403358 A	16-01-95

BEST AVAILABLE COPY			